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Abstract 
 
The maturation of early endosomes into multivesicular bodies (MVBs) 
and subsequent trafficking to lysosomes is an important event for the 
control and silencing of endocytosed membrane receptors.  The 
endosomal-sorting complex required for transport (ESCRT) proteins 
appear to play a key role in this event.   Phosphatidylinositol lipids 
including PtdIns(3,5)P2 have been implicated in the MVB-lysosomal 
pathway and an ESCRT-III component CHMP3 binds to this lipid in vitro. 
 
The purpose of this thesis was to investigate the link between ESCRT 
proteins, PtdIns(3,5)P2 and endo-lysosomal trafficking.  Firstly, a protein 
expressed by Salmonella, which is a phosphatase that acts on 
PtdIns(3,5)P2, was investigated as a potential tool for manipulating 
cellular PtdIns(3,5)P2 levels.  Our results suggest that it is potentially a 
useful tool for this purpose and that expression of SopB perturbs 
endosome to lysosome trafficking.  These findings provide further 
evidence for a role of PtdIns(3,5)P2 in endo-lysosomal trafficking. 
 
In order to characterise PIKfyve, the kinase that produces PtdIns(3,5)P2, 
polyclonal antibodies were raised against this protein.  Purification and 
characterisation of the antibody suggest that it recognises recombinant 
and endogenous PIKfyve. 
 
Thirdly, with the aim of characterising the full protein complement needed 
for MVB formation, a method was developed to isolate a subcellular 
compartment and associated proteins (including ESCRT proteins) 
induced by a dominant negative Vps4 protein.   
  
Finally, we discovered a role for functional ESCRT-III in cytokinesis.  
Mutant ESCRT-III components expressed in mammalian cells impaired 
cytokinesis suggesting that these proteins are not only necessary for 
MVB formation but are very important for the completion of cytokinesis. 
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1  Introduction 
 
 
1.1  Multivesicular bodies and membrane trafficking 
 
Membrane trafficking is controlled by the addition and removal of proteins 
from membrane compartments.  In the case of the plasma membrane, 
removal of existing plasma membrane proteins often occurs via the 
clathrin-mediated process of endocytosis [reviewed in 1].  Once protein-
containing vesicles have been formed via endocytosis, the fate of such 
proteins in the cell is usually coordinated by endosomes [reviewed in 2].  
Endosomes can help determine trafficking of proteins between the trans-
Golgi network (TGN) to be returned to the plasma membrane, and lytic 
organelles such as lysosomes in mammalian cells or vacuoles for 
example in yeast.  Such control and direction of vesicle transport is of 
utmost importance, as different membrane receptors require different 
fates.  For example, many housekeeping receptors such as the 
transferrin receptor are sometimes recycled back to the plasma 
membrane [3].  By trafficking through the early endosomal compartments 
of the cell, such recycling receptors are able to rid themselves of their 
bound ligands by dissociation as a result of the mildly acidic compartment 
they have been trafficked to.  Once the ligand has been removed in such 
a manner they are free to be recycled back to the plasma membrane and 
this process can be repeated upon ligand binding. 
 
Other cellular plasma membrane receptors are not usually recycled back 
to the plasma membrane as this may be detrimental to the cell or 
organism due to repetitive signalling events.  For example many growth 
factor receptors signal the cell to proliferate and divide, and if this process 
is not tightly regulated, the cell can end up uncontrollably proliferating 
which may be harmful to the cell [4].  In such cases these signalling 
receptors may be directed to the lytic lysosome to allow initially for 
cessation of the signal and secondly the destruction of the protein by 
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proteolysis.  The mediator between delivery to the lytic lysosome of such 
signalling receptors and the early endosomal compartments is the subset 
of late endosomes known as multivesicular bodies (MVB) [reviewed in 4-
11].  MVBs are given their name due to their prominent appearance of 
vesicles contained within a spherical late endosomal structure.  It would 
appear that MVBs play an initial role in the trafficking of activated 
signalling receptors by the silencing of their signals.  This is achieved by 
sequestering the cytoplasmic domains of signalling receptors away from 
the cytoplasm via the delivery of these proteins by inward budding of 
vesicles into the lumen of the MVB.  Once this process has occurred, the 
trafficking of the MVB can be followed to fusion with the lysosome where 
the lumenal contents will be delivered to the lytic environment of the 
lysosome and degradation can occur [12]. 
 
 
1.2  The Endocytic Pathway 
 
Endosomes can be classed typically as either ‘early’ or ‘late’ endosomes 
depending upon their kinetics of organisation and how they sort protein 
cargo [reviewed in 7, 13].  Morphologically, early endosomes are seen to 
have a more tubular appearance when compared with late endosomes, 
which are characteristically much more spherical in appearance.  In 
mammalian cells the localisation of early endosomal compartments is 
often found near the periphery of the plasma membrane, whereas late 
endosomes are found more adjacent to the nucleus.  MVBs are 
considered a subset of late endosomes, possessing a unique multi-
vesicular appearance, a result of the budding of vesicles containing 
receptor cargo from the limiting membrane into their lumen.   
 
One of the most studied transmembrane signalling receptors is the 
epithelial growth factor receptor (EGFR).  The ligand that binds EGFR is 
epithelial growth factor (EGF), which is a small, secreted peptide that 
signals the target  cell to proliferate  and divide.    Activation  of EGFR  by  
 14 
 
 
Figure 1.1 – The MVB-lysosomal degradation pathway.  A transmembrane receptor, 
such as EGFR is activated by its ligand (yellow circle) and consequentially endocytosed.  
After trafficking and sorting through the early endosome, it is directed to the MVB where 
it is delivered into the lumen as an internal vesicle.  The MVB then fuses with the lytic 
lysosome where degradation can occur.  Early endosomes may also be responsible for 
recycling of membrane receptors as well as trafficking from the Golgi apparatus to the 
plasma membrane. 
 
binding of EGF at  the plasma membrane  results in a  signalling cascade 
of events primarily through activation of the tyrosine kinase activity that 
the intracellular domain of EGFR possesses.  Due to the nature of the 
signal that EGF produces, the cell has to employ measures to make sure 
that constant stimulation of the tyrosine-kinase activity does not occur, 
thus the attenuation of EGFR signalling is very important.  Using various 
differently labelled EGF molecules to study this downregulation, it was 
shown that EGF bound to EGFR was delivered into the lumen of MVBs 
en route to the lysosome where its degradation occurred [14-16].  The 
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suppression of the tyrosine kinase activity occurs once delivery of the 
ligand-receptor complex to the MVB lumen has been made, as opposed 
to its delivery to the lysosome [17].  This highlights the importance of 
MVBs in the control and cessation of signalling events and that the MVB 
is an important organelle in the trafficking of such signalling proteins.  
 
The molecular mechanism of delivering cargo into the lumen of MVBs is 
not one that is well understood.  This process differs from classical 
endocytosis in that the direction of budding is away from the cytoplasm.  
Studies carried out in Saccharomyces cerevisiae initially identified a 
family of at least 18 conserved proteins known as the class E vacuolar 
protein sorting (Vps) proteins [reviewed in 4; 18-20].  Disruption of the 
class E VPS genes resulted in a swollen endosomal phenotype (the class 
E compartment), with protein cargo not being delivered to the yeast 
vacuole.  This swollen endosomal phenotype is a consequence of the 
addition of membrane to the MVB structure, but due to impaired MVB 
machinery there is no removal of membrane via the internalisation of 
vesicles. As a result, the membrane of the MVB increases in size 
resulting in an enlarged endosomal phenotype (the class E 
compartment).  Thus it seemed apparent that the Vps proteins are 
involved somehow in the delivery of cargo into the lumen of MVBs.  Class 
E Vps proteins are highly conserved in eukaryotes which emphasises 
their importance in the cell, and disruption of their protein functions in 
most cases leads to similar phenotypes as seen in yeast.  This suggests 
that similar mechanisms may occur in mammalian cells as in yeast.  It 
must also be noted that many proteins undergo repeated rounds of 
internalisation and recycling back to the plasma membrane, thus the 
process of MVB formation must also be tightly controlled and a fairly 
selective event [reviewed in 5, 6]. 
 
To understand how selectivity of MVB cargo may be achieved, EGFR 
studies have again given us insight into this matter.  Studies were carried 
out where a point mutation in the kinase domain of EGFR giving a kinase-
dead protein resulted in the activated receptor being delivered to the 
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MVB’s limiting membrane, but not internally delivered [17].  Further 
studies found that the addition of a single ubiquitin molecule onto EGFR 
(or most other receptors destined for the MVB-lysosomal degradation 
pathway) was necessary for targeting the cargo for MVB lumenal delivery 
[21-23].  Removal of residues necessary for ubiquitin addition from 
membrane receptors results in impaired sorting and degradation of these 
activated proteins.  Likewise, the addition of a mono-ubiquitin molecule to 
receptors not normally degraded through the MVB pathway causes these 
receptors to be sorted into MVB lumens [24].  Thus it appears that for 
cargo to be targeted to the MVB lumen for lysosomal degradation, 
monoubiquitylation may be the method by which the cell marks a protein 
for such a fate.  This has more recently been further supported by 
findings that indicate ubiquitin removal proteins are required in the late 
stages of delivery of cargo to the lumen of the MVB [25-34]. 
 
 
1.3  The ESCRT machinery 
 
The class E Vps proteins can generally be subdivided into four separate 
endosomal sorting complexes required for transport (ESCRT-0, -I, -II, -III) 
[reviewed in 4; 9, 35-37].  Much of the initial work that has defined the 
ESCRT machinery and their roles has been carried out in yeast.  Given 
the high level of conservation between the yeast Vps proteins and 
mammalian ESCRT proteins, it has been suggested that the mechanisms 
for MVB formation may also be highly conserved.  Indeed many studies 
have shown that homologues of yeast proteins carry out similar roles in 
mammalian cells.  There are however apparent differences between the 
roles of yeast Vps proteins and mammalian ESCRT proteins.  For 
example, in mammalian cells it has been demonstrated that the ESCRT-I 
complex does not directly interact with the ESCRT-III complex [38, 39].  
The two complexes do however both interact with ALIX, the homologue of 
the yeast Vps31 (Bro1) protein [40, 41].  This has been suggested to link 
the two complexes together, as it has additionally been implied that 
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ESCRT-II may not be necessary in mammalian cells for proper MVB-
lysosomal pathway function, in contrast to yeast [42].  Despite this, in 
yeast it has been shown that ESCRT-I does interact with ESCRT-III 
directly and furthermore that the ALIX homologue Vps31 does not 
associate with the ESCRT-I complex [43].  Thus although it is apparent 
that similar components of the same machinery are present in yeast and 
mammalian cells, their functions and mechanisms may differ.  It should 
be noted however that despite one study that suggests the ESCRT-II 
components are not needed for the degradation of receptors via the 
MVB-lysosomal route [42], a more recent study contradicts these 
findings, showing that silencing of certain ESCRT-II components does 
impair receptor degradation [44].  Thus the exact role of ESCRT-II in 
mammalian cell has yet to be elucidated. 
 
The Vps proteins that form the ESCRT complexes are recruited from the 
cell cytosol to the limiting membrane of the endosomal structure where 
their exact role in delivery of cargo into the MVB lumen and the 
biogenesis of the MVB itself is not well understood.  From studies in yeast 
a current model has been proposed that involves three main processes 
occurring on the limiting membrane of endosomes destined to be MVBs 
(for a schematic representation see Fig 1.3) [reviewed in 4, 9, 45].  In the 
early stages of MVB biogenesis, cargo recognition occurs, which includes 
ubiquitin-binding proteins such as Vps27 and Hse1 (Hrs and STAM in 
mammals; referred to as the ESCRT-0 complex) binding 
monoubiquitylated protein cargo, and complexing them together.  An 
important point to make here is that the localisation of Vps27 on the 
endosomal membrane is dependent on its binding of the endosomally 
localised lipid PtdIns(3)P [46-48].  Secondly, concentration of the cargo 
occurs.  This process involves the recruitment of ESCRT-I machinery 
(Vps23, 28, 37 in yeast or TSG101, VPS28 and VPS37 in mammals) by 
Vps27 to assemble at the soon to be MVB membrane [49].  ESCRT-I 
interacts with monoubiquitylated cargo and in turn recruits the ESCRT-II 
complex (Vps22, 25, 26 in yeast, EAP30, 25 and 45 in mammals).  
Assembled ESCRT-II initiates the oligomerisation of at least four small, 
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coiled-coil CHMP proteins that make up the ESCRT-III complex (Vps2, 
20, 24 and Snf7 in yeast, also referred to as CHMP2, 6, 3 and 4 in 
mammals, respectively) [35].  The exact role of ESCRT-III is not known, 
however it is thought that the complex recruits additional proteins 
including Vps31/Bro1 (ALIX in mammals) and the AAA-type (ATPase 
associated with various cellular activities) ATPase Vps4.  Bro1 is thought 
to recruit the de-ubiquitylating enzyme Doa4 (UBPY in mammals) [50, 
51], while Vps4 is responsible for the dissociation of the ESCRT 
complexes from the MVB membrane to be released back into the cytosol 
[52, 53].  Dominant negative mutations in Vps4 result in a swollen 
endosomal (class E compartment) phenotype, implying that the 
dissociation of the ESCRT machinery is necessary for delivery of cargo 
into the lumen of the MVB [52], however it is not known if this dissociation 
is the necessary force to drive inward invagination. 
 
The third step in MVB formation is the actual formation of internal vesicles 
– that is, the invagination and budding of vesicles containing cargo, into 
the MVB lumen.  This process is poorly understood, and although it is 
thought that local asymmetry in lipids such as LBPA may play a role in 
causing membrane deformation and hence curvature, there is currently 
no comprehensive model for this process [54, 55].  It is thought however 
that ESCRT-III proteins (CHMPs) are involved in the final stages of MVB 
formation with regards to inward vesiculation of cargo, however there is 
conflicting evidence of this anticipated role [56].  Different models have 
been proposed as to how the ESCRT complexes may facilitate such a 
process (for an in depth discussion of this see Chapter 7).  However 
these models are based on many different individual experiments 
including in vitro findings, and thus there is not much evidence and these 
models tend to be rather speculative [4, 57].  Other proteins appear to be 
necessary for the MVB formation process to occur.  These may include 
deubquitinating enzymes such as Doa4 and Ubp7 (of which UBPY and 
AMSH are the mammalian homologues, respectively), where in yeast 
Doa4 has been shown to remove the ubiquitin molecule just prior to cargo 
delivery into a vacuole [58, 59]. 
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Mammalian 
protein 
Yeast 
Homologue 
Complex Notes 
HRS Vps27 FYVE domain, binds Ub (UIM) 
STAM Hse1 
"ESCRT-0" 
Binds Ub (UIM) 
TSG101 Vps23 Binds Ub, coiled-coil domain 
VPS28 Vps28   
VPS37 (A-D) 
MVB12 (A-B) 
Vps37 
Mvb12 
 
ESCRT-I 
 
?? ESCRT-I ?? 
Coiled-coil domain 
EAP30 Vps22 Coiled-coil domain 
EAP25 Vps25   
EAP45 Vps36 
ESCRT-II 
  
CHMP2 (A-B) Vps2/Did4 Coiled-coil domain 
CHMP3 Vps24 Coiled-coil, binds PI(3,5)P2 
CHMP4 (A-C) Vps32/Snf7 Coiled-coil 
CHMP6 Vps20 
ESCRT-III 
Coiled-coil, myristoylated 
CHMP1 (A-B) Fti1/Did2 ??ESCRT-III?? Coiled-coil domain 
CHMP5 Vps60/Mos10 ??ESCRT-III?? Coiled-coil 
CHMP7 ? ??ESCRT-III?? Snf7 domain, binds CHMP4B 
VPS4 (A-B) Vps4 Vps4 complex AAA-ATPase, MIT domain 
ALIX 
UBPY 
AMSH 
Vta1 
Vps31/Bro1 
Doa4 
Ubp7 
LIP5 
 Binds LBPA 
De-ubiquitylating enzyme 
De-ubiquitylating enzyme 
MIT domain, binds Vps4/CHMPs 
PIKfyve Fab1p ??  FYVE domain, PI(3)P to PI(3,5)P2 
Table 1.1 – Mammalian and yeast homologues of ESCRT and other proteins 
involved in MVB formation. 
 
 
1.4  Phosphoinositides and Endocytosis 
 
It appears that phosphoinositides seem to also play a key role in proper 
endocytic trafficking events including MVB formation [60-62].  
Phosphoinositides are formed by the phosphorylation at various positions 
of phosphatidylinositol (PtdIns), and their production within the cell can be 
spatially and temporally regulated [reviewed in 63].  For example, the 
phosphoinositide lipid PtdIns(4,5)P2 is generally synthesised at the 
plasma membrane.  PtdIns(3)P on the other hand is typically considered 
to be early endosomally localised.  Whereas, PtdIns(4,5)P2 has been 
implicated in playing a role with clathrin-mediated endocytosis, PtdIns(3)P 
may play a role in endosomal trafficking and recognition of proteins 
involved in these pathways.  As already mentioned, the ESCRT-0 protein 
Vps27 (Hrs in mammals) specifically binds to PtdIns(3)P which 
determines its endosomal localisation.  Vps27 possesses a FYVE 
domain, a domain that is known for binding to the PtdIns(3)P lipid.  
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Substitution of this FYVE domain in Vps27 impairs its endosomal 
membrane targeting [4, 48].  As the sub-cellular localisation of proteins 
can ultimately determine their function within a cell, mis-localised Vps27 
proteins as a result of FYVE-domain substitutions hence impair the 
proper cellular function of Vps27. 
 
The FYVE domain originally was named this due to four proteins this 
domain was common in: Fab1, YOTB, Vac1 and early endosome 
antigen-1 (EEA1), although this domain is found in several other proteins, 
including Vps27/Hrs [64].  FYVE domains bind phosphoinositides with 
great preference to PtdIns(3)P.  The actual domain is a small zinc finger 
and its binding to PtdIns(3)P results in it being “anchored” to the 
membrane by both electrostatic and resulting hydrophobic interactions 
with PtdIns(3)P and surrounding membrane lipids [65].  Hydrophobic 
residues contained in the FYVE domain actually form what is referred to 
as an insertion loop.  This insertion loops is what enables a tightly bound 
interaction with the membrane, as hydrophobic residues present on the 
domain insert into the lipid bilayer of the membrane, forming a loop that 
sits inside the hydrophobic tail domain region of the membrane lipids.  
Additionally, there is a specific lipid binding interaction that occurs with 
the FYVE domain and the inositol head group of PtdIns(3)P [66].  Such 
specificity is important for a protein given that many different forms of 
inositol lipids are found throughout the cell at various different 
membranes, from the Golgi apparatus, to endosomal membranes, to the 
plasma membrane itself.  Thus the cellular localisation of a protein is very 
important in determining its primary cellular role.  For example, a protein 
containing a domain that recognises PtdIns(4,5)P2 is likely to be localised 
to the plasma membrane and its resultant effects will be manifested at 
this compartment. 
 
One phosphorylated product of the early endosomally localised 
phosphoinositide PtdIns(3)P is the lipid PtdIns(3,5)P2. This 
phosphoinositide has been proposed to be synthesised at endosomal 
membranes [reviewed in 67].  In yeast, the protein kinase Fab1 is 
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responsible for the conversion of PtdIns(3)P to PtdIns(3,5)P2 and 
mutations in the lipid kinase domain of Fab1 result in decreased levels of 
PtdIns(3,5)P2 and altered vacuolar morphology [61, 62].  The yeast strain 
∆fab1 is completely devoid of the lipid PtdIns(3,5)P2 and displays 
phenotypes that are typified by dramatically enlarged vacuoles, some 
defects in MVB sorting and various other negative cellular effects that the 
yeast vacuole helps to control [reviewed in 67; 68].  Conversely, a mutant 
of Fab1 that results in increased levels of PtdIns(3,5)P2 results in 
abnormal decreased vacuolar size suggesting that this lipid is important 
in the maintenance of vacuolar size with the levels of PtdIns(3,5)P2 
needing to be carefully regulated by Fab1 [69]. 
 
The mammalian homologue of Fab1 is PIKfyve, which has also been 
reported to give swollen vacuolar phenotypes when its normal function is 
impaired [60, 70].  It should be noted that PIKfyve contains a FYVE 
domain, as does Fab1.  In addition to these studies, the ESCRT-III 
component Vps24 (CHMP3) has also been identified as a potential 
PtdIns(3,5)P2 binding partner [71].  In vitro, Vps24 appears to show 
specificity for PtdIns(3,5)P2 however the relevance of this in vitro binding 
to in vivo function is not yet clear [71].  Dominant negative truncated 
forms of Vps24 when overexpressed in mammalian cells give a large 
swollen vacuolar phenotype.  Additionally, in the absence of 
PtdIns(3,5)P2, membrane protein cargo in yeast found on the limiting 
membrane of the MVB fails to be delivered to the lumen [62].  Further to 
Vps24, several other potential effector proteins of PtdIns(3,5)P2 have 
been identified in vitro, including the cytokine-independent survival kinase 
(CISK) protein, a soy bean protein termed Ssh1p, and the S. cerevisiae 
protein Gcs1p [72].  Despite the identification of these proteins binding 
PtdIns(3,5)P2 in vitro, the relevance of their cellular roles and that of 
PIKfyve/Fab1’s apparent function is not obvious.  The role of PIKfyve in 
the endocytic pathway will be discussed in further depth later on in this 
chapter. 
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1.5  CHMP proteins 
 
The ESCRT-III complex in mammalian cells is made up of proteins 
referred to as CHMPs.  These are homologues of the yeast Vps proteins; 
however they all possess similar properties in their structures and actions 
[reviewed in 4, 9; 73, 74].  CHMP proteins are quite small, being around 
200 amino acids in length, and are highly charged molecules, with basic 
N-terminal and acidic C-terminal domains.  They appear to contain coiled-
coil domains, predicted by sequence studies [75].  There have been 
reported to be at least 11 CHMP proteins in mammalian cells, belonging 
to one of 7 families, CHMP1-7 [76].  It is not clear what the role of each of 
these 11 CHMPs are, however mutations, gene silencing, and dominant 
negative overexpression of many of these proteins lead to MVB sorting 
defects. 
 
CHMP proteins are notable for their distinctly charged N- and C-terminal 
residues.  The basic N-terminus is positively charged compared with the 
acidic, negatively charged C-terminal domain.  It has been proposed that 
the C-terminus interacts with the N-terminus inhibiting the function of the 
N-terminal domain [77].  Thus the C-terminus has therefore been called 
an autoinhibitory domain.  For the CHMP to properly function its role in 
MVB biogenesis, some sort of event (possibly membrane binding) must 
occur which allows the autoinhibitory C-terminal domain to be removed 
from binding the N-terminal domain.  Truncations that remove the C-
terminal inhibitory domain result in impaired CHMP functions and 
membrane localisation [78].  In the case of ESCRT-III components 
however, the Vps4 binding site is also found in the C-terminal domain, 
thus removal of the autoinhibitory C-terminal domain would likely impair 
the ability of Vps4’s AAA-ATPase activity on CHMPs. 
 
The ESCRT-III complex made up in mammalian cells of these CHMPs is 
thought to play an important role in endosomal invagination and the 
delivery of cargo to the MVB lumen.  Precisely how ESCRT-III is involved 
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in this invagination process, if at all, is subject to much debate and the 
exact mechanisms involved are not well known.  What is acknowledged 
however is that recruitment of ESCRT-III components, as already 
mentioned, is usually the result of ESCRT-II complex formation and 
endosomal membrane recruitment, at least in yeast.  The ESCRT-III 
complex is thought to be made up of a core of 4 CHMP proteins: CHMP2 
(Vps2/Did4), CHMP6 (Vps20), CHMP3 (Vps24) and CHMP4 
(Vps32/Snf7) [4, 45].  The other mammalian CHMPs identified (CHMP1, 
5 and 7) may be involved in some way such as in having regulatory roles, 
however these are very poorly understood.  The recruitment of ESCRT-III 
by ESCRT-II complex formation is a process that results in the 
oligomerisation of these 4 CHMP proteins, giving a concentrated ESCRT-
III complex.  Yeast two-hybrid studies have identified interactions 
between these four CHMPs, showing that CHMP3 interacts with both 
CHMP2 and CHMP4 and CHMP4 interacts with all other members of the 
complex (CHMP2, 3 and 6) [4].  CHMP2 then interacts with CHMP3 and 
4 and CHMP6 only interacts with CHMP4 (see Fig 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 – The interactions of the four core mammalian CHMP proteins.  The four 
CHMPs thought to make up the ESCRT-III complex are represented by spheres 
(CHMP2, 3, 4 and 6).  Interactions with other CHMPs are indicated by a dashed line 
connecting the proteins that interact with each other, as identified by yeast two-hybrid 
studies [43]. 
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Following the oligomerisation of the four CHMP proteins, the ESCRT-III 
complex seems to concentrate membrane cargo as well as recruit 
additional proteins (see Fig. 1.3).  The recruitment of Bro1 (ALIX) allows 
this protein to further recruit Doa4, which appears to have a role in 
removal of the ubiquitin molecules from the cargo destined for delivery to 
the MVB lumen.  Several other proteins have been implicated in ESCRT-
III association at this stage such as Vta1 (which binds Vps4 and is 
thought to link some CHMPs to Vps4 by direct CHMP binding), but these 
are more recently described [79].  The ESCRT-III complex then seems to 
serve as a platform that allows ubiquitylated cargo to be concentrated in a 
place where ubiquitin molecules are recycled back to the cytosol.  This 
cargo destined for degradation via the lysosome can then be delivered to 
the lumen of the MVB.  The dodecameric AAA-ATPase, Vps4, is 
responsible for removal of the ESCRT-III machinery complex, which is 
recycled back to the cytosol after having been removed from the 
endosomal membrane [35-37, 52, 80] (Fig. 1.3).  This removal process 
carried out by Vps4 seems to be essential for cargo delivery to the lumen.  
Evidence to support this includes the fact that when a dominant negative 
Vps4 lacking AAA-ATPase activity is expressed in cells, a swollen 
vacuolar phenotype is observed and cargo accumulates on the 
endosomal membrane.  This cargo is not delivered into the MVB lumen, 
and a reduction of internal vesicles is observed [53].  Thus Vps4 acts as a 
vital component of MVB biogenesis with removal of the ESCRT-III 
machinery being necessary for proper MVB formation.  In addition, the 
lipid LBPA seems to be highly concentrated and almost found exclusively 
on internal vesicles of MVBs [54, 55].  The structure of this lipid allows it 
to perhaps give local asymmetry and membrane curvature, which has 
hence been suggested to aid in the formation of MVB vesicles [4].  
However, it is likely that the presence of LBPA is merely a contributing 
factor to a much more complex process of invagination and lumenal 
vesicle formation, and it should be noted that LBPA is not present in 
yeast.  
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Figure 1.3 – The mammalian ESCRT-III complex and associated proteins in MVB 
biogenesis.  The CHMP proteins (mammalian ESCRT-III components) typically reside 
in the cytosol.  Activation and formation of ESCRT-I, and subsequently ESCRT-II 
complexes, results in the recruitment and oligomerisation of the ESCRT-III components; 
CHMP2, 3, 4 and 6.  The CHMP proteins reside as a more “closed” conformation, which 
involves their C-terminus autoinhibiting the N-terminus.  Through recruitment and 
possible binding to PtdIns(3,5)P2, the CHMPs open up to an active form whereby 
membrane binding and protein interactions at the N-terminus can occur.  Cargo already 
concentrated by previous ESCRT complexes may also be additionally concentrated by 
ESCRT-III.  Cargo that was initially concentrated by ubiquitin (Ub) recognition is 
deubiquitylated by enzymes such as Bro1.  Interactions of the C-termini of CHMPs with 
the dodecameric Vps4 complex take place which results in the removal of CHMPs from 
the membrane possibly causing the membrane to close and pinch off forming an internal 
vesicle containing concentrated cargo.  Local asymmetry may be aided by the presence 
of the lipid LBPA (represented by black triangles).  CHMP proteins are then recycled 
back to the cytosol where they exist in their autoinhibited form.  Note, in the concentric 
circle theory (reviewed in chapter 7, [57]) important points to make are that it is 
hypothesised that the ESCRT-II, -I and –0 complexes are found more above and inward 
to the invaginating vesicle and are removed prior to full invagination and vesicle 
formation. 
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One of the ESCRT-III components, CHMP3, has already been mentioned 
to bind PtdIns(3,5)P2 in vitro [71].  Due to the localisation of ESCRT 
complexes being thought to be largely determined by Vps27/Hrs 
membrane binding to PtdIns(3)P, it would be of no surprise if the 
generation of PtdIns(3,5)P2 occurred at the same membrane.  Indeed, 
due to the high concentration of PtdIns(3)P found on endosomal 
membranes, it the generation of PtdIns(3,5)P2 is thought to occur at 
endosomal membranes.  Given the fact that CHMP3 appears to bind 
PtdIns(3,5)P2 specifically in vitro, and that this lipid has a strong negative 
charge, it is possible that PtdIns(3,5)P2 plays some role in ESCRT-III 
recruitment and CHMP activation.  This may occur as binding of the 
highly positive N-terminal domain to the membrane is one suggested 
mechanism by which the CHMP is released of its autoinhibitory C-
terminal domain in some fashion.  Despite this, there is currently little in 
vivo evidence to support CHMP3 being an effector of PtdIns(3,5)P2. 
 
 
1.6  The role of PIKfyve in the endocytic pathway 
 
The enzyme responsible for PtdIns(3,5)P2 formation, PIKfyve, would 
appear to play some role in the endo-lysosomal pathway and hence 
potentially in proper ESCRT function [60, 70, 81, 82].  Certainly, 
overexpression of a dominant negative mutant PIKfyve lacking kinase 
activity in mammalian cells has been reported to give a similar swollen 
endosomal phenotype as seen in mutations of ESCRT proteins [70, 83].  
There have been some conflicting studies regarding the localisation of 
PIKfyve, with it having been reported to be early endosomal as well as 
late endosomal [84-86].  It is possible that PIKfyve localises to a 
compartment that contains both early and late endosomal markers.   
Such a hybrid compartment has been perceived as perhaps what MVB 
organelles exist as, instead of merely a subset of late endosomes, and 
has been suggested by others [71].  Also it should be noted that cellular 
localisation studies are often based on dominant negative and mutant 
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proteins that perturb proper cellular functions, often resulting in abnormal 
endosomal structures, which may then not be a true physiological 
representation of the actual markers found on MVBs within the cell. 
 
PIKfyve, like Vps27, contains a FYVE domain, which as already 
discussed is a domain specific for the binding of PtdIns(3)P.  This domain 
allows PIKfyve to be localised to the exact lipid which it phosphorylates, 
to give the product PtdIns(3,5)P2.  Although there is still some debate on 
the exact role of the product of PIKfyve, PtdIns(3,5)P2 has been 
implicated in the endo-lysosomal pathway so it is likely that PIKfyve does 
play some role in this pathway [62, 71].  In spite of this, PIKfyve is a 
difficult protein to study and thus the literature on PIKfyve is not as 
extensive as it is with other MVB proteins. 
 
Despite the lack of extensive studies carried out on PIKfyve, the few that 
are present in the literature have often provided conflicting reports as to 
what PIKfyve’s role within the mammalian cell is.   Regardless of the 
findings of PIKfyve’s involvements with endocytic trafficking and MVB 
defects, unlike ESCRT-I component mutants, one study found in 
Drosophila that fab1 mutant cells resulted in the accumulation of 
endocytosed receptors at endosomal membranes.  However this 
occurred with no accumulation of ubiquitin at these compartments, 
suggesting cargo was not ubiquitylated or had been deubiquitylated [84].   
Furthermore, the Drosophila fab1 mutant cells resulted in enlarged 
endosomal structures, which accumulated both receptors and ligands in 
late endosomal compartments.  These compartments contained ESCRT 
components (Hrs and Tsg101) however despite being enlarged 
compared with control cells, the cargo was found to be in the lumen of the 
compartment, suggesting MVB formation was not fully inhibited, although 
receptor degradation was [84].  Thus one of the conclusions of this study 
was that Fab1 does not affect silencing of endocytosed receptors but it 
does however affect their degradation.  Interestingly, it has similarly been 
shown in mammalian cells that CHMP3 depletion perturbs EGFR 
degradation but not its silencing. This is contrasted by earlier ESCRT 
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components such as Tsg101 which when silenced by siRNA result in 
endocytosed receptors still signalling at the endosomal membrane [56].  
These results imply a role of PIKfyve (and consequently PtdIns(3,5)P2) in 
the trafficking of MVBs to the lysosome as opposed to the actual 
formation of MVBs.  This may also be a potential role for ESCRT-III 
components given the similar findings, which could link these proteins as 
being necessary for a common trafficking pathway.   
 
Other recent studies have contradicted these findings suggesting an 
alternative role for that of PIKfyve in endosomal trafficking.  A recent 
study found that the suppression of endogenous PIKfyve by siRNA 
appears to result in enlarged early and late endosomal structures, 
however it does not affect the internalisation and degradation of EGFR 
nor the internalisation, degradation or recycling of the transferrin receptor 
(TfR) [86].  However in cells that have suppression of PIKfyve there was 
found to be abnormal early endosome to TGN retrograde trafficking.  The 
accumulation of membrane resulting in enlarged endosomal structures 
then was not put down to arresting the inward invagination process that 
occurs in MVB formation but rather the disruption in trafficking to the TGN 
due to suppression of endogenous PIKfyve.  It should be noted that MVB 
formation per se seemed to be unaffected in that cargo was still delivered 
to the MVB lumen and more importantly cargo was successfully degraded 
via the lysosome [86]. 
 
Other studies have suggested yet further roles for PIKfyve.  It has been 
stated that in some tumour cells EGFR is transported to the nucleus 
where it can transmit gene regulation properties.  In one study 
endogenous PIKfyve was apparently identified as a binding partner of 
endogenous EGFR and transient expression of wild-type PIKfyve resulted 
in an increase of EGFR found in the nuclei of cells compared with the 
kinase-dead mutant PIKfyve whose expression inhibited EGFR trafficking 
to the nucleus [87].  Furthermore, by silencing PIKfyve’s endogenous 
expression it was found that nuclear EGFR was significantly reduced. 
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Another study using an orthologue of PIKfyve/Fab-1 (PPK-3) found that 
deletion of this kinase in C. elegans is embryonic lethal with partial loss 
leading to growth retardation [88].  At the cellular level it was found that 
enlarged vacuoles were observed in many cell types, and that these 
vacuoles were positive for lysosomal markers such as LAMP-1.  From 
this study then it was concluded that the role of PPK-3 was in one of 
membrane retrieval from lysosomes and thus due to some mechanism 
through cellular PtdIns(3,5)P2 level control, PPK-3 was largely involved in 
the cellular process of lysosomal maturation [88].  Additionally it should 
be noted that protein and receptor degradation in the lysosome was 
unaffected by altering levels of PPK-3. 
 
These studies appear to suggest a rather complicated role of PIKfyve in 
endosomal trafficking, without distinct cellular functions being clear.  
Studies however seem to lack consistent findings in simply the 
localisation of PIKfyve, let alone what parts of the endocytic pathway this 
kinase helps control.  It is significant however that Rusten et al 
demonstrate that PIKfyve is necessary for the degradation of signalling 
receptors but not the silencing [84], which parallels the findings from 
Bache et al’s study of silencing CHMP3 [56].  As CHMP3 has been 
implicated as a potential binding partner of PIKfyve’s product, 
PtdIns(3,5)P2 [71], these two studies then are consistent with the roles of 
both PIKfyve and CHMP3 as being potential regulators for the trafficking 
of MVBs to the lysosome.  One thing that is certain from the literature 
however is that much work is needed to be carried out on PIKfyve to 
better understand its exact function in the mammalian cell and the role of 
PtdIns(3,5)P2 in the endo-lysosomal trafficking pathway. 
 
 
1.7  The AAA-ATPase Vps4 
 
The recruitment and binding to the membrane of CHMPs is only part of 
the process when it comes to proper ESCRT-III function and MVB 
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biogenesis.  It would appear that as well as binding to the membrane, 
removal of the ESCRT-III components from the membrane is just as 
crucial a step in MVB biogenesis.  The AAA-ATPase (ATPase associated 
with various cellular activities) Vps4 is the necessary ESCRT-associated 
component that allows this process to occur [52, 53, 80].  By mutating the 
glutamic acid (E) at position 235 in the Vps4B protein to glutamine (Q), a 
dominant negative Vps4 protein is obtained that is ATPase deficient [89].  
Over-expression of this dominant negative Vps4E235Q protein results in 
large, swollen endosomal structures, which perturb membrane receptor 
degradation and proper MVB formation.  In addition, ESCRT-III 
components localise to these swollen compartments, co-localising with 
the Vps4E235Q protein [71].  It would appear that Vps4 interacts with the C-
termini of CHMPs via a MIT (microtubule interacting and transport) 
domain at the N-terminus of Vps4 [89-91].  This interaction seems to be 
quite specific, with strong binding affinities for a conserved heptad leucine 
repeat found at the C-terminus of most CHMP proteins.  This process 
may be reliant of the autoinhibitory C-terminal domain being removed 
from the N-terminus.  With the C-terminal removed from inhibiting the N-
terminal domain of the CHMP, this allows membrane binding which 
occurs via the positively charged N-terminus.  The C-terminus of the 
CHMP is now exposed away from the surface of the endosomal 
membrane.  Upon oligomerisation of the ESCRT-III complex, the 
functional dodecameric Vps4 protein can interact with the C-terminal 
domains of various CHMP proteins.  This will allow for their removal from 
the membrane through a central pore in the Vps4 oligomer, due to ATP 
hydrolysis.  Without the capacity to effectively hydrolyse ATP, the mutant 
Vps4E235Q protein would then bind CHMPs via its MIT domain resulting in 
it becoming permanently bound to the C-terminus of CHMPs.  This would 
result in impaired MVB formation, due to ESCRT-III not being removed 
from the endosomal membrane, and a swollen endosome arising.  One 
can envisage then that perhaps the actual removal of the ESCRT-III 
machinery by Vps4 may play a crucial if not central role in the inward 
invagination and lumenal vesicle formation that occurs during proper 
MVB biogenesis. 
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In addition to the dominant negative Vps4E235Q protein, several mutant 
forms of ESCRT-III and related proteins have been produced and 
characterised.  In particular one protein of significance in this field has 
been the truncation of the CHMP3 protein.  As already discussed, 
CHMP3 has been reported to contain an autoinhibitory C-terminal 
domain.  Removal of this domain to leave a CHMP3 construct of roughly 
half its original size (N-terminus only) results in MVB defects and swollen 
endosomal phenotypes [78].  In addition to this, there have been several 
reports that merely adding a GFP molecule to the N-terminus of CHMP3 
results in impaired MVB formation and typical phenotypes associated with 
perturbed endosomal trafficking [78].  Constructs that contain a GFP-
fusion tag on the C-terminus of CHMP3 however do not exhibit such 
phenotypes [71, 78].  Additionally, it has been recently shown that varying 
the length of the truncation of the C-terminus of CHMP3 can alter how 
strong the phenotype is.  Truncations of CHMP3 that remove slightly less 
than half of the C-terminal domain (50-70 amino acids) give much 
stronger phenotypes associated with mutant CHMP3 than removal of the 
whole C-terminal half [78].  The exact reasons for the difference however 
in the strength of the phenotype are not clear. 
 
Such dominant negative mutants can prove very important for trying to 
better understand the full and proper function of the ESCRT and related 
proteins as cellular functions they may be involved with are often 
perturbed in such cases.  In addition, they may help provide us with clues 
about further interaction partners and other proteins that have not yet 
been identified but are important in proper MVB formation.  As mentioned 
already, the mechanism by which ESCRT proteins allow for MVB 
biogenesis and cargo delivery into the MVB lumen is poorly understood.  
In addition to this, the full complement of proteins involved with ESCRTs 
and MVB formation may also not be known, and indeed it is possible that 
there are other proteins involved in this process that have yet to be 
identified as playing a role in MVB formation.  Certainly ubiquitin for 
example has been shown to play a key role, however the exact 
recognition process is still under scrutiny.  Furthermore, it may be more 
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complex than simply mono-ubiquitination that determines a protein’s fate 
for lysosomal degradation [92, 93].  Additionally, there have been several 
deubiquitination proteins identified besides UBPY (Doa4 in yeast) which 
may also be involved somehow with deubiquitination of cargo when 
concentrated into ESCRT-containing MVB membranes [reviewed in 94]. 
 
As ESCRTs play a key and central role in the formation of MVBs for the 
proper downregulation of signalling receptors, one can imagine then that 
dysfunctional ESCRTs may result in signalling events being prolonged.  
Thus ESCRTs certainly play a key role in the basic control of signalling 
events which is obviously then important in certain disease states.  
Further to this however, there are several other disease states and 
cellular processes that ESCRTs play crucial roles in.  This emphasises 
the importance to more fully understand this class of proteins and their 
mechanisms. 
 
 
1.8  ESCRTs and retroviral budding, cytokinesis, other 
cellular functions and disease states 
 
One major area of research that has been under much scrutiny recently 
due to ESCRT involvement is that of viral budding, in particular HIV 
budding [65, 78, 95-103].  HIV spreads by the production of particles that 
enter uninfected cells and are released in extracellular virons that have 
bud from infected cells.  It would seem that the HIV virus hijacks some of 
the ESCRT machinery to escape from infected cells (Fig. 1.3A) [95].  
Certainly, the direction of budding of a virus at the plasma membrane is 
the same direction as that of vesicle formation into the lumen of the MVB, 
that is, away from the cytoplasm.  Thus it is of little surprise that the HIV 
virus has adapted to use similar machinery to that of MVB formation.  
HIV-1 viral protein components (Gag) have been shown to bind to 
Tsg101, an ESCRT-I component [99, 101, 102].  Furthermore, the 
expression of dominant negative CHMP proteins including CHMP1-4 
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results in the blocking of HIV-1 release and reduced infectivity [78].  More 
specifically, these dominant negative proteins appear to arrest HIV-1 
release at a late stage.  This leaves the mature viral particles in budding-
like structures from the plasma membrane, unable to pinch off from the 
membrane, staying connected by a thin stalk-like membrane construction.  
Not only is this the case with dominant negative CHMP proteins but also 
with a dominant negative ATPase deficient Vps4 protein.  This suggests 
that the ESCRT machinery and some associated proteins are vital for 
HIV-1 release from an infected cell, thus highlighting the importance of 
more fully understanding the mechanisms of ESCRT proteins.  
Furthermore these findings also suggest that the CHMP proteins along 
with Vps4 may be needed for the final “pinching off” of the membrane 
from invagination taking place in a direction that is away from the 
cytoplasm.  This may well then be that the specific role of ESCRT-III and 
Vps4 in MVB biogenesis and lumenal cargo delivery is related to actual 
vesicle formation instead of other roles such as in cargo recognition, or 
similar. 
 
As already mentioned, various truncations of CHMP3 that remove the 
autoinhibitory C-terminal domain have been described [78].  One of the 
ways in which the potency of these truncations was measured was in fact 
by measuring its effects on viral budding.  The wild type CHMP3 protein 
is 222 amino acids long, and original truncations of the C-terminus 
resulted in an N-terminal CHMP3 protein of 113 amino acids in length.  
The 113 amino acid protein did inhibit HIV-1 viral budding, however much 
shorter truncations of 200, 179 and 150 amino acids all inhibited HIV-1 
viral budding more potently [78].  The 150 amino acid truncation however 
was reported to be the most potent inhibitor of HIV-1 budding.  These 
results demonstrate not only the importance of the autoinhibitory C-
terminal domain but also the key role that CHMP3 plays in the budding 
and thus infectivity of the HIV-1 virus.  Further understanding the exact 
mechanisms as to how this occurs may be useful for developing 
therapeutic targets in the treatment of HIV infection.  
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Figure 1.4 – ESCRT proteins play a role in retroviral budding and cytokinesis.  (A) 
In mammalian cells infected with HIV-1 the virus hijacks the ESCRT machinery and 
related proteins (Vps4) to escape from the cell by budding off from the plasma 
membrane.  Dominant negative mutations in ESCRT components result in impaired 
infectivity of the virus due to inability to bud off the membrane [78].  (B) In cytokinesis the 
last stage is the abscission of the thin tether-like membrane that joins the two daughter 
cells together, to produce two separate cells.  Mutations in ESCRT proteins result in 
impaired cytokinesis and cells possessing multinuclei [104, 105].  These mutant ESCRT 
proteins are found at the mid-body of cytokinesis, in the protein dense Flemming body. 
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It has recently emerged that the ESCRT proteins also play a key role in a 
vital cellular process, that of cytokinesis [104, 105].  The process of 
cytokinesis is a highly precise yet complex process necessary for the 
formation of two daughter cells from a single parent cell.  During the final 
stages of cytokinesis, a mid-body is formed which is a thin tether-like 
structure connecting the two daughter cells together (Fig 1.3B).  The end 
of cytokinesis is typified by the abscission of this structure at the mid-
body, which seems to be an event heavily reliant on membrane dynamics 
[106].  This has been paralleled then to the abscission events that take 
place in retroviral budding, that is, the pinching off of the membrane stalk 
formed by viral buds, which seems to involve the ESCRT machinery 
[105].   
 
There are several theories as to how abscission occurs in cytokinesis to 
separate the two daughter cells.  Perhaps the most attractive theory is the 
trafficking of membrane vesicles to the mid-body where some apparent 
fusion event occurs allowing the separation of the two cells and 
abscission of the plasma membrane at this region [reviewed in 107; 108-
109].  It has recently been shown that some ESCRT and related proteins 
are present at the mid-body and the mutation or silencing of such proteins 
results in impaired cytokinesis that is paralleled to impaired retroviral 
budding [105]. 
 
In mammalian cells it seems apparent that Rab GTPase proteins are 
essential for cytokinesis, in particular Rab11 [110].  Rab11 has been 
shown to be a recycling Rab, involved with the trafficking of endosomes 
[111-113].  ESCRT proteins have also been found to be involved in 
cytokinesis, present at the mid-body prior to abscission, similar to Rab11.  
The area of research involving ESCRT proteins and cytokinesis is very 
recent, and much of this initial work has focused on the earlier ESCRT 
and associated proteins, for example ESCRT-I proteins.  TSG101 
(Vps23) is a component of the mammalian ESCRT-I complex, and this 
was found to localise to the mid-body in cytokinesis, more specifically a 
dense structure at the mid-body known as the “Flemming body,” which is 
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known to contain many other proteins involved in abscission.  TSG101 
appears to be localised to the mid-body by interactions with the 
centrosomal protein Cep55, which also localises to the mid-body in 
cytokinesis, suggesting a role for ESCRT proteins then in the process of 
cytokinesis [105].  Furthermore, depleting cells of TSG101 resulted in 
abnormal cytokinesis typified by the presence of multinucleated cells, 
adding further evidence that TSG101 is important in proper cytokinesis 
[105]. 
 
Further to this, a component of ESCRT-III as well as the AAA-ATPase 
Vps4 was also investigated for potential roles in cytokinesis [104, 105].  It 
was found that overexpression of dominant negative versions of CHMP4 
and Vps4 both inhibited proper cytokinesis and gave abnormally high 
levels of multinucleated cells.  Note however that ESCRT-II components 
were not found to have such an effect on cytokinesis when dominant 
negative constructs or RNA interference was used.  Thus these findings 
highlight the diversity of the ESCRT proteins’ role within the cell further 
than simply MVB biogenesis.  It is likely then that the function of ESCRT 
and related proteins in cytokinesis is very similar to the role that 
retroviruses such as HIV-1 hijack the machinery for.  Indeed in all 
scenarios there is a requirement for an abscission event to occur, and 
clearly in both HIV-1 viral budding and cytokinesis, defects in certain 
ESCRT components result in these events being disrupted.  As these 
events are heavily reliant on membrane dynamics in their late stages, it 
may be postulated that the ESCRT complexes along with Vps4, in 
particular ESCRT-III and Vps4 being the last complex on MVBs, are 
similarly heavily involved in the membrane dynamic events that occur in 
lumenal vesiculation at the MVB. 
 
Although retroviral infection and budding along with cytokinesis are very 
important fields of study, ESCRT proteins have further been implicated in 
several other cellular pathways and disease states as well.  Certainly 
many neurodegenerative diseases have had components of their 
pathology attributed to aberrant endosomal pathways and dysfunction of 
 37 
ESCRT proteins.  ESCRT-III has been identified to play a role in 
autophagasome accumulation and neurodegeneration due to loss of 
expression of certain CHMP proteins [114, 115].  Autophagy is an 
important process that allows for cellular processes such as the turnover 
of aggregated proteins as well as organelles and other cytosolic 
components.  Aggregated proteins in neuronal cells are a hallmark of 
many age-related neurodegenerative diseases, such as Alzheimer and 
Huntington’s diseases.  ESCRT proteins then play a key role in 
autophagy due to their importance in MVB trafficking to the lysosome.  
Thus loss of function of ESCRT components in neuronal cells can result 
in such neurodegeneration occurring. 
 
MVB and ESCRT proteins have also been shown to be involved in other 
events, such as antigen presentation in T-cells, Notch signalling in 
development, exosome release, cancers, and even in disease states 
such as cataracts [19, 45, 116].  Thus understanding the exact roles and 
mechanisms of action for the ESCRT complexes is very important and 
would certainly enable us to better understand certain disease states and 
crucial cellular processes, allowing for better therapeutics and 
approaches to research in these areas. 
 
 
1.9  Experimental aims of the project described in the 
thesis 
 
There were three main experimental aims of this thesis: 
To more fully understand the role of lipids, in particular PtdIns(3,5)P2 in 
MVB biogenesis. 
To better characterise proteins in and associated with the ESCRT-III 
complex, in particular CHMPs, PIKfyve and Vps4. 
To further investigate dominant negative mutations in CHMPs and their 
resultant effects in mammalian cells. 
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Investigations to better understand the role of PtdIns(3,5)P2 in MVB 
formation were undertaken using a protein expressed by Salmonella 
bacteria as a potential tool for manipulating PtdIns(3,5)P2 levels.  The 
localisation of this protein, SopB, was determined by 
immunofluorescence studies and its effects on the degradation of the 
tyrosine-kinase receptor EGFR were also investigated, by utilising a 
strain of Salmonella that had the expression of SopB deleted. 
 
Secondly, investigations were carried out to better characterise PIKfyve, 
the mammalian enzyme responsible for the production of PtdIns(3,5)P2 
from PtdIns(3)P.  As this protein has not been studied for very long, there 
was no known commercial antibody, so much of this work was focused 
on the production and characterisation of an antibody that would 
recognise PIKfyve.  Furthermore, to aid in the aim to better understand 
the ESCRT-III complex and proteins associated with it, an assay was 
devised and set-up, which would allow a possible mass proteomic 
approach to the full complement of proteins that are found on MVB 
membranes.  This was achieved using a relatively new tagging and 
labelling technique, known as Halo-tag, and involved isolating swollen 
endosomal compartments that the dominant negative Vps4E235Q was 
found on when expressed in mammalian cells. 
 
Finally, the effects of truncating and various mutations of CHMP proteins, 
in particular CHMP3 was looked at more fully.  Previously described 
truncations of CHMP3 and point mutations were investigated to see their 
effects on endosomal trafficking as well as membrane binding abilities.  
The effects of such mutant proteins expressed in mammalian cells on 
cytokinesis were also investigated. 
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CHAPTER 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
2  Materials and Methods 
 
 
2.1  Materials 
All general laboratory chemicals were of analytical grade and purchased 
from either Sigma-Aldrich Chemical Company or Fisher Scientific UK Ltd. 
unless otherwise stated. 
 
2.1.1  Buffers 
Phosphate Buffered Saline (PBS):  
154 mM NaCl, 12.5 mM Na2HPO4.12 H2O, (pH 7.2). 
 
Tris Buffered Saline - Tween 20 (TBST):  
10 mM Tris, (pH 7.4), 154 mM NaCl, 0.1% (v/v) Tween-20. 
 
Sample Buffer:  
Protein samples were solubilised in 2% (w/v) SDS, 62.5 mM Tris HCl (pH 
6.8), 0.01% (w/v) bromophenol blue, 10% (v/v) glycerol with the reducing 
agent being 100 mM Dithiothreitol (DTT). 
 
Resolving Gel Buffer:  
1.5 M Tris HCl, 0.4% (w/v) SDS, (pH 8.8). 
 
Stacking Gel Buffer:  
0.5 M Tris HCl, 0.4% (w/v) SDS, (pH 6.1). 
 
Electrophoresis Running Buffer:  
25 mM Tris HCl, (pH 6.3), 0.1% (w/v) SDS, 0.2 M Glycine. 
 
Transfer Buffer:  
39 mM Glycine, 48 mM Tris, 0.0375% SDS (w/v), 20% methanol (v/v), 
(pH 8.8). 
Ponceau S Stain:  
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0.1% (w/v) Ponceau S, 3% (w/v) trichloroacetic acid. 
Coupling Buffer:  
0.2 M NaHCO3, 0.5 M NaCl 
 
ELISA Plate Coating Buffer:  
15 mM Na2CO3, 35 mM NaHCO3, 0.01% (v/v) Na Azide, (pH 9.6). 
 
ELISA Plate Blocking Buffer:  
PBS, 0.1% (v/v) Tween-20, 1% (w/v) Casein, add casein and dissolve 
with mixing overnight at 4°C. 
 
Luria Broth (LB):  
1% (w/v) Bacto™ Tryptone [BD Biosciences], 0.5% (w/v) Bacto™ Yeast 
Extract [BD Biosciences], 0.5% NaCl, (pH 7.5; autoclaved). 
 
Agar Plates:  
1% (w/v) Bacto™ Tryptone [BD Biosciences], 0.5% (w/v) Bacto™ Yeast 
Extract [BD Biosciences], 0.5% NaCl, 1.5% (w/v) Agar, (pH 7.5) 
(autoclaved). 
 
ECL Reagent: 
Solution A – 100 mM glycine (pH 10), 0.4 mM luminol, 8 mM 4-
iodophenol 
Solution B – 0.12% (w/w) hydrogen peroxide in water 
 
TESA Buffer: 
255 mM sucrose, 5 mM EDTA, 10 mM Tris-HCl, 2 mM ATP, pH 7.2 
 
2.1.2  Antibodies 
Table 2.1 gives a list of antibodies along with their suppliers and dilutions 
used for different applications.  For immunofluorescence studies, primary 
and fluorescent secondary antibodies were diluted in PBS containing 2%  
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Table 2.1 – Various antibodies used experimentally.  In-house antibodies (α-CHMP2, 
3 and 4) were already made and purified by Dr Paul Whitley.  α-PIKfyve production and 
purification is discussed in Chapter 4.  All antibodies are polyclonal unless stated and 
where known, clone numbers are given.  Dilutions are of original supplied stocks.  
Abbreviations: IF = immunofluorescence, IP = immunoprecipitation, WB = Western 
blotting. 
Antibody Species Source Dilution / Application 
α-EGFR (Trans Labs) 
mouse, 
monoclonal 
Transduction 
Laboratories 
WB – 1:2000 
IF – 1:250 
α-GFP rabbit serum 
Molecular 
Probes 
WB – 1:1000 
α-GFPIgG2a 
mouse, 
monoclonal 
Molecular 
Probes 
IP – 2-4µg 
α-EEA1 rabbit 
Gift, Dr Michael 
Clague 
IF – 1:1000 
α-myc 4A6 
mouse, 
monoclonal 
Upstate IF – 1:300 
α-FLAG M2 
mouse, 
monoclonal 
Sigma  
WB – 1:3000 
IF – 1:300 
α-His6 
mouse, 
monoclonal 
Amersham WB – 1:2000 
α-TSG101 4A10 
mouse, 
monoclonal 
Abcam WB – 1:500-1000 
α-β,tubulin TUB2.1 
mouse, 
monoclonal 
Sigma WB – 1:1000 
α-Vps4 rabbit Santa Cruz WB – 1:1000 
α-HA 
rat, 
monoclonal 
Roche IF – 1:300 
α-M6PR rabbit 
Gift, Dr Paul 
Luzio 
IF – 1:1200 
α-TGN46 sheep Serotec IF – 1:300 
α-CHMP2 rabbit In-house WB – 1:200 
α-CHMP3 rabbit In-house WB – 1:200 
α-CHMP4 rabbit In-house WB – 1:200 
α-PIKfyve sheep 
In-house, see 
chapter 4 
WB - 1:4000 
α-CD63 
mouse, 
monoclonal 
BD Biosciences IF – 1:1000 
α-Ub FK2 
mouse, 
monoclonal 
Biomol WB – 1:1000 
α-Rab11IgG2a mouse 
BD Transduction 
Laboratories 
IF – 1:50 
α−mouse Alexa Fluor 
546 
goat 
Molecular 
Probes 
IF – 1:100 
α−rabbit Alexa Fluor 546 goat 
Molecular 
Probes 
IF – 1:100 
α-mouse-HRP goat Sigma 1:2000-5000 
α-rabbit-HRP goat Pierce 1:5000+ 
α-sheep-HRP goat Pierce 1:5000+ 
 43 
(v/v) fetal calf serum (FCS).  Primary antibodies used for Western blotting 
were diluted in TBST containing 5% (w/v) Marvel®, whereas secondary 
horse-radish peroxidase (HRP) conjugated antibodies were diluted in 
TBST containing 1% (w/v) BSA. 
 
 
2.2  Methods 
 
2.2.1  Tissue culture 
 
Cos7 (African green monkey kidney), A431 (a human epidermoid 
carcinoma cell), HeLa (Human cervix carcinoma), NRK cells (normal rat 
kidney cell line) and CHO-K1 (Chinese hamster ovary) cells were the 
mammalian cell lines used. Cells (except CHO-K1) were maintained at 
37oC, 5% CO2 (except A431 cells which were maintained at 10% CO2) in 
Dulbecco’s modified minimal essential medium (DMEM) containing 10% 
fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin.  CHO-K1 cells were maintained similarly except in Ham’s 
F12 medium supplemented as DMEM.  All media and media supplements 
(including sterile Dulbecco’s PBS; DPBS) were purchased from Cambrex, 
and mammalian cells were originally purchased from ATCC. 
 
 
2.2.2  General Immunofluorescence studies 
 
Cells were plated onto glass coverslips in 35mm or 16mm wells and 
grown until ~60-80% confluent prior to transfection using Lipofectamine 
2000™ (Invitrogen) or FuGENE 6 transfection reagent (Roche 
Diagnostics) or TransIT-LT1 (Mirus) according to the manufacturer’s 
instructions. Cells grown on glass cover slips were transfected ~16 hours 
prior to fixation (unless stated otherwise) and processed for 
immunofluorescence microscopy as follows.  
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Media was removed from cells and cells were then rinsed once with PBS 
and fixed with 4% (w/v) paraformaldehyde (PFA) dissolved in PBS for 20 
minutes. Cells were then permeabilised using methanol at -20oC for 5 
minutes.  Primary antibodies were diluted in PBS containing 2% FCS and 
incubated with the cells for 2 hours at ~18oC. Appropriate species-specific 
fluorophore conjugated secondary antibodies were also diluted in PBS 
containing 2% FCS.  Incubations with secondary antibodies were for 1 
hour at ~18oC in the dark. Cells were washed 5 times for 5 minutes in 
PBS containing 2% FCS following all antibody incubations with a further 3 
washes in PBS alone.  In immunofluorescence studies where nuclear 
staining was necessary, a 1:500 dilution of DAPI was used during the 
secondary antibody incubation.  Cover slips were mounted in Mowiol 
(Calbiochem). Cells were examined and images obtained on a Zeiss 
LSM510 laser scanning confocal microscope unless stated. 
 
Wortmannin treatment: 
Transfected cells were treated with 500 nM wortmannin with the media 
being changed to fresh wortmannin every 1 hour for a period of 3 hours 
after which they were fixed and processed as necessary. 
 
2.2.2.1  HaloTag fluorescent labelling 
 
Fluorescent labelling of cells expressing proteins with the HaloTag were 
processed according to the manufacturer’s instructions (Promega).  
Briefly, at least 16 hours post-transfection the media covering the cells 
was removed to leave 100µl in each 16mm well.  A further 100µl of the 
diluted Halo-ligand (diluted 1:500; either diAcFAM or TMR ligands) was 
added to each well and cells incubated at 37oC, 5% CO2 in the dark for 
15 min.  After 15 min incubation, media was removed, cells washed twice 
with PBS and then fixed in 4% PFA being processed as other 
immunofluorescence studies. 
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2.2.2.2  EGF degradation studies 
 
HeLa cells were transfected with appropriate constructs as above and 
allowed to express for 24 hours until serum-containing medium was 
removed and replaced with DMEM containing 1% BSA.  Cells were 
serum starved overnight for 16 hours and then incubated with 500ng/ml 
Alexa-Fluor® 555-conjugated EGF (Invitrogen) for 2 minutes or 60 
minutes at 37oC in the dark.  Cells were then fixed and viewed under a 
confocal microscope.  
 
2.2.2.3  Multinucleation counts 
 
HeLa cells were seeded on 13 mm coverslips 24 hours prior to 
transfections.  Cells were then transiently transfected with various 
constructs.  Cells were fixed 24 hours post-transfection and 
immunostained with anti-ubiquitin followed by Alexa® Fluor 568-
conjugated IgG secondary antibodies and DAPI.  All transfected cells 
present on the coverslip were then scored for multinucleation and the 
results were represented graphically as percentages of multinucleate 
cells (Graphpad Prism; averaged over 3 experiments). 
 
 
2.2.3  Salmonella infection studies 
 
Wild type and ∆SopB Salmonella dublin strains have been described 
previously.  A431 cells were seeded at ~ 100,000 cells/well into 35mm 
tissue culture wells (containing a glass cover slip if the cells were later to 
be used for immunofluorescence studies) and were maintained for 3 days 
at 37oC in a 10% CO2 incubator.  Cells were infected with log phase 
Salmonella cultures that had been grown overnight in LB medium 
(supplemented with 30 µg/ml kanamycin when required) and subcultured 
(1:25 dilution) for ~ 3 hours in fresh medium.  Bacteria for inoculation 
were prepared by pelleting at 10,000 x g for 2 minutes and 
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resuspending/diluting in PBS.  The A431 cells were infected with ~5x107 
bacterial cells (multiplicity of infection of ~100:1) for 1 hour. Cells were 
washed with PBS prior to fixation and processing for immunofluorescence 
or further downstream processing. 
 
 
2.2.4  EGFR degradation studies of Salmonella infected 
cells 
 
A431 cells were infected with Salmonella as described above, with the 
following modifications.  Cells were grown in 35mm tissue culture wells 
without a cover slip. 16 hours prior to infection, the A431 cells were 
washed twice with PBS and the medium was changed to a reduced 
serum medium lacking antibiotics (DMEM containing 1% bovine serum 
albumin 2mM L-glutamine).  Following infection the media was removed, 
cells were washed twice in PBS and fresh DMEM, 1% BSA 2mM 
glutamine was added.  Cells were immediately stimulated with 500 ng/ml 
EGF (Calbiochem) for different times (0, 8 and 16 minutes).  Following 
EGF stimulation A431 cells were washed in ice cold PBS and then 
harvested in 100 µl RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
0.5% Na-deoxycholate, 0.1% SDS, 0.1% NP40) containing protease 
inhibitor cocktail for mammalian cell extracts (Sigma).  The protein 
concentrations of the cell lysates were determined using BCA reagent 
(Pierce).  40 µg of each sample was separated by SDS PAGE, 
transferred to nitrocellulose membranes and immunoblotted for the 
presence of the EGFR and β-tubulin.  Signals were detected by ECL and 
quantified using an Optichem detector with associated software (Ultra 
Violet Products).  For quantification, the amount of EGFR was normalised 
to the amount of β-tubulin (loading control) in the same sample. 
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2.2.5  Protein biochemistry techniques 
 
Protein Assay: 
The bicinchoninic acid (BCA) protein assay (Pierce) was used to 
determine protein concentrations.  A standard curve of BSA was 
prepared with a range of 0-10µg total BSA protein from a stock of 2 
mg/ml.  The BCA working solution was prepared by adding Reagent A 
and Reagent B together in a ratio of 50:1.  200 µl of this was then added 
to each of the wells of a 96-well plate containing standard or appropriate 
samples.  The plate was incubated at 37oC for 30 min, and then read on a 
Spectra Rainbow Thermo microplate spectrophotometer (Tecan) at 565 
nm.  Results were analysed using Microsoft Excel to determine unknown 
protein concentration estimations. 
 
Sodiumdodecyl Sulphate – Poly-Acrylamide Gel Electrophoresis (SDS-
PAGE): 
Electrophoresis was carried out using the Laemmli discontinuous buffer 
system [117].  Gels were of 1.5 mm thickness and prepared using 
acrylamide/bis-acrylamide (30% (w/v) acrylamide) and gel buffers already 
described.  Polymerisation of the gels was instigated by the addition of 
10% (w/v) ammonium persulphate (APS) and N,N,N,N’-
tetramethylethylenediamine (TEMED).  The composition of the resolving 
and stacking gels resulting in different gel percentages is given in Table 
2.2.  Unless otherwise stated, 50µg of protein samples were solubilised 
by the addition of sample buffer containing a reducing agent and 
incubated for 15-20 min at room temperature with occasional vortexing.  
Samples were loaded onto the gels with different broad range markers as 
described in Table 2.3.  The gels were run at 30 mA per gel for about 45 
min until the dye front had just run out of the gel.  
 
Transfer of proteins to nitrocellulose membrane: 
Following SDS-PAGE, gels were soaked along with fourteen pieces of 
filter paper and one nitrocellulose membrane cut to size, in transfer buffer 
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for ~ 5 min.  Seven pieces of the filter paper were then placed on the 
anode of the electrophoretic apparatus with any air bubbles being 
removed.   The nitrocellulose membrane was then placed on top of the 
first seven pieces of filter paper with the gel then carefully laid on top of 
this.  Finally, the last seven pieces of filter paper were placed on top of 
this gel stack and smoothed out to remove any last air bubbles.  The 
cathode was placed on top of this assembly and secured.  Transfer of 
proteins was completed by running the electrophoretic apparatus at 1 mA 
per square cm of nitrocellulose membrane for 150 min.  Typically each 
gel and nitrocellulose membrane was of dimensions 9 cm wide by 6 cm in 
length.  Following the transfer, nitrocellulose membranes were briefly 
washed in ddH2O to remove any transfer buffer or gel remnants, and 
incubated briefly with Ponceau S stain for confirmation of protein and lane 
identification. 
Table 2.2 – Volumes of stock solutions used for making SDS-PAGE gels.  6% gels 
were used for separation of higher molecular weight proteins.  12% gels were used for 
lower molecular weights.  Volumes given are for one mini-gel. 
 
Western blotting: 
Following transfer of proteins separated by SDS-PAGE onto 
nitrocellulose membranes, Western blotting techniques were performed.  
Briefly, membranes were washed in TBST to remove all Ponceau S stain 
and then blocked using 5% (w/v) Marvel dissolved in TBST, for at least 
30 min.  Membranes were then washed twice in TBST to remove any 
Stock Solutions 
Resolving Gel 
    6%              12% 
Stacking    
Gel 
Resolving gel buffer (ml) 2.5 2.5 - 
Stacking gel buffer (ml) - - 1.25 
Acrylamide stock (ml) 1.5 3.0 0.85 
Double-distilled water (ml) 3.5 2.0 1.875 
Ammonium persulphate (µl) 50 50 20 
TEMED (µl) 4 40 5 
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blocking agent and incubated with the primary antibody for ~ 2 hr at room 
temperature.  Membranes were then washed for a minimum of 5 washes 
in TBST, each wash lasting a minimum of 5 min.  Secondary HRP-
conjugated (unless stated) antibodies were incubated with membranes 
for ~ 1 hr at room temperature.  Final washes were carried out similar to 
washes after primary antibody incubations.  Membranes were then 
incubated for 1 min with equal volumes of Solution A and B of the ECL 
Reagent or 5 min when using ECL Advanced Reagent (Amersham).  
Membranes were then developed and images taken using an EPI Chemi 
II darkroom (UVP) with a Hamamatsu camera attached.  Labworks 
version 4 (UVP) was used for analysis and quantification of bands 
performed with the Western blots. 
 
Table 2.3 – Molecular weight markers run on SDS-PAGE gels.  The prestained 
protein broad range markers (New England Biolabs) were primarily used for SDS-PAGE 
and identification of proteins from Western blotting.  The multicoloured markers 
(Invitrogen) were used when identification of proteins larger than 200kDa was 
necessary. 
 
2.2.6  Molecular biology techniques 
 
Standard protocols for recombinant DNA manipulations were used.  
Table 2.4 shows the main specific constructs and plasmids the relevant 
construct was cloned into.  The GFP expression plasmid used to 
Prestained Protein Marker, Broad 
Range 
Multicoloured Standard 
Protein Mol Weight (kDa) Protein Mol Weight (kDa) 
MBP-b-galactosidase 175 Myosin 250 
MBP-paramyosin 83 Phosphorylase B 148 
Glutamic dehydrogenase 62 Glutamic dehydrogenase 60 
Aldolase 47.5 Carbonic anhydrase 42 
Triosephosphate isomerase 32.5 Myoglobin blue 30 
b-Lactoglobulin A 25 Myoglobin red 22 
Lysozyme 16.5 Lysozyme 17 
Aprotinin 6.5 Aprotinin 6 
  Insulin 4 
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transform S. dublin strains for use in immunofluorescence microscopy 
was pSU2007. 
 
2.2.6.1  DNA constructs cloned 
 
When cloning desired constructs, the polymerase chain reaction (PCR) 
was used in conjunction with specifically designed primers for the 
template DNA.  Table 2.5 shows a typical cycle for PCR that was used 
when cloning constructs throughout the experimental side of this thesis.  
Note the annealing temperature generally varies based upon the lowest 
Tm of the primers used, as indicated. 
 
DNA 
Construct Plasmid Manipulations/Notes 
Tag on 
protein 
pEGFPC1 GFP 
pHM6 
Previously constructed, rat 
HA 
pHT2 Cloned, see below Halo 
Vps4 
pTRE2pur Cloned, see below Halo 
pEGFPC1 GFP 
pHM6 
Previously constructed, rat 
HA 
pHT2 Cloned, see below Halo 
Vps4E235Q 
pTRE2pur Cloned, see below Halo 
pEGFPC1 GFP 
CHMP3 
pFLAG-CMV5c 
Previously constructed, rat 
FLAG 
pEGFPC1 Cloned, see below GFP 
CHMP31-179 
pFLAG-CMV5c Cloned, see below FLAG 
pEGFPC1 Cloned, see below GFP 
CHMP31-150 
pFLAG-CMV5c Cloned, see below FLAG 
CHMP31-112 pEGFPC1 Previously constructed, rat GFP 
CHMP31-179M1 pEGFPC1 Quickchange mutagenesis (Clontech) kit used on CHMP31-179 GFP 
CHMP31-179M2 pEGFPC1 Quickchange mutagenesis (Clontech) kit used on CHMP31-179 GFP 
PIKfyve pcdna3-EGFP GFP 
PIKfyve MUT pcdna3-EGFP 
Gift, Dr Pete Cullen 
GFP 
FENS-FYVE pEGFPC2-iFENS-FYVE-1 Gift, Dr Michael Clague GFP 
pRK5myc CMV promoter, previously constructed. myc 
SopB 
pHM6 Cloned, see below HA 
pRK5myc CMV promoter, previously constructed. myc 
SopBC460S 
pHM6 Cloned, see below HA 
 
Table 2.4 – Mammalian DNA constructs used experimentally in this thesis.  Several 
constructs used were already designed and made prior to the commencement of this 
work.  In the case of DNA constructs that were made during this thesis, the details of 
these can be found in experimental methods below. 
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PCR Stage Temperature Time Repeat 
1 - Denaturation 95oC 1 min  
2 - Denaturation 94oC 1 min  
3 - Annealing 65oC * 30 sec  
4 - Elongation 72oC 2 min** Go to step 2 (x 29) 
Hold 4oC   
 
Table 2.5 – A typical PCR cycle used.  *Annealing temperature varies depending on 
the lowest Tm of primers used.  Typcially annealing temperature is 5
oC lower than the 
smallest Tm of primers.  **The time for elongation depended upon the length of the DNA 
that was being amplified – 1 min was used for every kb of DNA. 
 
Additionally, the PCR reaction volume included the following components: 
• 500 ng of the appropriate DNA template 
• 10 x polymerase reaction buffer (usually 5 µl if PCR reaction 
volume is 50 µl) 
• 0.2 mM dNTPs (New England Biolabs) 
• 0.4 µM of each oligonucleotide primer 
• 0.05 U Pfu polymerase enzyme (Stratagene) 
This mixture was usually made up to a total volume of 50 µl by using 
ddH2O.  MWG Biotech’s sequencing service was used to confirm correct 
DNA sequences of all constructs cloned.  For lists of primers used in 
cloning, see Table 2.6. 
 
SopB-HA and SopBC460S-HA: 
The SopB and SopBC460S genes that had been originally cloned into the 
pRK5myc vector were used as templates to amplify the fragments for 
isolation.  Primers were used that introduced an EcoRI and HindIII 
restriction sites to either end of the gene (see Table 2.6, No. 1-2).  
Following the PCR cycle, the products were run on a 1% (w/v) agarose 
gel and identified as 1.6 kb bands, which were subsequently cut out of 
the gel and purified.  Following gel purification, 5 µl of each fragment 
were end-converted using an end-conversion kit (Novagen) according to 
the manufacturer’s instructions.  Fragments were then ligated into a pT7 
vector (Novagen) by addition of 50ng of the pT7 vector and 1 µl of T4 
DNA ligase, and incubated at 22oC for 15 min.  1.5 µl of the ligation 
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product was transformed into NovaBlue® supercompetent cells using 
standard transformation techniques. 
 
DNA isolated from the transformations were digested using EcoR1 and 
HindIII (Promega), and positive colonies were identified from this 
digestion by agarose gel electrophoresis, and the correct fragment was 
gel extracted and purified.  2 µl (200ng) of this fragment was ligated to 2 
µl (100ng) of a pHM6 vector already cut with EcoR1 and HindIII using T4 
DNA ligase, at 22oC for 1 hr.  The resultant ligation was transformed into 
XL-1 blue cells and colonies were checked for a successful clone by 
digestion and electrophoresis by use of DNA ladders and comparison 
with uncut DNA. 
 
Halo-Vps4WT and Halo-Vps4E235Q: 
Primers for the Vps4WT and Vps4E235Q Halotag® cloning were designed 
against the rat sequences with NaeI and NotI sites incorporated (Table 
2.6, 3-4), and the pEGFPC1-Vps4WT and –Vps4E235Q constructs used as 
templates.  Fragments were similarly manipulated as described above 
(SopB-HA and SopBC460S-HA), being cloned into pT7 blue vectors prior to 
subcloning into the pHT2 vector.  Positive colonies for Halo-Vps4E235Q 
were identified, so to generate the Halo-Vps4WT construct, site directed 
mutagenesis of Halo-Vps4E235Q was carried out.  Primers were designed 
according to the Stratagene Quickchange protocol to mutate Q235 of 
Halo-Vps4E235Q to a glutamic acid (Table 2.6, 5-6), via a single nucleotide 
change (c891g).  By following the manufacturer’s instructions 
(Stratagene) successful clones of Halo-Vps4E235Q were mutated to give 
Halo-Vps4WT. 
 
pTRE2pur-Halo-Vps4WT and –Vps4E235Q: 
The Halo-Vps4WT and Halo-Vps4E235Q constructs cloned previously were 
used to obtain a Halo-Vps4WT and Halo-Vps4E235Q fragments.  This was 
achieved by cutting the 2 µg Halo-tagged constructs firstly with NotI 
enzyme overnight.  The cut product was run on an agarose gel and gel 
purified (Promega kit) to obtain pure NotI cut pHT2-Halo-Vps4WT and 
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pHT2-Halo-Vps4E235Q DNA fragments.  These were then cut as usual for 
3 hours with the PvuII restriction enzyme to give the fragments Halo-
Vps4WT and Halo-Vps4E235Q with NotI and PvuII cut ends.  This was 
directly cloned by ligation into the pTRE2pur vector, which had also been 
cut with both NotI and PvuII enzymes.  The ligation was checked by 
cutting with the enzyme NheI, a restriction site not present in the 
fragments but present in the vector.  Transformations into NovaBlue® 
single competent cells were carried out, and successful clones checked 
by colony PCR.  One successful clone for pTRE2pur-Halo-Vps4E235Q was 
identified, and using the Stratagene Quickchange mutagenesis technique 
(primers already made, see Table 2.6, 5-6) to convert Q at 235 back to E, 
successful clones of pTRE2pur-Halo-Vps4WT were also obtained. 
 
Truncated CHMP3 constructs and mutants: 
Forward oligonucleotide primers for GFP-CHMP3 and FLAG-CHMP3 
DNA sequences had been previously used in the lab (Table 2.6, 7, 9, 11, 
13), with a HindIII restriction site present for the FLAG-CHMP3 and a 
BglII restriction site for GFP-CHMP3.  For generation of the truncated 
FLAG-CHMP31-150 and GFP-CHMP31-150, primers were appropriately 
designed containing Acc65i restriction sites (Table 2.6, 8 and 10 
respectively) just prior to the amino acid at position 150 or 179 of FLAG-
CHMP3 appropriately.  This was similar for the cloning of FLAG-CHMP31-
179 and GFP-CHMP31-179 (Table 2.6, 12 and 14 respectively).  Constructs 
were amplified by PCR and manipulated as already described, cloning 
into the pT7 vector then followed by sub-cloning into the pFLAG-CMV5c 
or pEGFPC1 vector for FLAG- and GFP-tagged constructs respectively. 
 
2.2.6.2  DNA Digestions 
 
To check for successful clones from PCR products digestions of the 
cloned DNA were used, employing restriction enzymes that cleaved the 
DNA at points within the cloned product and/or outside of the cloned 
region (in the vector).  This technique along with size estimations was 
 
5
4
 
 
N
o
. 
P
ri
m
e
r 
n
a
m
e
 
S
e
q
u
e
n
c
e
 
U
s
e
/N
o
te
s
 
1
 
S
o
p
B
-E
co
R
1
 
5
’
-
c
t
c
g
a
a
t
t
c
t
c
a
a
g
a
t
g
t
g
a
t
t
a
a
t
g
a
a
g
a
a
a
t
-
3
’
 
F
W
D
 p
ri
m
e
r 
- 
S
o
p
B
- 
+
 S
o
p
B
C
4
6
0
S
-H
A
 
2
 
S
o
p
B
-H
in
d
II
I 
5
’
-
c
a
c
a
a
g
c
t
t
g
a
t
g
c
a
a
a
t
a
c
a
g
a
g
c
t
t
c
t
a
t
c
a
c
t
-
3
’
 
R
E
V
 p
ri
m
e
r 
- 
S
o
p
B
- 
+
 S
o
p
B
C
4
6
0
S
-H
A
 
3
 
V
p
s4
-N
a
e
I 
5
'
-
g
a
g
g
c
c
g
g
c
a
t
g
g
c
g
t
c
c
a
c
g
a
a
c
a
c
c
a
a
c
c
t
g
-
3
'
 
F
W
D
 p
ri
m
e
r 
- 
H
a
lo
-V
p
s4
 +
 -
V
p
s4
E
Q
 
4
 
V
p
s4
-N
o
tI
 
5
'
-
g
a
g
g
c
g
g
c
c
g
c
t
t
a
g
c
c
t
t
c
c
t
g
g
c
c
a
a
a
a
t
c
t
t
c
-
3
'
 
R
E
V
 p
ri
m
e
r 
- 
H
a
lo
-V
p
s4
 +
 -
V
p
s4
E
Q
 
5
 
V
p
s4
Q
E
-F
W
D
 
5
'
-
c
c
a
t
c
a
t
c
t
t
c
a
t
c
g
a
t
g
a
g
a
t
t
g
a
c
t
c
t
c
t
g
t
g
c
-
3
'
 
F
W
D
 p
ri
m
e
r 
fo
r 
S
D
M
 o
f 
V
p
s4
E
Q
 
6
 
V
p
s4
Q
E
-R
E
V
 
5
'
-
g
c
a
c
a
g
a
g
a
g
t
c
a
a
t
c
t
c
a
t
c
g
a
t
g
a
a
g
a
t
g
a
t
g
g
-
3
'
 
R
E
V
 p
ri
m
e
r 
fo
r 
S
D
M
 o
f 
V
p
s4
E
Q
 
7
 
C
H
M
P
3
1
-1
5
0
F
L
A
G
-H
in
d
II
I*
 5
'
-
g
a
g
a
a
g
c
t
t
a
t
g
g
g
g
c
t
g
t
t
t
g
g
a
a
a
a
a
c
c
c
a
a
g
-
3
'
 
F
W
D
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
5
0
 F
L
A
G
 
8
 
C
H
M
P
3
1
-1
5
0
F
L
A
G
-A
cc
 
5
'
-
c
t
c
g
g
t
a
c
c
t
g
c
t
t
t
c
a
a
a
c
g
t
a
t
c
c
t
c
t
a
-
3
'
 
R
E
V
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
5
0
 F
L
A
G
 
9
 
C
H
M
P
3
1
-1
5
0
G
F
P
-B
g
l*
 
5
'
-
g
a
g
a
g
a
t
c
t
a
t
g
g
g
g
c
t
g
t
t
t
g
g
a
a
a
a
a
c
c
-
3
'
 
F
W
D
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
5
0
 G
F
P
 
1
0
 
C
H
M
P
3
1
-1
5
0
G
F
P
-A
cc
 
5
'
-
c
t
c
g
g
t
a
c
c
a
t
g
c
t
t
t
c
a
a
a
c
g
t
a
t
c
c
t
c
t
a
-
3
'
 
R
E
V
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
5
0
 G
F
P
 
1
1
 
C
H
M
P
3
1
-1
7
9
F
L
A
G
-H
in
d
II
I*
 
S
a
m
e
 
a
s
 
C
H
M
P
3
1
-
1
5
0
F
L
A
G
-
H
i
n
d
I
I
I
 
F
W
D
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
7
9
 F
L
A
G
 
1
2
 
C
H
M
P
3
1
-1
7
9
F
L
A
G
-A
cc
 
5
'
-
c
t
c
g
g
t
a
c
c
c
t
t
t
g
c
c
c
a
a
g
g
c
t
c
c
t
g
c
t
g
-
3
'
 
R
E
V
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
7
9
 F
L
A
G
 
1
3
 
C
H
M
P
3
1
-1
7
9
G
F
P
-B
g
l*
 
S
a
m
e
 
a
s
 
C
H
M
P
3
1
-
1
5
0
G
F
P
-
B
g
l
 
F
W
D
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
7
9
 G
F
P
 
1
4
 
C
H
M
P
3
1
-1
7
9
G
F
P
-A
cc
 
5
'
-
c
t
c
g
g
t
a
c
c
g
c
t
t
t
g
c
c
c
a
a
g
g
c
t
c
c
t
g
c
t
g
-
3
'
 
R
E
V
 p
ri
m
e
r 
- 
fo
r 
C
H
M
P
3
1
-1
7
9
 G
F
P
 
 T
a
b
le
 2
.6
 –
 P
ri
m
e
rs
 u
s
e
d
 f
o
r 
c
lo
n
in
g
 o
f 
v
a
ri
o
u
s
 c
o
n
s
tr
u
c
ts
. 
 T
h
e
 p
ri
m
e
rs
 d
is
cu
ss
e
d
 in
 t
h
e
 m
e
th
o
d
s 
a
b
o
ve
 a
re
 d
e
sc
ri
b
e
d
 h
e
re
 a
n
d
 t
h
e
ir
 s
e
q
u
e
n
ce
s 
g
iv
e
n
. 
 
B
o
ld
 a
n
d
 u
n
d
e
rl
in
e
d
 t
e
xt
 i
n
d
ic
a
te
s 
re
st
ri
ct
io
n
 s
ite
s 
b
e
in
g
 i
n
tr
o
d
u
ce
d
 i
n
to
 t
h
e
 c
lo
n
e
d
 f
ra
g
m
e
n
t.
  
S
D
M
 r
e
p
re
se
n
ts
 s
ite
 d
ir
e
ct
e
d
 m
u
ta
g
e
n
e
si
s;
 F
W
D
 i
s 
fo
rw
a
rd
; 
R
E
V
 is
 r
e
ve
rs
e
. 
 *
T
h
e
se
 p
ri
m
e
rs
 w
e
re
 a
lr
e
a
d
y 
p
re
se
n
t 
in
 t
h
e
 la
b
 f
ro
m
 p
re
vi
o
u
s 
cl
o
n
in
g
 e
xp
e
ri
m
e
n
ts
. 
 
 55 
useful in identifying positive PCR clones and also necessary for creating 
linear vector DNA with appropriate restriction enzymes. 
 
For checking of PCR products cloned, 1 U of the appropriate enzymes 
were incubated with a small volume (10 µl) of the PCR product for 1 hr at 
37oC and then analysed by agarose gel electrophoresis.  In the case of 
linearization of vector DNA, more complete digestions were necessary 
and so 5 U of each restriction enzyme was incubated with the DNA 
product for 3 hours at 37oC. 
 
2.2.6.3  DNA analysis by agarose gel electrophoresis 
 
PCR products and digested DNA were loaded onto a 1% (w/v) agarose 
Tris-acetate EDTA (TAE) gel and run in the presence of ethidium 
bromide for DNA visualisation under UV light at 120 V for 20-40 min 
depending on size of DNA.  Images were examined using an EPI Chemi 
II darkroom (UVP) with a Hamamatsu camera attached.  For the case of 
DNA isolation from gels, a gel extraction kit (Promega) was followed 
according to the manufacturer’s instructions. 
 
2.2.6.4  Transformations and DNA isolation 
 
For expression and multiplication of DNA constructs, the plasmids were 
transformed into competent E. coli cells.  A small amount (1 µl) of the 
cloned DNA construct was added to 50 µl of competent XL-1 blue cells 
(unless otherwise stated) on ice and incubated for 5 min.  Cells were 
then heat shocked by incubating at 42oC for 30 seconds exactly, and 
then placed back on ice for a further 2 min.  250 µl of LB media was 
added to the heat shocked DNA-cell mixture and this was incubated at 
37oC for 1 hr.  50 µl of this mixture was then plated on LB plates that 
contained the appropriate antibiotic selection that the parental plasmid 
had resistance to, to ensure selectability, and plates were grown 
overnight at 37oC. 
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To obtain a highly concentrated volume of desired DNA, individual 
colonies were picked and grown in 10 ml cultures (containing relevant 
antibiotics) overnight, shaking at 37oC.  Cultures were pelleted by 
spinning at 1500 x g for 10 min, and DNA was extracted using mini-prep 
kits (Promega) or Midi-prep kits (Qiagen) according to the manufacturer’s 
instructions. 
 
 
2.2.7  Antibody generation 
 
2.2.7.1  Peptide synthesis 
 
A DNA construct was previously cloned into a pET15b vector, of a 118 
amino acid hydrophilic rich region of the human PIKfyve protein 
(including a His6 tag at the N-terminus of the peptide) aligning from 
E1083 to D1200 of the sequence, termed His6-PIK.  This peptide was 
used as the antigen for raising antibodies against in a sheep. 
 
The pET-PIK DNA construct was transformed into E. coli Rosetta® 
competent cells as previously described.  Colonies were picked from 
ampicilin containing agar plates and grown overnight in 100 ml cultures 
of LB-Amp.  The following morning a 1 in 100 dilution of the culture was 
made into 1 L flasks of LB-Amp and the new cultures were grown until 
the optical density (OD) at 600 nm reached 0.6.  Cells were induced with 
100 mM of IPTG for 3 hr shaking at 37oC.  Cells were then pelleted by 
spinning at 2000 x g for 10 min, and pellets were resuspended in HEPES 
lysis buffer and sonicated on ice.  Large debris was removed by a 
second pelleting spin and the resulting supernatant was rotated at 4oC 
with 1 ml of talon resin for 3 hr.  The resin was then gently spun down 
(600 x g) and washed several times with cold HEPES buffer.  Resin was 
resuspended in 10 ml of the lysis buffer, spun down again and then 
resuspended in a minimal volume of lysis buffer.  The purified His6-PIK 
protein was then eluted in lysis buffer with 200mM imidazole (pH 8.0) 
added.  Five elutions of 0.5 ml volume were collected and dialysed 
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against 5 L of PBS overnight to remove all lysis buffer, using a 3,000 kDa 
cut-off dia-lyser cassette (Pierce).  Dialysed His6-PIK samples were 
made to 20% (v/v) glycerol and stored at -20oC until further use.  
Samples were checked for purity by running on SDS-PAGE gel. 
 
2.2.7.2  ELISA plate assay 
 
ELISA plate coating buffer was made to a 50% (v/v) glycerol stock.  2 ml 
of this solution was added to 2 mg of the His6-PIK polypeptide.  100 µl of 
this was further diluted in 10 ml coating buffer to give a concentration of 
10 µg/ml.  C8 Maxisorp plates (Nunc) were coated with 100 µl per well of 
the 10 µg/ml His6-PIK solution, covered and incubated overnight at 4
 oC.  
The following day wells were washed three times with PBST (PBS with 
0.1% v/v Tween-20) with rigorous expulsion of liquid out of the wells.  
The wells were filled with 200 µl ELISA plate blocking buffer and 
incubated, for 1 hr at room temperature, shaking.  The plate was then 
washed twice with PBST.  A 1:100 dilution of pre-immune and first bleed 
of the antibody was made in PBST.  200 µl of this was placed in the first 
well.  100 µl was withdrawn and placed into the second well containing 
100 µl PBST.  This serial dilution was performed 12 times across the 
plate.  The plate was then covered and incubated with gentle shaking for 
2 hr at room temperature.  Wells were washed three times with PBST 
and then 100 µl of 1:4000 diluted (PBST) anti-sheep IgG HRP was 
added to each well and the plate was incubated shaking, for a further 2 
hr at room temperature.  The plates were then washed three times with 
PBST and twice with PBS.  ELISA sodium acetate/citrate buffer was 
diluted 1:20 in ddH2O and 49.5 ml of the solution was added to 0.5 ml 
Tetramethyl Benzidine (TMB; 10 mg/ml in DMSO) and 10 µl 30% (v/v) 
H2O2.  100 µl of this was added to each of the wells and incubated at 
room temperature until a blue colour had developed over the range of 
dilutions.  The reaction was stopped by the addition of 50 µl 1.84 M 
H2SO4 per well.  The plates were then read in a Spectra Rainbow 
Thermo microplate spectrophotometer (Tecan) with filter 1 measuring 
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OD at 450 nm and filter 2 measuring OD at 700 nm (to eliminate 
background readings). 
 
2.2.7.3  Generation of an affinity column 
 
For coupling of the His6-PIK antigen to a column, a 1 ml Hi-Trap™ NHS-
activated HP column (Amersham) was used according to the 
manufacturer’s instructions.  Firstly, a drop of ice-cold 1 mM HCl was 
added to the column to avoid air bubbles and the column was further 
washed out three times with 2 ml of ice-cold 1 mM HCl without 
exceeding a flow rate of 1 ml/min.  1 ml of the antigen (His6-PIK) was 
immediately injected onto the column and allowed to stand at room 
temperature for 30 min.  The column was then washed three times with 2 
ml Buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3), three times with 2 
ml Buffer B (0.1 M acetate, 0.5 M NaCl, pH 4) and a further three times 
with Buffer A, then left at room temperature for 30 min.  Column was 
then washed three times with 2 ml Buffer B, three times with 2 ml Buffer 
A and finally 3 times of 2 ml with Buffer B again.  2 ml of PBS with 0.2% 
(w/v) sodium azide was then injected into the column and the column 
was stored at 4oC until needed. 
 
 
 
 
2.2.7.4  Purifying antibodies from serum using FPLC  
 
For purification of the antibody from the serum of the sheep bleeds, the 
column coupled with the His6-PIK antigen was attached to an FPLC™ 
system (Amersham).  The column was flushed with 5 ml cold PBS and 
then 1.5 ml of the serum was mixed with 1.5 ml of PBS and 0.5 ml 
injected into the column every 30 min.  Between each injection the 
column was closed and incubated standing at room temperature.  After 
full injection of the antibody containing serum into the column, it was 
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attached to the FPLC™ system and washed with PBS until the 
absorbance reading at 280 nm levelled off at zero. 
 
The antibody was then eluted into 0.5 ml fractions with 100 mM glycine 
(pH 2.5) at a flow rate of 0.02 ml/min.  Fractions (0.5 ml) were collected 
in eppendorf tubes that contained 0.2 ml 1M Tris-HCl (pH 8.0) to 
neutralise, with the absorption at 280 nm monitored and graphed to 
identify the fractions that contained eluted antibody.  Fractions within the 
range of the peak were pooled and dialysed against 5 L of PBS, 
overnight at 4oC.  The concentration of the purified antibody was then 
estimated using the extinction coefficient for IgG where at 280 nm, an 
absorption of 1.0 relates to 0.75 mg/ml IgG.  Glycerol was added to the 
purified antibody to a final concentration of 40% (v/v), and aliquots of 100 
µl were made for storage at –20oC until further use. 
 
The purification process was carried out for the first bleed fraction from 
the immunised sheep and also for the third bleed.  When bleeds were 
received they were dispensed into 20 ml aliquots and stored at –20oC. 
 
 
 
 
 
 
 
2.2.8  Detergent-free cell lysis and immunoprecipitations 
(IP) 
 
Detergent-free lysis: 
Cells transfected with GFP-Vps4E235Q or GFP-Vps4WT were removed 
from flasks ~ 16 hours post-transfection by incubation with trypsin for 5 
min.  Complete growth medium was added to neutralise the trypsin and 
cells were spun at 1000 x g for 3 min to pellet cells.  Pellets were washed 
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once with ice-cold PBS then incubated with 2 ml of TESA buffer 
(detergent free) containing a mammalian protease inhibitor cocktail 
(Sigma), and gently pipetted up and down several times.  Pellet 
suspended in TESA buffer were then passed through a 23G needle 10 
times followed by passing through a 27G needle a further 10 times.  
Cells were allowed to sit on ice for a further 15 min to aid in lysis.  Cells 
were then passed through a ball-bearing syringe homogenizer at least 7 
x at a clearance of 12 µm to shear cells, then a further 7 passes through 
a clearance of 4 µm to ensure a full lysis of cells as possible.  Lysed cells 
were then spun at 14,000 x g for 30 min to remove any large and nuclear 
debris.   
 
GFP IP: 
50µl of Protein G beads were washed twice with ice-cold PBS by 
spinning for 1 min at 6000 x g.  Following washes, 4µg of the mouse α-
GFPIgG2a antibody was added to beads and allowed to mix at 4
oC 
rotating for 3 hours.  Beads were then spun down and the supernatant 
(any unbound antibody) was removed.  Beads were further washed a 
minimum of three times using ice-cold TESA buffer.  Cell lysis 
homogenate was then added to the beads and allowed to mix overnight 
at 4oC.  The following morning, beads were spun down and the 
supernatant stored at –20oC to be later run on SDS-PAGE.  Beads were 
washed twice with cold TESA buffer and a further three times with cold 
PBS by spinning.  After the last spin the supernatant was carefully 
aspirated off and the remaining beads were incubated with 1x sample 
buffer and boiled for 5 min, with lengthy vortexing before and after 
boiling.  Beads were then run on three lanes of a SDS-PAGE gel along 
with samples of the cell lysate and the supernatant of the IP (that is, 
unbound fraction of lysate).  Western blotting techniques were used to 
blot for GFP (using rabbit antibody) and other proteins of interest. 
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HaloTag precipitations: 
HaloLink methods of isolating HaloTag proteins were followed similarly 
to the manufacturer’s instructions being optimised for specific 
experimental demands.  Cells transfected with proteins expressing the 
HaloTag (Halo-Vps4WT or Halo-Vps4E235Q) were processed for cell lysis 
as described above.  Following cell lysis, 50 µl of the HaloLink resin 
(which allows covalent binding of the HaloTag to the HaloLink resin) 
was washed three times with ice-cold TESA buffer to remove any 
ethanol and equilibrate the resin with the TESA buffer.  500-750 µl of the 
prepared cell lysates was then added to the beads, and rotated at 4oC 
overnight.  The following morning the resin was spun down (800 x g for 1 
min) and the supernatant (unbound cell lysate) was removed and stored 
at –20oC until needed for SDS-PAGE.  The resin was washed three 
times using TBS buffer with 10 mg/ml BSA and a further five times using 
TBS buffer with no BSA, to remove the BSA thus allowing for a cleaner 
Western blot.  After the last wash the resin was spun down for 2 min and 
100 µl of sample buffer was added.  Samples were vortexed and boiled 
for 5 min and allowed to sit at room temperature for 15-20 min before 
loading onto an SDS gel along with a sample of the total cell lysate and 
the unbound cell lysate fraction.  Gels were transferred to nitrocellulose 
and Western blotting techniques were used to identify various proteins of 
interest. 
 
Dextran-red uptake assay: 
Cells transfected with Halo-Vps4WT, Halo-Vps4E235Q or untransfected 
were incubated with Texas-Red Dextran (Invitrogen; 1:10,000 dilution) 
and incubated at 37oC, 5% CO2 overnight.  Cells were then lysed in 
detergent-free lysis buffer as already described, and incubated with the 
HaloLink resin as above.  Following final washes of lysate-resin 
complexes, resins were incubated with 1% (v/v) TritonX-100 for 30 min 
at room temperature.  Fractions were then read on a Fluoro-scan plate 
reader with excitation of 545 nm and emission read at 612 nm.  Values 
were normalised per mg of protein (using BCA protein assay to 
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determine protein concentrations) and the relative fluorescent units 
(RFU) of TritonX-100 measured alone was subtracted as background.  
RFU values of transfected cell lysates were normalised to untransfected 
cells treated with Dextran with this RFU value being taken as zero. 
 
 
2.2.9  Production of stable cells expressing Halo-Vps4WT 
or Halo-Vps4E235Q 
 
For producing stable cell lines the Tet-Off™ system (Clontech) was 
used.  Briefly, the Tet-Off/On™ systems allows for the expression of a 
stably expressed construct to be turned on or off via the addition or 
removal of the antibiotic tetracycline.  In the case of Tet-Off™ cell lines, 
the addition of tetracycline (or doxycycline) results in the expression of 
the stable construct to be silenced and turned off.  Removal of 
tetracycline/doxycycline allows for the expression of the gene of interest 
to resume.  Doxycycline may also be used as the repression agent for 
Tet-Off™ systems and is often favoured due to much lower 
concentrations needed as well as its superior half-life compared to 
tetracycline.  For these experiments, doxycycline was the preferred 
choice of inducibility agent. 
 
For the Tet-Off™ system to properly function, the gene of interest needs 
to be cloned into a vector containing the tetracycline repressor element, 
a pTRE vector.  Furthermore, to allow the selectability of stably 
expressing cells, a second antibiotic marker may be used that is 
additionally added to certain pTRE vectors for this selection purpose.  In 
this case, a pTRE2pur vector was used, which allows for selection of 
stably-expressing cells to be isolated via puramycin resistance.  Finally, 
cells already possessing the Tet-Off™ system have a third selectable 
antibiotic marker of G418, which ensures that the cells that proliferate in 
the culture are Tet-Off™ cells.  The cells used for production of stable 
cells expressing Halo-Vps4WT or Halo-Vps4E235Q were HeLa Tet-Off™ 
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cells, which were a kind gift from Prof George Banting.  For more details 
on the cloning of Halo-Vps4WT and -Vps4E235Q constructs into the 
pTRE2pur vectors please refer to section 2.2.6.1. 
 
HeLa Tet-Off™ cells were revived from liquid nitrogen stores and grown 
in flasks for the first few days under standard conditions (complete 
DMEM growth medium, 37oC, 5% CO2).  After the first passage of cells, 
400 µg/ml G418 was added to the medium to ensure all cells that grew 
were HeLa Tet-Off™ cells.  G418 was always present in the media used 
for these cells from this point on, at a concentration of 200-400 µg/ml.  
After the second passage, cells were seeded onto 10 cm plates and 
grown to ~80% confluency, when they were then transfected with 
pTRE2pur-Halo-Vps4WT or pTRE2pur-Halo-Vps4E235Q using 
Lipofectamine 2000™ or FuGene 6™ transfection reagents, according to 
manufacturer’s instructions.  Following transfections, puromycin and 
doxycycline were both added to the media at concentrations of 1 µg/ml.  
The media was ensured to be changed every 2 days with fresh 
antibiotics.  Transiently transfected cells seeded on 13 mm coverslips 
were also transfected similarly with wells containing doxycycline and 
those without doxycycline, and viewed under a fluorescence microscope 
to demonstrate and ensure doxycycline inducibility. 
 
After at least 10-14 days of transfected cells having been incubated in 
the presence of puramycin and doxycycline, small individual colonies of 
clonal cells were isolated and removed from the 10 cm dish to a 96-well 
tissue culture plate.  Each colony of cells were allowed to grow to 
confluency in a 96-well and then were passaged into a maintenance 35 
mm dish as well as coverslips for both +dox and –dox conditions for 
detection of inducible expression.  Cells were incubated on coverslips in 
the presence of doxycycline or without for 24 hr and then incubated with 
Halo-ligands and fixed as previously described, being then examined 
under a fluorescence microscope to confirm expression, doxycycline 
inducibility and appropriate phenotypes.  Cell colonies that lacked any 
visible expression of the Halo-tagged constructs were discarded.  Some 
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colonies were also assayed for expression of Halo-Vps4WT or -Vps4E235Q 
constructs via Western blotting techniques to determine if over-
expression of the constructs was occurring in an inducible manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
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3  The effects of the Salmonella phosphoinositide 
phosphatase SopB on ESCRT and MVB function
*
 
 
3.1  Introduction 
 
Salmonella enterica serovars are facultative intracellular bacteria that 
can target a variety of eukaryotic hosts and are the causative agents of 
diseases such as food-borne gastroenteritis in humans [reviewed in 118].  
These bacteria have developed complicated strategies to regulate host 
cell responses, which allow them to be internalised, survive and replicate 
in membrane bound compartments, known as Salmonella-containing 
vacuoles (SCVs) [reviewed in 119].  Upon bacterial invasion of the host, 
SCVs undergo a remodelling, resembling that of the host cell’s endocytic 
pathway, but their progression down the endocytic pathway is arrested 
prior to fusion with degradative lysosomes thus aiding bacterial survival 
[120].   
 
The formation and remodelling of SCVs is dependent upon the secretion, 
during and immediately after internalisation, of bacterial effector proteins 
into the host cell cytoplasm.  This secretion occurs via a Type III 
secretion system (TTSS) encoded within pathogenicity island 1 (SPI-1) 
of the Salmonella genome [119, 121].  Among these SPI-1 effectors is 
SopE, which is a RhoGEF that initiates actin rearrangement in the host 
cell, leading to plasma membrane ruffling and nascent SCV formation 
[122, 123].  Another protein secreted by the SPI-I TTSS is SopB (also 
referred to as SigD), which is a phosphoinositide phosphatase [124-127].  
 
SopB has been shown to possess 5’-phosphatase activity specifically 
towards PtdIns(3,5)P2 [128].  Recent evidence suggests that SopB may 
contribute to the arrest of progression of the SCV down the endosomal 
trafficking pathway leading to fusion with lysosomes through this 
phosphatase mechanism [128].  This activity is responsible for the 
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conversion of PtdIns(3,5)P2 to PtdIns(3)P by removal of phosphate from 
the 5’ position of the inositol lipid head-group.  SopB has additional 
phosphoinositide and inositol phosphate substrates in vitro, and in vivo 
has been implicated in a variety of other host cell manipulations such as 
Akt activation and modulation of chloride secretory responses [125, 129, 
130].  As SopB acts on various phosphoinositide substrates in vitro, its 
localisation within the cell would most likely determine its natural 
physiological substrate, and indeed different phosphoinositides are 
considered to be quite specific in their spatial distribution on membranes 
in mammalian cells.  Furthermore, the localisation of phosphoinositides 
is considered to be temporal given the fact that their generation can often 
occur due to activation or expression of enzymes that produce specific 
phosphoinositides from one form to another. 
 
Some studies have already been carried out that suggest the generation 
of PtdIns(3,5)P2 may play some role in endosomal trafficking [61, 71, 
131].  The aim of this work was then to investigate the localisation and 
action of SopB, and consequently whether it may be a useful tool to 
manipulate levels of PtdIns(3,5)P2 in cells.  In doing so, the role of this 
lipid in endosomal trafficking may be further investigated.   
 
 
 
 
 
 
 
 
*The work described in this chapter was submitted to the Biochemistry Journal and 
accepted for publication on 6 January, 2006: 
Dukes JD, Lee H, Hagen R, Reaves BJ, Layton AN, Galyov EE, Whitley P.  The 
secreted Salmonella dublin phosphoinositide phosphatase, SopB, localizes to 
PtdIns(3)P-containing endosomes and perturbs normal endosome to lysosome 
trafficking. Biochem J, 2006. Apr 15;395(2):239-47 
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3.2  Results 
 
 
3.2.1  SopB localises to early endosomal membranes that 
contain PtdIns(3)P 
 
Although SopB expressed heterologously in mammalian cells has 
previously been shown to be present on Salmonella containing vacuoles 
(SCVs) and cell membranes in Salmonella infected cells [132], a more 
detailed characterisation of the subcellular localisation of SopB had not 
yet been performed.  By staining with antibodies against SopB, Marcus 
et al were able to demonstrate that the expression of SopB in Salmonella 
infected cells led to localisation of SopB to the membranes of SCVs.  
Subcellular fractionation also revealed that SopB was absent from the 
cytoplasm but present in the host-cell membrane fraction [132].   
 
To further investigate the subcellular location of SopB, we transiently 
transfected COS-7 cells with pRK5myc SopB or pRK5myc SopBC460S 
(see 2.2.6.1). These plasmids encode a myc-tagged SopB wild type 
protein (SopB-wt) and a phosphatase dead myc-tagged SopB protein 
(SopBC460S) respectively. SopBC460S is a mutant form of SopB, which 
lacks phosphatase activity.  Given that the localisation of SopB has been 
reported to be independent of its phosphatase activity [132], it was 
reasoned that this mutant form although lacking phosphatase activity 
would still localise to the same sub-cellular compartment as the active 
SopB protein.   
 
Expression of SopB-wt from pRK5myc SopB was highly toxic to the cells 
and appeared to result in rounded up cells that were dying (Fig. 3.1b).  
The transfection efficiency for SopB-wt was extremely low (>0.01%) and 
we suspect that this was due to most transfected cells rounding up and 
detaching from the coverslips prior to fixation, although this was not 
directly shown.  In transfected cells not observed to be rounded up, 
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SopB-wt was observed to be associated with the membranes of 
dramatically swollen organelles presumably at a stage prior to the cells 
rounding up and detaching from the coverslips (Fig. 3.1a).  The 
phosphatase dead mutant, SopBC460S was not found to be so toxic to the 
cells, and showed a punctate localisation throughout the cytoplasm of 
COS-7 cells (Fig. 3.1c). This staining observed resembled such a 
staining seen of early endosomes, such as with EEA1 (Fig. 3.1d).  It had 
no apparent dramatic effect on the morphology of the membranes it was 
apparently associated with, unlike SopB-wt.  Due to the toxicity and low 
transfection efficiency of SopB-wt, the remainder of the localisation 
studies were performed with the SopBC460S phosphatase dead protein.  
   
To determine whether the observed SopBC460S containing punctae were 
associated with specific cellular organelles, double immunostaining with 
markers for different organelles was performed (Fig. 3.2).  These studies 
revealed that SopBC460S localised primarily to early endosomes, as there 
was a high degree of co-localisation with early endosomal autoantigen-1 
(EEA1; Fig. 3.2a-c).  There was no evidence that SopB associated with 
other internal membranes such as late endosomes or the trans-Golgi 
network (TGN) as there was only very limited co-localisation of 
SopBC460S with CI-M6PR or TGN46 respectively (Fig. 3.2d-i).  The co-
localisation with EEA1, which is directed to early endosomes via an 
interaction with Rab5 and PtdIns(3)P, gives an indication that SopB is 
targeted primarily to membranes containing PtdIns(3)P. 
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Figure 3.1 – Transient expression of SopB-wt and SopB
C460S
 in Cos-7 cells.  COS-
7 cells were transfected with (a and b) pRK5myc SopB or (c) pRK5myc SopBC460S. 
Cells were fixed after 16 hours and immunostained with anti-myc antibodies, followed 
by Alexa® Fluor 568-conjugated anti-mouse IgG secondary antibodies. Untransfected 
cells (d) were immunostained with anti-EEA1 antibodies followed by Alexa® Fluor 568-
conjugated anti-rabbit IgG secondary antibodies. 
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Figure 3.2 – SopB
C460S
 localises to early endosomes.  Cos-7 cells were transfected 
(a-i) with pRK5mycSopBC460S. Cells were fixed after 16 hours and immunostained with 
anti-myc antibodies, followed by (a-f) Alexa® Fluor 568-conjugated anti-mouse IgG 
secondary antibodies or (g-i) Alexa® Fluor 488-conjugated anti-mouse IgG secondary 
antibodies. Cells were co-immunostained with (a-c) anti-EEA1, (d-f) anti-CI-M6PR or (g-
i) anti-TGN46 antibodies followed by (a-f) Alexa® Fluor 488 conjugated anti-rabbit IgG 
or (g-i) Alexa® Fluor 568 conjugated anti-sheep IgG antibodies. Fluorescence 
corresponding to (myc) SopB C460S is shown in a, d (red) and g (green). Fluorescence 
corresponding to EEA1, CI-M6PR and TGN46 is shown in b, e (green) and h (red) 
respectively. Images of merged fluorescence are shown in c, f and i (yellow 
fluorescence indicates co-localisation). Insets (a-c) are magnifications of boxed areas. 
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3.2.2  Membrane association of SopB is independent of 
any interaction with PtdIns(3)P 
 
 
To address more directly whether SopB localises primarily to PtdIns(3)P 
containing cellular compartments we co-expressed SopBC460S together 
with GFP-iFYVE-FENS-1 which is a probe for PtdIns(3)P (Fig. 3.3).  As 
has been shown previously [133], exogenous expression of GFP-iFYVE-
FENS-1 causes swelling and vacuolation of early endosomal 
compartments.  SopBC460S showed substantial co-localisation with GFP-
iFYVE-FENS-1 on these swollen early endosomes, clearly 
demonstrating that SopB localises to PtdIns(3)P containing membranes 
(Fig. 3.3a-c).  To test whether SopB localises to PtdIns(3)P containing 
endosomes via a direct interaction with PtdIns(3)P, SopBC460S 
transfected Cos-7 cells were treated with the PI3-kinase inhibitor, 
wortmannin.  This treatment did not result in dissociation of SopBC460S 
from membranes whereas GFP-iFYVE FENS-1 expressed in the same 
cells did not remain membrane associated, indicating that PtdIns(3)P 
levels had been depleted as a result of wortmannin treatment (Fig. 3.3d-
f). 
 
These results provide further evidence that the physiological substrate of 
SopB-wt may in fact be PtdIns(3,5)P2 as SopB
C460S localises to a 
compartment where PtdIns(3)P is found.  The mammalian kinase that 
converts PtdIns(3)P to PtdIns(3,5)P2 is PIKfyve, thus these results 
indicate that SopB is in a location to antagonise the effects of PIKfyve’s 
conversion of PtdIns(3)P to PtdIns(3,5)P2.  It should further be noted that 
some reports have indicated a plasma membrane localisation of SopB 
[134].  However in most of the SopBC460S transfected cells observed, no 
staining was detected at the plasma membrane.  However at higher 
expression levels of the SopB-wt protein, there may have been some 
localisation to the plasma membrane in rounded up cells (Fig. 3.1b), 
although these cells appeared to be expressing large amounts of the 
SopB-wt protein.  This indicates that although SopB may possess a 
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broad range of phosphorylated substrates in vitro, including 
PtdIns(4,5)P2 which is found at the plasma membrane, its sub-cellular 
localisation to PtdIns(3)P containing compartments suggest its primary 
physiological substrate is more likely to be an endosomal 
phosphoinositide such as PtdIns(3,5)P2 rather than a plasma membrane 
phosphoinositide similar to PtdIns(4,5)P2. 
 
 
3.2.3  SopB localises to ESCRT-containing compartments 
 
It has previously been shown that an ESCRT-III component, CHMP3, 
binds to PtdIns(3,5)P2 in vitro and therefore may act as an effector of this 
phosphoinositide [71]. Thus the action of SopB (by preventing 
accumulation of PtdIns(3,5)P2 on ESCRT containing membranes) may 
manifest itself by compromising ESCRT function or localisation. However 
there is a lack of in vivo evidence to support this hypothesis.  As a result 
of this, SopBC460S was co-expressed together with the dominant negative 
ESCRT components CHMP31-112-GFP or GFP-Vps4E235Q (Fig. 3.4). 
CHMP31-112-GFP associates with intracellular membranes of endocytic 
origin and induces their vacuolation [71].  
 
Vps4 is not strictly a component of ESCRT-I, II or III but catalyses the 
disassembly and release of ESCRT components from membranes.  The 
dominant negative GFP-Vps4E235Q is ATPase defective, associates with 
intracellular membranes and is not able to catalyse ESCRT disassembly, 
also resulting in vacuolation [135].  Co-localisation of SopBC460S with 
CHMP31-112-GFP (Fig. 3.4a- c) and GFP-Vps4E235Q (Fig. 3.4d-f) was 
observed. This co-localisation is entirely consistent with the action of 
SopB having an effect on ESCRT function.  Thus the co-localisation of 
the SopB phosphatase that is proposed to manipulate PtdIns(3,5)P2 
levels with ESCRT proteins (CHMP3) put these ESCRT proteins in a 
location where they could potentially be PtdIns(3,5)P2 effectors. Despite 
these  findings,   there  is  still a  lack of  evidence to  support  any  direct  
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Figure 3.3 – SopB
C460S
 associates with membranes independent of any interaction 
with PtdIns(3)P.  Cos-7 cells were co-transfected (a-f) with pRK5mycSopBC460S and 
GFP-iFYVE FENS-1. Cells in panels a-c were mock treated and in panels d-f were 
treated for 3 hr with 100 nM wortmannin (WM) in serum free medium.  Cells were fixed 
and immunostained with (a-f) anti-myc antibodies followed by Alexa® Fluor 568-
conjugated anti-mouse IgG secondary antibodies. Fluorescence corresponding to (myc) 
SopBC460S is shown in a and d (red).  Fluorescence corresponding to GFP-iFYVE 
FENS-1 is shown in b and e (green). Images of merged fluorescence are shown in c 
and f (yellow indicates co-localisation).  Scale bar on panels a and d represent 10 µm. 
 
effector properties of ESCRT proteins with PtdIns(3,5)P2. 
 
To more fully examine the localisation of SopB with PIKfyve, the kinase 
that synthesises PtdIns(3,5)P2, experiments to co-transfect SopB
C460S 
and GFP-PIKfyve into Cos-7 cells were attempted but were not 
successful as GFP-PIKfyve expression could not be detected in these 
cells. GFP-PIKfyve could, however, be expressed in CHO-K1 cells, in 
which co-expressed SopBC460S showed significant punctate co-
localisation with GFP-PIKfyve (Fig. 3.4g-i).  These results again indicate 
that SopBC460S can localise to a compartment that may allow it to have a 
quick turnover in antagonising the effects of PIKfyve’s actions on 
PtdIns(3,5)P2 synthesis. 
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It must be noted however that regardless of these findings, these 
experiments were performed with the phosphatase dead mutant 
SopBC460S.  It would have been desirable however for such experiments 
to be carried out using the wild-type SopB protein.  These may have 
given better clues as to the effect of depleting PtdIns(3,5)P2 levels on 
ESCRT localisation.  However, given the highly toxic nature of SopB-wt 
expression to cells, such studies were not possible. 
 
 
3.2.4  Cells infected with Salmonella expressing SopB 
contain SCVs with enriched EEA1 on membranes 
 
It has been observed that PtdIns(3)P accumulates on SCVs of Henle-
407 cells infected with wt Salmonella but not a Salmonella deletion 
mutant lacking SopB [128].  To see if this is a general phenomena for 
other mammalian cell types, A431 cells were infected with wild type 
Salmonella (wt S. dublin) or an isogenic deletion mutant lacking SopB 
(∆SopB S. dublin).  In order to visualise the intracellular bacteria the wt 
S. dublin and ∆SopB S. dublin were transformed with a GFP expressing 
plasmid pSU2007 (gift from Dr David Clarke).  The presence or absence 
of PtdIns(3)P on SCVs was monitored by immunostaining fixed cells for 
endogenous EEA1.  Observation of a large number of cells clearly 
showed that SCVs from wt S. dublin infected cells had large amounts of 
EEA1 associated with them (Fig. 3.5a-c), whereas those from ∆SopB S.  
dublin infected cells had much reduced levels of EEA1 associated with 
them (Fig. 3.5d-f).  We hypothesise that the wt S. dublin have increased 
levels of PtdIns(3)P because of the phosphatase activity of SopB being 
expressed by the bacterium.  This is in agreement with Hernandez et al 
who demonstrated that SopB maintains high levels of PtdIns(3)P levels 
in infected cells [128]. 
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Figure 3.4 – Dominant negative ESCRT components assemble on SopB 
containing membranes.  Cos-7 cells were co-transfected with (a-f) 
pRK5mycSopBC460S and either a construct for the expression of (a-c) CHMP31-112GFP 
or (d-f) GFP-Vps4E235Q.   CHO-K1 cells were co-transfected with GFP-PIKfyve (g-i).  
Cells were fixed and immunostained with anti-myc antibodies followed by Alexa® Fluor 
568-conjugated anti-mouse IgG antibodies. Fluorescence corresponding to (myc) 
SopBC460S is shown in a, d and h (red). Fluorescence corresponding to CHMP31-112-
GFP, GFP-Vps4E235Q and GFP-PIKfyve are shown in b, e and g respectively (green). 
Images of merged fluorescence are shown in c, f and i (yellow fluorescence indicates 
co-localisation). Inset panels (a-c, g-i) are magnifications of boxed areas. 
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3.2.5  Cells infected with Salmonella expressing SopB 
have defective receptor degradation kinetics 
 
The accumulation of PtdIns(3)P, due to SopB antagonising its transition 
to PtdIns(3,5)P2 on SCVs has been proposed to divert SCVs away from 
the endocytic pathway preventing fusion with destructive lysosomes 
[128].  In order to test whether SopB could divert endocytic trafficking to 
lysosomes, an EGFR degradation assay was used.  By serum starving 
cells that express EGFR, the receptor is upregulated to the plasma 
membrane.  Stimulation with EGF causes the internalisation of EGFR 
and it is well established that stimulated EGFR is endocytosed and 
trafficked through the endo-MVB-lysosomal pathway where it is 
degraded via the lysosome.  A431 cells were serum starved overnight to 
allow for upregulation and expression of EGFR at the plasma membrane.  
Following EGF stimulation of uninfected A431 cells, EGFR was rapidly 
internalised from the plasma membrane and degraded with a half-life of 
approximately 8 minutes (Fig. 3.6).  If, however the A431 cells were 
infected with wt S. dublin 60 minutes prior to EGF stimulation, the 
kinetics of EGFR degradation were much reduced.  Even 16 minutes 
after EGF stimulation 87% of the EGFR remained, ie was not degraded.  
The kinetics of degradation of EGFR in cells pre-infected with ∆SopB S. 
dublin 60 min prior to EGF stimulation was virtually identical to that in 
uninfected cells.  This was supported by immunofluorescence studies 
which showed the accumulation of EGFR in A431 cells infected with wt 
S. dublin for 60 min (Fig. 3.6c). 
 
Thus these studies imply that Salmonella maintains high levels of 
PtdIns(3)P via expression of SopB in order to arrest its progression to 
the lytic lysosome aiding its survival in the infected host cell.  The 
increased levels of EGFR detected in cells infected with SopB 
expressing S. dublin suggests that SopB perturbs the degradation of 
EGFR by preventing the maturation of compartments containing EGFR 
towards fusing with the lysosome.  However whether the exact actions of 
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SopB via inhibition of PtdIns(3,5)P2 production occur at the MVB 
biogenesis stage or the MVB-lysosomal fusion stage are not clear from 
this study, if indeed SopB’s actions are in fact via directly inhibiting levels 
of PtdIns(3,5)P2.  However evidence from this and other studies would 
suggest that this is likely to be the case. 
 
 
 
Figure 3.5 – A431 cells infected with wt S. dublin have EEA1 enriched SCVs. A431 
cells were infected with (a-c) wt S. dublin or (d-f) ∆SopB S.dublin, both transformed with 
the GFP expression plasmid, pSU2007, for visualisation purposes. Following infection, 
cells were washed, fixed and immunostained with anti-EEA1 antibodies followed by 
Alexa® Fluor 568-conjugated anti-rabbit IgG secondary antibody. GFP expressing (b) wt 
S. dublin and (e) ∆SopB S. dublin and (c) and (f) represent merged images. Inset 
panels in (a-c) are magnifications of boxed areas. Fluorescence corresponding to EEA1 
is shown in a and d (red). Fluorescence corresponding to wt S. dublin and ∆SopB 
S.dublin are shown in b and e respectively (green). Images of merged fluorescence are 
shown in c and f. Inset panels (a-c) are magnifications of boxed areas. 
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Figure 3.6 – Cells infected with wt-S.dublin have impaired EGFR trafficking to the 
lysosome.  A431 cells were infected with wt S. dublin, ∆SopB S.dublin or mock treated. 
Following infection, cells were washed and incubated in fresh media containing 500 
ng/ml EGF. Cell were harvested at the times indicated, protein extracts were made and 
analysed by Western blotting for EGFR and β-tubulin. (a) Immunoblots from a 
representative experiment are shown. (b) Shows a graphical representation of 
quantifications of immunoblots from 3 separate experiments. Significant differences * (t-
test; p < 0.05) are indicated. (c) A431 cells infected with wt S. dublin were incubated 
with EGF as described above. After 1 hr the cells were washed, fixed and 
immunostained with anti-EGFR antibodies followed by Alexa Fluor 568-conjugated anti-
mouse IgG secondary antibody. Panels i) ii) and iii) show GFP labelled wt S. dublin, 
EGFR staining and merged images respectively. Note: neighbouring cells not infected 
with bacteria do not accumulate an intracellular pool of EGFR. 
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3.3  Discussion 
 
This study sought to more fully characterise the subcellular localisation of 
SopB and thus whether it may be a useful tool for the manipulation of 
PtdIns(3,5)P2.  The subcellular localisation of SopB should be relevant to 
its site of action.  SopB has been shown to possess phosphoinositide 
phosphatase activity, with PtdIns(3,5)P2 being a preferred substrate, 
although in vitro SopB has been shown to possess a broad specificity as 
a lipid phosphatase [125, 126].  Different phosphoinositides seem to be 
spatially restricted on various compartments in eukaryotic cells, thus 
although SopB may act on other lipid substrates in vitro (such as 
PtdIns(4,5)P2 which is found in high concentrations at the plasma 
membrane), its localisation within the cell will determine which substrate 
it will dephosphorylate.  These results indicate that SopB has a 
subcellular localisation that puts it in the correct compartment to maintain 
high levels of PtdIns(3)P by antagonising the effects of PIKfyve’s 
production of PtdIns(3,5)P2 as the two proteins appear to be found on 
the same compartment.  Furthermore, infection of cells with Salmonella 
bacteria expressing active SopB impairs the normal degradation kinetics 
of EGFR, which is known to progress through the MVB-lysosomal 
pathway.  These results then indicate that SopB may prevent the SCV 
from fusion with the lysosome by keeping PtdIns(3,5)P2 levels at a 
minimum, suggesting that PtdIns(3,5)P2 plays a role in the endo-
lysosomal trafficking pathway. 
 
It has been proposed that by antagonising the effects of PIKfyve, SopB 
allows the bacteria to survive and replicate in its host.  This hypothesis 
was further strengthened by the findings that SopB localises to 
PtdIns(3)P containing membranes in addition to compartments that 
contain PIKfyve.  The membrane association of SopB appears to be 
independent of its phosphatase domain, so there is no reason to assume 
that the localisation of SopBC460S should differ any from that of SopB-wt 
[132].  To confirm this, a second tagged form of SopB was cloned into a 
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pHM6 vector, to give HA-SopB and HA-SopBC460S.  HA-tagged SopB 
was transiently transfected on several occasions with the aim to co-
transfect with myc-SopBC460S in order to demonstrate similar localisation 
upon overexpression within the cell; however there were various 
technical problems with the HA-tagged SopB which resulted in no visual 
detection of an immunofluorescent signal.  As this was seen to be a 
minor issue with the localisation of SopB having been reported 
elsewhere to be independent of its phosphatase activity [132], this 
approach was not further pursued after several attempts to overexpress 
HA-SopB. 
 
SopBC460S localised to membrane compartments that contained EEA1, 
however no obvious colocalisation was seen with the late endosomal 
marker CI-M6PR or the trans-Golgi network marker TGN46.  Some 
studies have suggested that SopB also localises to the plasma 
membrane [134], however these results show little if any localisation to 
the plasma membrane, but rather punctae that are typical of an early 
endosomal staining.  At very high levels of expression, SopB-wt may 
have appeared to localise partially to the plasma membrane, however 
such localisation was not observed in cells expressing moderate 
amounts of protein or in any cells expressing the phosphatase dead 
mutant SopBC460S.  When co-expressed with the PtdIns(3)P reporter 
FENS-FYVE, SopBC460S colocalised on the FENS-FYVE containing 
membranes. The EEA1 and FENS-FYVE colocalisation data all indicate 
that SopB associates with PtdIns(3)P containing membranes.  As EEA1 
associates with PtdIns(3)P these results are in agreement with previous 
findings that implicate SopB as being responsible for maintaining high 
levels of PtdIns(3)P on the SCV.  Thus SopB’s localisation seems 
consistent with its suggested role as a phosphoinositide phosphatase 
with activity for PtdIns(3,5)P2. 
 
In order to establish whether SopB associates with membranes via an 
interaction with PtdIns(3)P, production of this lipid was inhibited with the 
PI-3 kinase inhibitor, wortmannin.  SopB does not appear to associate 
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with PtdIns(3)P directly, as upon wortmannin treatment of Cos-7 cells co-
expressing SopBC460S and FENS-FYVE, the FENS-FYVE dissociated 
from the membranes whereas the SopBC460S remained membrane 
associated.  The basis for the association of SopB with endosomal 
membranes remains to be established although a predicted coiled-coil 
domain in SopB appears necessary for membrane targeting [132].  
 
It has previously been demonstrated that one of the ESCRT-III proteins, 
CHMP3, binds in vitro to PtdIns(3,5)P2 and that this lipid may be 
necessary for correct ESCRT-III assembly and function [71].  It is 
reasonable to assume then that if SopB acts on PtdIns(3,5)P2 that it may 
localise with CHMP3.  CHMP3 typically resides in the cytoplasm, 
however the dominant negative N-terminal construct of CHMP3 
(CHMP31-112) binds to endosomal membranes, resulting in swollen 
endosomal class E-like phenotypes.  We expressed SopBC460S in Cos-7 
cells along with CHMP31-112-GFP, and found a substantial degree of 
colocalisation.  In addition, the dominant negative ATP-ase defective 
GFP-Vps4E235Q was co-expressed with SopBC460S and clear 
colocalisation was observed.  As Vps4E235Q is unable to catalyse the 
removal of the ESCRT machinery from the limiting membranes of 
endosomes, a swollen endosomal phenotype is again observed.  In both 
cases SopBC460S was found on compartments that contain ESCRT 
machinery.  It would indeed be very interesting to observe the 
localisation of ESCRT machinery in SopB-wt expressing cells.  One 
might speculate that with an active phosphatase activity, SopB-wt may 
prevent components such as CHMP3 from binding to those membranes 
where SopB-wt is localised.  Such experiments were unable to be 
performed however due to the toxicity of SopB-wt when overexpressed 
in mammalian cells.  Despite this it must be again noted that the role of 
PtdIns(3,5)P2 in endo-lysosomal trafficking is uncertain and these studies 
do not provide conclusive findings about such a role. 
 
The effects of SopB on the cell would appear then as suggested, to be 
antagonistic to the actions of PIKfyve, the mammalian kinase that 
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catalyses the conversion of PtdIns(3)P to PtdIns(3,5)P2.  PIKfyve 
localises to membranes containing PtdIns(3)P via its FYVE domain 
which binds PtdIns(3)P.  It may be expected then that SopB would be 
found in a similar compartment to PIKfyve, as this would allow for a very 
quick turnaround of ensuring that PtdIns(3,5)P2 levels are kept as low as 
possible thus aiding in the avoidance of lysosomal fusion with the SCV.  
When GFP-PIKfyve was co-expressed with SopBC460S it was 
unsurprisingly found to have a considerable degree of colocalisation.  
This is entirely consistent with SopB having an antagonistic effect on the 
role of PIKfyve within an infected mammalian cell via manipulation of 
PtdIns(3)P levels. 
 
SopB appears to have a role of maintaining high levels of PtdIns(3)P in 
relation to the PIKfyve product PtdIns(3,5)P2.  This is an important 
mechanism for Salmonella’s survival within the host cell as the SCV 
needs to be diverted away from being trafficked to the lysosome.  EEA1 
specifically binds to PtdIns(3)P enriched membranes, and it was shown 
that the membranes surrounding the GFP-tagged wt-S. dublin are 
enriched with EEA1.  These results are consistent with SopB-producing 
Salmonella maintaining high levels of PtdIns(3)P on the SCV membrane, 
which is suggested to prevent its trafficking to and fusion with the lytic 
lysosome [128].  These results then suggest that SopB is antagonising 
PIKfyve in the production of PtdIns(3,5)P2, and that this lipid may play a 
role in endo-lysosomal trafficking. 
 
EGFR is a well-studied receptor in downregulation and receptor 
degradation experiments.  It is also well established that EGFR is 
degraded via the ESCRT-mediated MVB formation process and fusion 
with the lytic lysosome.  Thus to further investigate the action of SopB 
and thus PtdIns(3,5)P2 on receptor degradation, a combined use of an 
EGFR degradation assay and infection of mammalian cells with the 
Salmonella dublin strain of bacteria was used.  The wild-type strain of S. 
dublin contains the gene for a functional SopB protein, however the 
∆SopB S. dublin does not express SopB.  An EGFR downregulation 
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assay was carried out in A431 cells, and it was found that wt-S. dublin 
infected cells maintained high levels of EGFR compared with ∆SopB-S. 
dublin, which exhibited very similar degradation kinetics to the uninfected 
cells.  There is no statistically significant difference between the ∆SopB-
S. dublin and uninfected A431 cells, however there is a significant 
difference (p<0.05) between the wt-S. dublin and both ∆SopB-S. dublin 
and uninfected cells after 8 and 16 minutes of EGF stimulation.  
Following 16 minutes of EGF stimulation, wt-S. dublin infected cells 
maintained on average 87% of the EGFR present at t = 0, which is over 
three times more than the ∆SopB-S. dublin and uninfected cells.  These 
findings suggest that SopB is specifically responsible for delaying the 
degradation of EGFR as well as delaying processes that would be 
detrimental to the bacteria.   
 
These results would suggest that the action of antagonising 
PtdIns(3,5)P2 production in the cell by SopB may be what is responsible 
for delaying EGFR degradation.  There is however some inconsistency in 
the literature regarding the relationship between PtdIns(3,5)P2 levels and 
EGFR degradation.  Ikonomov et al expressed a mutant form of PIKfyve 
that lacks its lipid kinase activity (and hence is unable to convert 
PtdIns(3)P to PtdIns(3,5)P2) in mammalian cells, and determined the 
levels of EGFR present following stimulation with EGF using Western 
blotting techniques.  They found that there was no significant difference 
in the degradation of EGFR when expression of the kinase-dead PIKfyve 
protein was compared with expression of wild-type PIKfyve [136].  In 
contrast to this study however, overexpression of myotubularin (a 
phosphoinositide 3-phosphatase shown to bind to and thought to 
dephosphorylate PtdIns(3,5)P2 to PtdIns(5)P), was shown to delay the 
degradation of EGFR in Cos-7 cells compared with untransfected cells 
[137].  As PIKfyve has been demonstrated to be necessary for 
PtdIns(3,5)P2 production and myotubularin is suggested to 
dephosphorylate PtdIns(3,5)P2, these studies seem to be conflicting and 
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suggest that more work into fully understanding PIKfyve and its role(s) 
within the mammalian cell are necessary. 
 
Due to SopB’s localisation with respect to the SCV, it is reasonable to 
assume that the undegraded EGFR would be found in higher 
concentrations on the SCV in wt-S. dublin when compared to ∆SopB-S. 
dublin infected cells.  When infected cells were fixed after 16 min of EGF 
stimulation and EGFR stained for, this was in fact supported by 
immunofluorescence.  An accumulation of undegraded EGFR around the 
area where the bacteria is present is clearly seen, thus supporting the 
biochemical data from Western blots.  Such an accumulation is not seen 
in uninfected cells (see neighbouring cells in Fig. 3.6c) nor in ∆SopB-S. 
dublin infected cells (not shown).  These results are hence consistent 
with PtdIns(3,5)P2 being a lipid that is necessary for normal receptor 
degradation kinetics, as evidence suggests PtdIns(3,5)P2 is a substrate 
for SopB.  The finding that EEA1 is present in high concentrations on the 
SCV of wt-S. dublin infected cells adds further support to this theory. 
 
 
3.4  Conclusion 
 
This study demonstrates that the lipid PtdIns(3,5)P2 may play a role in 
receptor degradation and further support the role of SopB as a 
phosphoinositide phosphatase with PtdIns(3,5)P2 as a substrate.  It is 
hypothesised that SopB diverts the SCV away from being targeted to the 
lytic lysosome via its phosphatase activity specifically on PtdIns(3,5)P2.  
The localisation of transiently transfected SopB within the cell also is in 
agreement with this hypothesis.  PtdIns(3,5)P2 may then play an 
important role in receptor degradation and MVB formation however its 
exact role is uncertain.  Studies on PIKfyve and its yeast homologue 
Fab1 have also suggested that PtdIns(3,5)P2 plays a role in endo-
lysosomal trafficking and possibly MVB formation, however little work 
has been done on PIKfyve [60-62, 70, 84, 88, 138].  As so little is known 
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about the exact role of PtdIns(3,5)P2 in the endocytic pathway, this study 
has further characterised SopB as a potentially useful tool for 
manipulation of PtdIns(3,5)P2.  Unfortunately high levels of wild-type 
SopB have been found to be highly toxic to mammalian cells.  As the 
myc-tagged SopB in these experiments was under the control of a CMV 
promoter which would result in high levels of expression, an expression 
system that has more controlled and lower levels of SopB would be an 
ideal approach for better manipulation of PtdIns(3,5)P2 levels. 
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4  Generation of an antibody against the 
mammalian phosphoinositide kinase PIKfyve 
 
 
4.1  Introduction 
 
The generation of PtdIns(3,5)P2 from its precursor PtdIns(3)P appears to 
be an important event in the proper function of the endo-lysosomal 
pathway [60, 70, 82, 131].  The early endosomally localised lipid 
PtdIns(3)P is an important lipid itself in the recruitment and hence 
localisation of cellular proteins to the early endosomal membrane [47, 
48].  In yeast it has been shown that the enzyme responsible for 
PtdIns(3)P conversion to PtdIns(3,5)P2 is Fab1, and the ∆fab1 mutant 
displays various growth defects along with a distinctly enlarged vacuole 
[139].  The mammalian homologue of Fab1 has been shown to be 
PIKfyve [140].  Like Fab1, PIKfyve also contains a FYVE domain, a 
domain known for interaction and binding to PtdIns(3)P at the endosomal 
membrane.  Additionally, a kinase-dead dominant negative form of 
PIKfyve when expressed in mammalian cells has been reported to give 
an enlarged vacuolar phenotype [70].  These swollen vacuoles appear to 
be endosomally derived, and the phenotype can be rescued by the 
introduction of wild-type PIKfyve [70]. 
 
The identification of PIKfyve and its importance in the endocytic pathway 
is quite recent, although its precise role(s) within the cell is far from clear.  
Studies that have taken place however have highlighted not only the 
importance of PIKfyve in membrane trafficking but in other membrane 
and signalling events, for example the regulation of specific trafficking 
pathways and the translocation of membrane transporters such as 
GLUT4 [141].  With regards to endo-lysosomal trafficking, kinase-dead 
mutants or cells that lack PIKfyve expression have been suggested to 
cause defects in the delivery and subsequent degradation of receptors to 
the lysosome [84, 88].  
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The study of this kinase is still relatively new and bearing in mind that the 
discovery of the phosphoinositide lipid PtdIns(3,5)P2 is also relatively 
recent, it is understandable that much has to be discovered about 
PIKfyve and its specific cellular roles.  However the current literature 
does provoke some confusion on PIKfyve’s role within mammalian cells.  
There have been conflicting reports on its sub-cellular localisation, 
having been reported to be both early- [84-86] and late-endosomal [142].  
The cellular events that PIKfyve may control have been reported to 
range from late endosomal maturation [131], to TGN retrograde 
trafficking [86], lysosomal maturation [84, 88], and even possibly nuclear 
transportation of receptors in tumour cells [87].  It is likely however that 
PIKfyve does not carry out a single task within the cell but has adapted 
to the complex system of mammalian trafficking to perform several 
cellular duties.  The lipid PtdIns(3,5)P2 itself may then consequently have 
promiscuity in its own cellular function. 
 
Given the confusing state of research with PIKfyve as well as the 
importance of PtdIns(3,5)P2 in proper MVB biogenesis and maturation, 
being able to better understand the role of PIKfyve in a cellular scenario 
is an important undertaking.  It is possible there is some role of PIKfyve 
in endosomal trafficking and thus it is desirable to have tools to be able 
to investigate this protein more extensively in this context.  Hence as 
PIKfyve has only recently begun to be characterised, useful tools such 
as commercial antibodies raised against PIKfyve have not been available 
for use.  Thus the aim of the work described in this chapter was to 
generate a reliable and specific antibody that would recognise 
endogenous PIKfyve in mammalian cells.  A small polypeptide that was 
taken from a hydrophilic portion of the PIKfyve protein was used to raise 
polyclonal antibodies to the human PIKfyve protein.  As this antigen was 
a hydrophilic sequence, it was likely to be readily accessible on the 
exterior of the native folded protein for recognition by polyclonal 
antibodies. 
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4.2  Results 
 
 
4.2.1  A polypeptide epitope for raising polyclonal anti-
PIKfyve antibodies against 
 
The human PIKfyve protein is a very large protein of approximately 235 
kDa and 2098 amino acids long.  Thus for raising polyclonal antibodies 
for recognition of this protein in its native form a region that should be 
exposed in the folded protein state is desired.  Hydrophobic residues 
tend to be sequestered away from contact with aqueous surroundings 
such as the cytoplasm.  Thus when a protein undergoes folding after 
synthesis, many of the hydrophobic residues are found buried in the 
protein’s interior.  Hydrophilic residues on the other hand are often left 
exposed at the exterior of the folded protein.  By choosing a region of 
amino acids from the protein’s sequence that consists of hydrophilic 
residues as an antigen, the epitope will be found at the surface of the 
protein.  The surface of the protein is exposed and therefore is 
recognisable by antibodies raised against this epitope when the protein 
is folded. 
 
One such hydrophilic polypeptide sequence can be found on the PIKfyve 
protein between the residues 1183 and 1200 (see hydrophobicity plot, 
Fig. 4.1).  The DNA sequence coding for this region (118 amino acids in 
length) was cloned into a pET15b vector with a His6 tag at the N-
terminus (see Fig. 4.2), to give a polypeptide of 152 amino acids in 
length termed His6-PIK.  This recombinant polypeptide was expressed 
and purified as previously described in 2.2.7, and sent to Diagnostics 
Scotland for immunization of a sheep.  An injection protocol into sheep 
was used which involved an initial subcutaneous injection of 1 mg of the 
polypeptide followed by booster injections every 28 days.  Test bleeds 
were taken 7 days after injections for a total of three separate bleeds.  
The sheep were not exsanguinated at the end of the procedure.  A total 
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of three bleeds totalling roughly 200 ml each along with a pre-immune 
bleed from the sheep were obtained. 
 
4.2.1.1  The purified His6-PIK polypeptide is approximately 16.5 kDa 
when run on SDS-PAGE 
 
Although the alignment of His6-PIK to the corresponding region of 
PIKfyve is only 118 amino acids in length, the total purified polypeptide is 
of 152 amino acids long and thus can be estimated to be roughly 16.5 
kDa in size.  To confirm this, a small amount of the purified His6-PIK was 
run on a high percentage SDS-PAGE gel and Coomassie stained (not 
shown). 
 
 
4.2.2  The first  bleed from a His6-PIK immunized sheep 
shows greater specificity for the antigen than pre-immune 
serum 
 
To determine the effectiveness of the post-immunization serum bleeds 
the first bleed serum was compared to the pre-immune serum, taken 
prior to the sheep being injected with His6-PIK.  To do this, both Western 
blotting and ELISA protocols were followed.  Firstly, the purified His6-PIK 
was run on a high percentage SDS-PAGE gel and transferred onto 
nitrocellulose membrane where it was incubated with a 1:1000 dilution of 
either the first bleed serum or the pre-immune serum.  Western blotting 
techniques were used and the developed membrane shows recognition 
of His6-PIK with the first bleed compared to the pre-immune serum (Fig 
4.3).  The strongest band is found to align with the 16.5 kDa marker, 
which would correlate to His6-PIK having an estimated molecular weight 
of 16.5 kDa.  Other bands are observed including one slightly above the 
32.5 kDa marker and quite a few bands below.  It is likely that the higher 
band is a dimerised form of His6-PIK and bands smaller than 16.5 kDa 
may be degraded protein.  It should be noted that the pre-immune and  
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Figure 4.3 – The first bleed sera from a His6-PIK immunized sheep shows high 
specificity for the His6-PIK polypeptide in comparison with pre-immune serum.  
Two lanes of a 12% Tris-glycine SDS-PAGE gel were loaded with approximately 1 µg 
purified His6-PIK along with pre-stained markers.  Marker weights are drawn on and 
indicated where numbers represent kDa size of protein.  Lane marked “1st Bleed” was 
blotted with a 1:1000 dilution of the first bleed of sheep serum obtained after injection of 
His6-PIK.  Lane marked “Pre-immune” was separated from the nitrocellulose the other 
lane was on, and similarly blotted at a 1:1000 dilution of the pre-immune serum from 
the sheep. Both lanes were incubated with goat α-sheep HRP-conjugated antibodies 
and developed at the same time for comparison of band intensities.  Note estimated 
molecular weight of His6-PIK is 16.5 kDa. 
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the first bleed were incubated with different halves of the membrane, but 
treated identically and exposed following secondary antibody anti-sheep-
HRP-conjugate developing for the exact same amount of time for 
comparable results. 
 
Following confirmation by Western that the first bleed serum recognised 
the antigen and the pre-immune largely did not, an ELISA was performed 
to further compare the specificity of the two bleeds at a range of serial 
dilutions from 1:100 to 1:250,000 (Fig. 4.4).  As clearly seen in Figure 
4.4, the binding of pre-immune sera to the antigen (His6-PIK) starts to 
diminish just before the 1:1000 dilution range, and continues falling to 
virtually background level at the highest dilutions.  In contrast, the first 
bleed appears to maintain practically the same level of antigen binding 
from the lowest dilution (1:100) to the highest dilution (1:248,000) 
suggesting that the recognition of the antigen by this sera is very good 
and that the sera has a very high affinity for the antigen.  This is 
demonstrated by the fact that the OD450 for the first bleed at a 1:100 
dilution is 1.242 compared with the OD450 at 1:124,000 and 1:248,000 
being 1.2525 and 1.222 (averaged from duplicate readings). 
 
 
4.2.3  Antibodies purified from the third bleed sera show 
greater specificity for His6-PIK than antibodies purified 
from the first bleed 
 
To obtain a purer form of the polyclonal antibodies that were raised 
against the His6-PIK polypeptide, the serum was purified using a NHS-
activated Hi-trap column prepared as described in 2.2.7.3.  The His6-PIK 
antigen was bound to this column and the serum run through the column 
allowing antibodies present in the serum to bind to the immobilised His6-
PIK polypeptides on the column.  The bound antibodies were then eluted 
and collected into fractions.  The fractions where the UV absorbance at 
280 nm (tyrosine and tryptophan absorption; A280) peaked were pooled 
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together and used as the purified polyclonal α-PIKfyve (see Fig. 4.5 for 
elution profile).  For the case of the first bleed, the purified antibodies are 
referred to as α-PIKfyve1 with the third bleed purification being α-
PIKfyve3.  No purification of the second bleed was carried out or 
characterised. 
 
To characterise the specificity and the ability of the affinity purified 
antibodies to recognise PIKfyve, CHO cells were transfected with a GFP-
PIKfyve construct, and these cell lysates along with untransfected 3T3 
cell adipocyte lysates (kindly provided by the Prof Geoff Holman lab) 
were run on an SDS-PAGE gel and blotted for using the sheep α-
PIKfyve1 purified antibody at a range of dilutions (note that the stock 
concentration of α-PIKfyve1 was 2.2 mg/ml).  Differentiated 3T3 
adipocyte cells were what the human PIKfyve protein was first identified 
in [140], thus it was reasoned that they might provide a good source of 
endogenous PIKfyve for testing the antibody on.  Although there 
appeared to be a fair amount of background bands appearing on the 
blots at lower molecular weights, there was an apparent intense band 
seen in the transfected CHO cell lysates that appeared to correlate to the 
expected size of GFP-PIKfyve (Fig. 4.6A).  A much less intense band 
can be seen slightly below the proposed GFP-PIKfyve band in the 3T3 
lysate lanes (at the 1:5000 and 1:10000 dilutions) that may relate to 
endogenous PIKfyve.  Even at a high dilution of 1:50,000 giving a 
concentration of 44 ng/ml α-PIKfyve1, there was clearly a band present in 
the GFP-PIKfyve transfected CHO lysate lane suggesting that the 
antibody has a very high affinity for the PIKfyve protein.  This band 
appears to run to roughly 250 kDa when compared to a broad range 
protein marker used, despite estimations of GFP-PIKfyve’s molecular 
weight being closer to 263 kDa.  It should be noted however that when 
this broad range protein marker is run alongside the pre-stained protein 
marker also used in our lab, the 148 kDa marker from the broad range 
marker runs very close to the 175 kDa band from the pre-stained marker.  
As the pre-stained marker from past experience has been shown to run  
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Figure 4.6 – α-PIKfyve
1
 recognises transiently transfected GFP-PIKfyve in CHO 
cell lysates.  CHO cells were transfected with GFP-PIKfyve as previously described.  
16 hours post-transfection cells were lysed and a protein assay determined the amount 
of total protein.  50 µg of total protein for CHO and 3T3 (from stocks of known 
concentration) cell lysates were ran on gels.  A.  A broad range marker was ran in Lane 
1 and the two highest molecular weights indicated.  Lanes 2, 4, 6 and 8 contained GFP-
PIKfyve transfected CHO cell lysates and incubated with α-PIKfyve1 at dilutions 
indicated on the bottom.  Similarly, lanes 3, 5, 7 and 9 contained untransfected 3T3 cell 
lysates.  The lane furthest to the right was blotted with the secondary antibody only for 
CHO lysate.  B.  GFP-PIKfyve transfected CHO cells and 3T3 cells were run for an 
extended period of time on a low percentage Tris-glycine gel and blotted for either α-
PIKfyve1 (left) or α-GFP (right) along with broad range protein markers (250 kDa band 
indicated although this is suspected to run higher than it should).  Arrows indicate the 
proposed band that represents GFP-PIKfyve. 
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fairly accurately with expected protein molecular weights, it is a 
possibility the broad range marker does not migrate as far as expected 
during SDS-PAGE. 
 
To further confirm that the intense band seen in the transfected CHO 
lysate was indeed GFP-PIKfyve, the lysate was run again in separate 
lanes where one lane was incubated with the α-PIKfyve1 antibody and 
another with an α-GFP antibody.  The two lanes were realigned with 
each other and exposed together to see if the band recognised by α-
PIKfyve1 in the transfected CHO cell lysate was also detected by α-GFP.  
As shown in Figure 4.6B it appears quite clear that the band recognised 
by α-PIKfyve1 is indeed GFP-PIKfyve as α-GFP also detects this band.  
This additionally suggests that either GFP-PIKfyve runs lower than its 
estimated molecular weight of 263 kDa or that the broad range protein 
markers used run higher than expected.  Thus when using the broad 
range protein markers it may be assumed that endogenous PIKfyve of 
estimated molecular weight 235 kDa would run slightly further below the 
250 kDa band. 
 
Having confirmed that the intense band seen on the Western blots 
performed appeared to be GFP-PIKfyve, it was hypothesised that an 
antibody that produced a cleaner blot with less background may also 
give a better indication of endogenous PIKfyve.  It is usually the case 
that later bleeds from an immunized animal can be more specific for the 
antigen the animal is immunized against.  This is due to the fact that over 
repeated exposure to the antigen, the B-cell population matures to 
produce and replicate those clones that bind the most tightly to the 
antigen.  In later bleeds then, many antibodies produced from B-cells 
that were not as specific in earlier bleeds are no longer produced as the 
B-cells were destroyed in the antibody selection process.  A more 
specific antibody, or rather population of antibodies being a polyclonal 
antibody population, should result in less background and ultimately 
better protein detection (for example, Western blotting).  As the original  
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Figure 4.7 - α-PIKfyve
3
 recognises GFP-PIKfyve on Western blots as well as 
apparent endogenous PIKfyve.  Purified α-PIKfyve3 (left) was used for Western blots 
to detect GFP-PIKfyve and endogenous PIKfyve in transfected and untransfected CHO 
cell lysates (“CHO-T” and “CHO-U” respectively).  The same cell lysates were also 
used for detection of GFP with α-GFP antibodies (right) having been run on the same 
gel and transferred to nitrocellulose membrane where membranes were realigned when 
exposed for comparison of bands between the two antibody incubations.  Both broad 
range markers (left) and pre-stained protein markers (right) were used and the 
molecular weights where the bands ran are indicated.  The upper arrow in the left panel 
and the arrow in the right panel indicate GFP-PIKfyve as seen in CHO-T lanes.  The 
lower arrow in the left panel indicates the proposed recognition of endogenous PIKfyve.  
Note that equal total protein was loaded for each lane on the basis of BCA protein 
assay (50 µg per lane). 
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first bleed was purified already, the decreased background expected 
from a later bleed may be marginal; however as the antigen-coupled 
column can be reused it was of minimal effort to also purify antibodies 
from later bleeds.  The third bleed was hence purified similarly to the first 
bleed and this antibody was tested on western blots of GFP-PIKfyve 
transfected and untransfected CHO cell lysates. 
 
As seen in Figure 4.7, the α-PIKfyve3 purified antibody appears to give 
an overall cleaner blot with recognition of transfected GFP-PIKfyve in 
CHO cell lysates.  Additionally, it is possible that the antibody is detecting 
endogenous PIKfyve at a dilution of 1:4000 (0.5 µg/ml from the stock α-
PIKfyve3 being 2 mg/ml).  It should further be noted however that the 
transfection of GFP-PIKfyve typically resulted in < 0.1% of cells being 
successfully transfected.  Various methods and optimisations were 
performed however the transfection efficiency was always very low.  It is 
interesting to note then the comparable intensities of the bands for GFP-
PIKfyve and suspected endogenous PIKfyve on the Western blot in Fig. 
4.7.  These bands appear to be of similar intensities, suggesting that if 1 
in every 1000 cells were successfully expressing GFP-PIKfyve, that this 
expression was in the region of 1000-fold over endogenous PIKfyve 
expression in CHO cells.  If then α-PIKfyve3 was recognising 
endogenous PIKfyve, it may be assumed that this recognition is quite 
sensitive and can detect low levels of PIKfyve. 
 
 
4.2.4  Characterisation of α-PIKfyve3 for use in 
immunofluorescence studies 
 
As the α-PIKfyve3 antibody had been already shown to recognise the 
SDS-solubilised form of PIKfyve, to further characterise α-PIKfyve3, 
immunofluorescence studies were performed.  HeLa cells were 
transfected with the GFP-fusion PIKfyve protein to help determine the 
ability of α-PIKfyve3 to recognise the native folded protein expressed in 
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the context of mammalian cells.  Successful transient transfections of 
GFP-PIKfyve into mammalian cell lines had proved to be very difficult as 
already discussed.  Despite varying the cell types used, transfection 
reagents and methods, ratios of transfection reagent to DNA and 
increasing the amount of DNA itself, the transfection efficiency of GFP-
PIKfyve was always much less than 1%.  On a typical 13 mm coverslip of 
~80% confluency, there may have only ever been between one and ten 
successfully transfected cells, and this number was on the low side and 
often even zero when using a kinase dead mutant form of GFP-PIKfyve 
(GFP-PIKfyvemut).   
 
Despite these transfection issues, the ability of α-PIKfyve3 to recognise 
PIKfyve in a cellular context was still investigated based on the few 
transfected cells observed at different antibody dilutions (Fig. 4.8).  A 
high dilution of the α-PIKfyve3 antibody at 1:2000 (stock antibody 
concentration of 2 mg/ml) resulted in some apparent low-level 
recognition of diffuse cytosolic protein in untransfected cells (Fig. 4.8a), 
confirmed by lack of staining with secondary only antibodies (not shown).  
Furthermore in some cells, there appeared to be concentrated areas of 
protein recognition by the antibody, as indicated by arrows in Fig. 4.8a.  
This was observed in a significant proportion of different untransfected 
cells and thus was not a rare phenomenon.  There certainly did seem to 
be some small punctae with increased antibody binding, suggesting that 
if indeed the antibody was recognising endogenous PIKfyve, that it may 
be present in higher concentrations on specific membrane 
compartments.  Previous work that was carried out during the work for 
this thesis looked at PIKfyve’s localisation using GFP-PIKfyve and found 
it to localise to early endosomal compartments, which is in agreement 
with the findings in 3.2.3 which found colocalisation with SopB, shown to 
be early endosomally localised. 
 
At the same dilution of 1:2000 of α-PIKfyve3, there appeared to be 
potential recognition of the exogenously expressed GFP-PIKfyve as 
demonstrated in Fig. 4.8b.  The sensitivity of the recognition was 
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apparently improved and a 1:1000 and 1:500 dilution (Fig. 4.8c-e), 
although the staining was starting to appear rather strong with the 1:500 
dilution.  Overexpression of GFP-PIKfyve can often result in slightly 
enlarged cellular structures and possible membranous compartments 
enriched with GFP signal, as seen in Fig. 4.8d.  The α-PIKfyve3 antibody 
did however appear to partially recognise these protein enrichments at 
the 1:500 dilution (Fig. 4.8d) however whether this was a specific 
recognition was not determined.  Furthermore, at such high levels of 
protein expression, it cannot be ruled out that these structures may 
simply be protein aggregates.  At the lowest dilution of 1:100 however, 
the staining of PIKfyve appeared to be very strong, perhaps too strong 
for both the GFP-PIKfyve and endogenous PIKfyve (Fig. 4.8f).   
 
As a result of these studies it appeared that the optimal dilution for use of 
α-PIKfyve3 in immunofluorescence studies was between 1:500 and 
1:1000, with the latter being probably most suited for both exogenous 
and endogenous staining.  Similar experiments were carried out with 
transfection of GFP-PIKfyvemut, however in this case there were no 
positively transfected cells observed. 
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4.3  Discussion 
 
The use of antibodies in research is clearly an important tool.  Over-
expression studies that involved tagged proteins are very useful 
approaches but offer limitations in interpretation of results due to the 
large amounts of dominant negative proteins or even wild-type proteins 
that result from an over-expressing cell.  Additionally in studies such as 
gene silencing and knockdowns, it is often essential to show the lack of 
expression of the target gene via absence of the corresponding protein, 
for which an effective antibody is hence needed.  Being able to detect 
endogenous proteins is a much more useful ability for a wide range of 
applications and coupled with studies such as over-expression and RNA 
silencing techniques, a better understanding of the protein at hand can 
be obtained by such methods.  Additionally, the use of affinity isolations 
and pull-down experiments provide useful clues to potential protein 
interaction partners and cellular localisation of proteins.  Having an 
antibody that one can be confident in detecting the protein of interest is 
vital for such studies. 
 
As the field of research with regards to the lipid kinase PIKfyve is still 
relatively new and limited, the availability of good antibodies to this 
protein is somewhat scarce.  Most publications that have made use of 
PIKfyve antibodies to date have relied on in-house production of such 
antibodies, with no apparent reliable commercial antibodies for PIKfyve 
seemingly available.  A common animal to raise polyclonal antibodies in 
is rabbit, however much of the work done in our lab involves the use of 
other antibodies of which many have been raised in rabbit.  Producing 
another antibody then that is from the rabbit species brings in limitations 
to the use of such an antibody in conjunction with detection of other 
proteins using common biochemical techniques such as 
immunofluorescence, immunoprecipitation and even Western blotting.  
Due to this reasoning, the animal used for α-PIKfyve production was a 
sheep. 
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The production of an antibody that recognises and specifically binds 
PIKfyve appears to have been successful, as demonstrated by these 
characterisation studies.  This antibody has also been given to other labs 
that carry out research on PIKfyve.  This antibody has been shown to 
recognise the same band that another antibody raised against PIKfyve 
recognises, and is currently being extensively used in the research of 
this lab (Prof Jeremy Tavare, personal communication).   
 
As already discussed, the exact role of PIKfyve within the cell is not well 
established and under much scrutiny within the literature.  There 
potentially are roles for PIKfyve in the endo-lysosomal trafficking 
pathway of some description.  However given the conflicting findings of 
various studies on PIKfyve it is hard to draw firm and meaningful 
conclusions that take into account most of these findings.  Some results 
may be cell-type specific, for example studies that suggest PIKfyve’s 
involvement in EGFR trafficking to the nucleus may be rather specific to 
a certain cell type as it is hard to envisage a transmembrane protein 
being trafficked to the nuclei of many different cell types [87].  On the 
other hand the methods used as well as potential various roles for 
PIKfyve from some studies may explain the conflicting results, such as 
subcellular localisation of PIKfyve having been reported previously to be 
late endosomal with more recent studies suggesting an early endosomal 
association [84-86].   The personal data that has been found from not 
only this particular study described in this chapter but also in other 
chapters (for example Chapter 3) would be in agreement with an early 
endosomal localisation of PIKfyve.  This would make sense given the 
FYVE domain that PIKfyve possesses; a domain that is known to bind 
the early endosomally localised lipid PtdIns(3)P.  It may be the case that 
over-expression of mutant forms of PIKfyve results in a membranous 
bound PIKfyve that is associated with a compartment that ultimately 
matures into a late endosomal structure.   This could explain the finding 
in over-expression studies of the kinase-dead mutant PIKfyve that it 
localises with late endosomal markers.  In this scenario, the advantages 
of silencing endogenous genes become obvious. 
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A recent study has shown that PIKfyve appears to be necessary for the 
degradation but not silencing of endocytosed receptors, suggesting that 
PIKfyve is not needed for delivery of cargo into the MVB lumen [84].  
Rusten et al showed that in mutant drosophila cells that did not contain 
the fab1/PIKfyve gene, enlarged MVBs were seen however there was a 
distinct lack of ubiquitylated cargo and endocytosed receptors were 
delivered into the lumens of MVBs [84].  Additionally, the lysosome was 
not correctly acidified and despite these endocytosed receptors being 
efficiently silenced, degradation was impaired in the mutant cells.  This 
study displays parallels to Bache et al, who demonstrated similarly that 
the ESCRT-III component hVps24 (CHMP3) is not necessary for the 
silencing of EGFR but is needed for its degradation.  By using gene 
silencing of CHMP3, Bache et al also showed that in CHMP3-depleted 
cells, EGFR was efficiently silenced despite the lack of CHMP3, in 
comparison to the ESCRT-I component TSG101 where silencing of this 
gene resulted in sustained activation of EGFR [56].  They then suggest 
that earlier ESCRT components (ESCRT-I for example) are necessary 
for delivery of cargo into the lumen of MVBs, however the ESCRT-III 
component CHMP3 plays a role in the fusion of the MVB with the 
lysosome.  These two studies of PIKfyve and CHMP3 seem to suggest 
when taken in conjunction with each other that PIKfyve and ESCRT-III 
may be closely linked.  Certainly this would explain then some of the 
findings that suggest that PtdIns(3,5)P2 may play a role in this pathway 
and additionally add support to CHMP3 being an effector of 
PtdIns(3,5)P2 despite the only current evidence for this comes from in 
vitro lipid binding studies [71]. 
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4.4  Conclusion 
 
Despite the confusing state of the literature with regards to PIKfyve, it is 
clear that this protein plays an important role in the proper function of 
endo-lysosomal pathways.  This suggests that the phosphorylated 
products of PIKfyve, such as PtdIns(3,5)P2 are hence important and 
perhaps more promiscuous than previously thought.  The production and 
characterisation of a polyclonal antibody population that specifically and 
clearly recognises this protein even at endogenous levels is a very useful 
tool to have for further investigation of PIKfyve.  This antibody is already 
being used by several other labs and has proven to be very effective for 
its given purpose, and certainly should be continued in its use to further 
our understanding of PIKfyve and help elucidate its precise role or roles 
within mammalian cells. 
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5  Development of a pull-down assay of the 
Vps4
E235Q
 compartment as a potential proteomic 
approach for identification of novel ESCRT and 
MVB-related proteins 
 
 
5.1  Introduction 
 
The biogenesis and maturation of the mammalian MVB compartment is 
already known to be a highly complex process that is not completely 
understood.  The formation of MVBs in mammalian cells bears many 
similarities to that in yeast, and certainly contains highly homologous 
proteins.  However in comparison to yeast it is already evident that the 
mammalian MVB pathway is even more multifaceted and contains a 
wider spectrum of protein involvement and interactions.  Many of these 
proteins and associated interaction partners are only recently beginning 
to be described and discovered.  Additionally it has been strongly 
suggested and implicated that ESCRT proteins are involved in other non-
endosomal functions as well as MVB formation.  As a result, some 
interaction partners identified through yeast two-hybrid and other similar 
studies may not actually play a role in MVB biogenesis [reviewed in 4; 
42].   
 
Ideally, it would be advantageous for one to be able to observe the MVB 
compartment and the proteins found therein, allowing us to study the 
properties and functions of such proteins in terms of MVB formation and 
maturation, resulting in a better and more complete understanding of 
how this process occurs.  Obviously the complexities of the MVB 
formation process itself limit such an approach of isolating an in vivo 
compartment; a compartment that is dynamic.  Furthermore, despite the 
identification of ESCRT protein complexes, it is not clear as to whether or 
not these complexes purely consist of the identified ESCRT proteins.  In 
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fact it is possible that there are other unidentified proteins involved in 
these complexes.  New ESCRT proteins previously not known to be 
involved in the ESCRT complexes have recently been identified as being 
necessary for proper MVB function [144-146].  Being able to identify 
proteins directly involved with the endogenous ESCRT complex is an 
important undertaking; however current technology and reagents such as 
good antibodies to endogenous ESCRT proteins have not currently 
allowed such an approach.  These approaches are also limited to pre-
existing knowledge, for example in the case of antibodies you can only 
probe a complex or cellular compartment with an antibody to a known 
protein. 
 
One approach that may yield a method for identification of proteins 
involved in ESCRT complexes and hence MVB formation is to isolate a 
stable compartment that is known to contain ESCRT components.  It is 
widely accepted that the expression of an AAA-ATPase dead mutant 
form of Vps4 (Vps4E235Q) results in a swollen endosomal phenotype in 
mammalian cells [53, 135].  This observed swollen endosomal structure 
can be referred to as the Vps4E235Q compartment.  It is accepted that 
exogenous expression of this dominant negative protein results in a 
defective Vps4 protein that binds to membranes but cannot be removed 
due to its lacking ATPase activity.  As the role of Vps4 is the removal of 
ESCRT components from the MVB limiting membrane, it should be 
expected that ESCRT proteins would colocalise with the dominant 
negative protein on swollen endosomal membranes, which has already 
been shown [53, 71, 73].  As Vps4 interacts with the ESCRT-III 
components for its localisation through its MIT domain [89, 91], its 
localisation is dependent upon ESCRT-III localisation.  The removal of 
ESCRT proteins from the MVB membrane is necessary to complete 
cargo delivery to the lumen and a defective Vps4 is unable to facilitate 
this reaction [53, 135].  Furthermore, it has been previously shown that 
the Vps4E235Q compartment stabilises a structure of >670 kDa involving 
other proteins additional to CHMPs [147].   
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Given these findings, it was hypothesised that an affinity pull-down assay 
could be constructed that allowed for the isolation of intact Vps4E235Q 
compartments that not only contained existing ESCRT components such 
as CHMPs but possibly other proteins not yet identified that are involved 
in MVB formation and associate with ESCRT complexes.  This could 
ultimately then lead to a large-scale screening of the proteomic 
complement found on such a compartment, with possible identification of 
novel proteins contained on this compartment not yet identified as 
ESCRT-related proteins. 
 
This chapter describes the work carried out to develop such an affinity 
pull-down assay of the Vps4E235Q compartment.  By transient transfection 
methods, a GFP-fusion Vps4E235Q protein was expressed in mammalian 
cells and the resulting swollen endosomal compartment was pulled down 
using immunoprecipitation methods.  Utilising a new tag developed by 
Promega called HaloTag® to better isolate Vps4E235Q compartments, it 
was shown using 2-d SDS-PAGE gel methods that a large number of 
proteins can be detected from the Vps4E235Q compartment.  Hence such 
an assay may provide useful information on the proteomic complement 
associated with ESCRT complexes. 
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5.2  Results 
 
 
5.2.1  The Vps4E235Q GFP-fusion protein can be efficiently 
immunoprecipitated from non-detergent lysed cells 
 
It was hypothesised that the membrane bound compartment that 
contains the GFP-Vps4E235Q protein would be best isolated as an intact 
compartment to ensure any stability of a complex reliant on the 
compartment’s lipid membrane was maintained.  As a result of this, a 
detergent-free lysis method was employed.  This involved using a non-
detergent lysis buffer for gentle cell lysis, known as TES.  Furthermore, it 
has been implied from a previously isolated ESCRT-complex that such a 
complex may need the presence of ATP to maintain assembled stability 
[147], thus 2 mM ATP was also added to this lysis buffer, resulting in a 
buffer termed TESA.  Cells were gently lysed on ice in this buffer and 
then homogenised using a syringe homogeniser, which sheared the cells 
through a ball-bearing with a clearance distance of 4 µm.  Further details 
of this process and the immunoprecipitation with α-GFP antibodies can 
be found in 2.2.8. 
 
Initially, the transfection of GFP-Vps4E235Q was optimised and it was 
determined that the use of Lipofectamine 2000™ was the optimal 
reagent for the most efficient transfection of GFP-Vps4E235Q.  
Additionally, the α-GFP antibody used for Western blotting was tested on 
the detergent-free lysed cells that had been transfected using the 
Lipofectamine reagent to determine how well this antibody would detect 
GFP-Vps4E235Q.  A range of protein amounts from the cell lysates (25-75 
µg protein) was loaded, and as seen in Figure 5.1, this antibody gives a 
very distinct band just below the 83 kDa marker with little background.  
The estimated MW of GFP-Vps4E235Q is 76 kDa.   
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Figure 5.1 – Transfection with GFP-Vps4E235Q using Lipfectamine 2000™ in 
detergent-free lysed HeLa cells is detectable by Western blotting.  HeLa cells were 
grown in a 25 cm2 flask to 60-80% confluency and then transfected using Lipofectamine 
2000™ reagent by standard protocol, allowing to express for 18 hours.  The following 
day cells were trypsinised, pelleted and resuspended in a small volume of TESA buffer, 
with protein concentration determined by BCA methods.  75 µg, 50 µg and 25 µg of 
total protein was run on an SDS-PAGE gel, transferred, and blotted with rabbit α-GFP 
and α-rabbit-HRP, as indicated on the above blot (75ug, 50ug, and 25ug respectively).  
The bands appear between the 62 and 83 kDa markers suggesting a correlation to 
GFP-Vps4E235Q, which has an estimated MW of 76 kDa.  The same process was 
previously carried out using FuGene® 6 as the transfection reagent however no obvious 
GFP-Vps4E235Q was detected using this method (not shown). 
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Following successful transfection and Western blot detection of GFP-
Vps4E235Q, immunoprecipitations of GFP-Vps4E235Q were performed to 
determine if GFP-Vps4E235Q could be successfully immunoprecipitated 
using the α-GFPIgG2a antibody.  Briefly, Protein G beads were bound with 
the mouse α-GFPIgG2a antibody and immunoprecipitations were 
performed on this affinity complex.  As the antibody used for the 
precipitations was a mouse monoclonal antibody, rabbit polyclonal 
antibodies could be used for Western blots, as antibodies from non-
mouse species should not detect the IgG bands that may have been 
detected with mouse antibodies, which could potentially provide 
confusing results.  As seen in Figure 5.2, it is evident that there is a loss 
of GFP signal from the fraction not bound to the Protein G beads 
(‘Unbound’ lane).  In contrast, the bound lanes show a signal of GFP 
detection, which appears to correlate to the correct size of GFP-
Vps4E235Q in the bound lanes (‘Bound IP’ lanes).  Thus these results 
demonstrate that GFP-Vps4E235Q can be successfully pulled out of a cell 
lysate using immunoprecipitation methods.  
 
As CHMP proteins and other ESCRT components are generally small 
proteins, it is possible to blot for these proteins in the same lanes on 
Western blots where the GFP-Vps4E235Q was being blotted for.  By 
separation of the blot below the 47.5 kDa marker in addition to 
separation of the various bound immunoprecipitate lanes, various 
CHMPs could be probed for, using CHMP antibodies already developed 
and characterised in the lab.  It was apparent that in the corresponding 
pull-down of GFP-Vps4E235Q that there was possible enrichment of 
endogenous CHMP3, as demonstrated by the detection of a faint band at 
the approximate size of CHMP3 (Fig. 5.2).  However, upon blotting the 
immunoprecipitate with the α-CHMP4A antibody, there appeared to be 
little to no band present, suggesting that CHMP4 was not pulled down.  It 
should be noted that for detection of CHMP bands that the use of ECL 
Advance® solutions was necessary as regular ECL development resulted 
in no apparent bands. 
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To address whether or not the pull-down was a specific 
immunoprecipitation, an IgG only control was needed.  Thus the 
experiment was repeated using mouse IgG binding to Protein G beads in 
parallel to mouse α- GFPIgG2a antibody.  Initial experiments resulted in a 
GFP positive band of similar intensity in the IgG control bound lane 
compared with the α- GFPIgG2a  lane,  suggesting  that the pull-down  of 
GFP-Vps4E235Q  may  be  a non-specific interaction with IgG molecules 
(not shown).  However upon increasing the number of washes and 
adding a small amount of BSA into some of the washes of the beads, the 
specificity of the α-GFPIgG2a antibody appeared to improve greatly, 
although there did still appear to be some small amount of non-specific 
immunoprecipitation occurring (Fig. 5.3).  Despite possible recognition of 
enriched CHMP3 in the bound immunoprecipitate of previous blots (see 
Fig. 5.2, lower panel), endogenous CHMPs were not detected again in 
HeLa cells using this method including the IgG control.  Although pull-
downs of GFP-Vps4E235Q seemed successful, we cannot be sure that we 
were pulling down an intact ESCRT-machinery complex. 
 
 
5.2.2  Characterisation of the HaloTag® labelling system 
with Vps4E235Q for isolation of the Vps4E235Q compartment 
 
A recent product that had been introduced by Promega is a novel tag 
that allows for expression of a fusion protein of a 33 kDa tag termed 
HaloTag®.  There are several advantages of this tag over other large 
tags; one being the use of HaloLigands® which can be biotinylated or 
fluorescent ligands.  Such fluorescent ligands are membrane permeable 
and bind specifically to the Halo-tagged protein, allowing for quick, easy 
and versatile detection of a tagged protein.  A further advantage of the 
HaloTag® is the product referred to as HaloLink® which is a resin that 
covalently binds the HaloTag® thus allowing a tagged-protein to be 
covalently bound to a resin as opposed to other affinity and immuno-
interactions which are less stable than covalent
 
1
2
0
 
               Fi
g
u
re
 5
.3
 –
 P
u
ll
-d
o
w
n
s
 o
f 
G
F
P
-V
p
s
4
E
2
3
5
Q
 a
re
 s
p
e
c
if
ic
 w
it
h
 t
h
e
 α
-G
F
P
 a
n
ti
b
o
d
y
. 
 H
e
L
a
 c
e
lls
 w
e
re
 t
ra
n
sf
e
ct
e
d
 a
n
d
 p
ro
ce
ss
e
d
 w
ith
 d
e
te
rg
e
n
t-
fr
e
e
 l
ys
is
 
b
u
ff
e
r 
a
s 
a
lr
e
a
d
y 
d
e
sc
ri
b
e
d
. 
 L
ys
a
te
s 
w
e
re
 i
n
cu
b
a
te
d
 w
ith
 I
g
G
–
P
ro
te
in
 G
 o
r 
α
-G
F
P
–
P
ro
te
in
 G
 b
e
a
d
 c
o
m
p
le
xe
s 
a
n
d
 f
ra
ct
io
n
s 
ru
n
 o
n
 S
D
S
-P
A
G
E
 g
e
l, 
tr
a
n
sf
e
rr
e
d
, 
a
n
d
 b
lo
tt
e
d
 f
o
r 
u
si
n
g
 i
n
d
ic
a
te
d
 a
n
tib
o
d
ie
s.
  
α
-r
a
b
b
it 
re
p
re
se
n
ts
 a
 s
e
co
n
d
a
ry
 o
n
ly
 c
o
n
tr
o
l. 
‘a
-G
F
P
’ 
re
fe
rs
 t
o
 t
h
e
 α
-G
F
P
–
P
ro
te
in
 G
 b
e
a
d
s;
 ‘
Ig
G
’ 
re
fe
rs
 t
o
 I
g
G
–
P
ro
te
in
 G
 b
e
a
d
 c
o
n
tr
o
l. 
 121 
bonds.  The HaloLink® resin then is a useful tool for pull-downs and can 
act as a replacement for using Protein G or Protein A beads in an 
immunoprecipitation pull-down assay.  As the covalent link to the 
HaloTag® is specific, there should be a large decrease in non-specific 
proteins pulled down from a cell lysate.  Using the pHT2 vector that 
contains the HaloTag® coding sequence, Vps4WT and Vps4E235Q were 
both cloned into this vector to give a fusion protein with the HaloTag® at 
the N-terminus of each protein when expressed.  For details of this 
cloning, see Chapter 2.2.6.  These Halo-tagged constructs were hence 
named Halo-Vps4WT and Halo-Vps4E235Q.  
 
To determine the phenotype of the Halo-Vps4E235Q protein when 
expressed in mammalian cells, constructs were transiently transfected 
into Cos-7 cells and examined by confocal microscopy after incubation 
with fluorescent Halo-ligands (Fig. 5.4A).  As expected, the dominant 
negative expression of Halo-Vps4E235Q resulted in an enlarged 
endosomal phenotype, with a punctate staining obvious.  There is 
however a difference in the phenotype visible by eye when observing 
positively transfected Halo-Vps4E235Q cells in comparison to GFP-
Vps4E235Q expression, namely the size of swollen endosomes.  In Cos-7 
cells the expression of GFP-Vps4E235Q often results in giant aberrant 
endosomal structures with the overexpressed protein present on its 
membranes.  However with expression of Halo-Vps4E235Q similarly in 
Cos-7 cells, the swollen vesicles did not appear to be as enlarged by 
comparison.   
 
Additionally with transfection of Halo-Vps4E235Q it was typically noted that 
the general expression levels were lower than that often seen with GFP-
Vps4E235Q transfection, with fewer more highly expressing cells present.  
Thus it was determined that the Halo-tagged constructs would be useful 
for trying to isolate the Vps4E235Q compartment using the HaloLink® resin, 
and subsequent studies were hence carried out with these constructs 
instead of the GFP-tagged constructs. 
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Figure 5.4 – Halo-Vps4E235Q expression gives enlarged endosomal structure 
and expression can be induced by removal of doxycycline when transfected into 
HeLa-Tet-Off
®
 cells.  A. Cos-7 cells were transfected with constructs as indicated and 
processed (described in 2.2.2).  Expression of Halo-Vps4E235Q and incubation with the 
green TMR® Halo-ligand (i; see 2.2.2.1) results in a punctate cellular localisation, with 
enlarged vesicles.  GFP-Vps4E235Q expression (green; ii) also results in enlarged 
vesicular structures however typically these structures are much more enlarged by 
comparison.  B.  HeLa-Tet-Off® cells were transiently transfected with Vps4WT or 
Vps4E235Q sequences cloned into the pTRE2pur vectors.  Removal of doxycycline post-
transfection allowed expression of appropriate proteins as indicated.  Cells were 
incubated with the DiACFam red Halo-ligand and the Halo-Vps4WT gives a diffuse 
cytoplasmic staining (i) whereas Halo-Vps4E235Q localises to enlarged vesicular 
structures (ii). 
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5.2.3  Generation of stable cell lines that express Halo-
Vps4WT or Halo-Vps4E235Q in an inducible manner 
 
One problem with a transient transfection method for producing cell 
lysates with the Vps4E235Q compartment is the inconsistency in and often 
low-level of successfully transfected cells.  This will hence vary the 
endogenous proteins that will be detected by antibodies.  This is 
because the degree of enrichment of these endogenous proteins 
associated with the complex will be dependant on the number of 
complexes in the cell lysate, which in turn is dependant upon the 
transfection efficiency.  Having a stable cell line that expresses 
Vps4E235Q would result in 100% of the cells expressing the Vps4E235Q 
compartment thus allowing for a large quantity of these compartments to 
be isolated, enabling better detection of proteins that may be associated 
with the complex. 
 
One potential dilemma with the use of a stable cell line is that the Vps4 
protein is essential for proper cell function in terms of proper endo-
lysosomal trafficking and receptor silencing.  Continual expression of 
such a dominant negative protein is likely to be somewhat detrimental to 
a cell line, and it would be reasonable to expect that the cell would not 
grow and proliferate under such expression of a dominant negative Vps4 
protein.  The Tet-Off/On™ system provides a technique by which stable 
cell lines can be produced that possesses inducible protein expression.  
For these experiments the Tet-Off™ system was used which relies on 
the presence of tetracycline or doxycycline to keep the incorporated 
construct’s expression constitutively turned off.  By removal of 
tetracycline or doxycycline from the cell media, expression of the protein 
is no longer repressed and allowed to occur.  For more details with 
regards to the Tet-Off™ system and methods used for cloning of the 
Halo-Vps4WT and Halo-Vps4E235Q constructs into appropriate vectors for 
production of stable cells, see Chapter 2.2.9. 
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For the generation of inducible stable cell lines, cells were transiently 
transfected and selected with appropriate antibiotic markers as outlined 
in 2.2.9.  To test whether the constructs transiently transfected were 
indeed inducible, cells were transfected and fixed in both the presence 
(repression) and absence (expression) of doxycycline.  This resulted in 
clear inducibility as the cells that had doxycycline removed for both Halo-
Vps4WT and Halo-Vps4E235Q transfection both showed clear expression 
(Fig. 5.4B) compared with transfected cells in the presence of 
doxycycline which did not show any notable expression (not shown). 
 
Despite screening of over 200 colonies that showed selectable antibiotic 
marker properties for both Halo-Vps4WT and Halo-Vps4E235Q stable cell 
lines, no colonies were found to obviously express either protein when 
doxycycline was removed from the cell media.  Protein expression was 
assayed for by both immunofluorescence and Western blotting 
techniques using fluorescent Halo-ligands and α-Vps4 antibodies 
respectively.  No fluorescence was seen in any of the colonies tested, 
and in the case of Western blotting, the endogenous Vps4 protein was 
detected, however the Halo-Vps4WT or Halo-Vps4E235Q protein (33 kDa 
heavier than endogenous Vps4) was not detected in the + or – 
doxycycline conditions (Fig. 5.5).  Thus due to the time-scale and volume 
of unsuccessful screening for positive stable colonies being already 
greater than 6 months, it was decided to not further pursue this 
approach. 
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Figure 5.5 – Colonies from HeLa-Tet-Off
®
 cells screened for presence of Halo-
Vps4
E235Q
 in the presence and absence of doxycycline show no apparent 
expression.  Colonies of HeLa-Tet-Off® cells showing resistance to selective antibiotic 
containing media were screened using Western blotting techniques by incubating 35 
mm dishes with or without doxycycline for 24-48 hours prior to cell lysis.  Protein 
content was determined by BCA methods and 30 µg of protein was loaded for each 
clone except clone 10 (which had too low a protein to load 30 µg).  Lysates were run on 
SDS-PAGE gels, transferred and blotted using α-Vps4.  The three blots represent 
twelve separate colonies, a fraction of the total number screened (>200).  The 
estimated MW of Halo-Vps4E235Q is 81 kDa; arrows indicate bands that represent 
endogenous Vps4.  Doxycycline presence is indicated by ‘dox +’ (doxycycline present) 
or ‘dox –‘ (doxycycline absent).  No obvious bands are seen at the estimated MW of 
Halo-Vps4E235Q that show doxycycline expression inducibility; any bands visible near 
the 83 kDa marker are fainter than endogenous Vps4 bands. 
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5.2.4  Pull-downs of Halo-Vps4E235Q from detergent-free 
lysed cells shows the presence of ESCRT components 
TSG101 and CHMP3 
 
From other studies carried out in the lab, it was found that NRK cells 
appeared to express higher amounts of some endogenous CHMP 
proteins when compared with other cell lines such as HeLa cells (Dr 
Judith Richardson, personal communication).  Thus it was decided to 
use these cells for the pull-down experiments using the HaloLink® resin 
as an enrichment of CHMP proteins may be more easily detected.  For 
full details of the methods used for pull-down with the resin see 2.2.8. 
 
As the Halo-Vps4E235Q protein binds covalently to the HaloLink® resin, 
one is unable to detect the transfection efficiency or successful pull-down 
by Western blotting as the Halo-Vps4E235Q protein remains bound to the 
resin.  However any proteins hence associated with the Halo-Vps4E235Q 
compartment would be detected using SDS-PAGE and Western blotting 
methods as the gel sample preparation process disrupts the protein-
protein and protein-lipid interactions.  Using the HaloLink® resin to pull-
down Halo-Vps4E235Q compartments, the ESCRT-I component TSG101 
and the ESCRT-III component CHMP3 were both detected to be 
enriched in bound fractions (Fig. 5.6).  The ESCRT-III component 
CHMP4A however was not detected in the bound fraction of these 
experiments (Fig. 5.6A).  These experiments were repeated with Halo-
Vps4WT, however there was no detection by Western blotting of 
TSG101, CHMP3 or CHMP4A from these pull-downs (not shown).  This 
suggests that the proteins detected in the Halo-Vps4E235Q pull-downs are 
likely to be specifically pulled down due to Halo-Vps4E235Q protein 
expression. 
 
 
 127 
Figure 5.6 – Affinity pull-downs of Halo-Vps4
E235Q
 contain ESCRT proteins as well 
as a large number of other unknown proteins.  NRK cells transfected with Halo-
Vps4E235Q were subjected to detergent free lysis and affinity purified for Halo-Vps4E235Q 
via HaloLink® resin by methods described.  A. The bound fractions were solublised from 
the resin using SDS sample buffer and boiling.  Samples were run on an SDS-PAGE 
gel, transferred, and Western blotted for CHMP3, CHMP4 and TSG101 as indicated 
above the lanes.  Known marker weights are indicated to the left of blots.  B. Affinity 
pull-downs from NRK transfected lysates were solublised in SDS sample buffer, boiled, 
and run on a 2-d gel.  Markers of known size are indicated on the far left; the pH range 
is from pH 3 (far right) to pH 10 (left) as indicated.  Individual spots were counted as 
being in the range of 90-100 unique spots. 
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5.2.5  HaloLink® resin pulls down a significant number of 
different endogenous proteins from the Vps4E235Q 
compartment that may be ESCRT-associated 
 
To determine whether or not various different endogenous proteins could 
be pulled down using the recently developed HaloLink® pull-down assay, 
the resin from a pull-down experiment of NRK cell lysates transfected 
with Halo-Vps4E235Q (lysed in detergent-free buffer) was loaded and run 
on a 2-d gel.  This gel was run with appropriate markers, from a pH 
range of 3.0 to 10.0 by Dr Ursula Gereike (University of Bath).  The 2-d 
gel shows a range of individual spots, approximately 90-100 in total, 
which suggests that there are many possible proteins that have yet to be 
identified as being present on the Vps4E235Q compartment and thus 
potentially important in proper ESCRT function and MVB biogenesis (Fig. 
5.6B). 
 
 
5.2.6  Intact vesicles can be  successfully pulled down 
using HaloLink® resin  
 
The ability of the developed method to be able to pull down intact 
vesicles cannot be assumed simply by detection of other proteins.  
Indeed these proteins may simply have been pulled down as a result of 
protein-protein interactions between the Halo-Vps4E235Q and other 
endogenous proteins that form a complex.  Thus the detection of other 
proteins pulled down with Halo-Vps4E235Q such as TSG101 and CHMP3 
does not provide evidence that an integral vesicular compartment has 
been successfully affinity isolated.  Being able to isolate such a 
compartment is a useful process as this could allow the possibility of 
many other in vitro experiments on such a compartment.  To address this 
question, a simple dextran-red uptake assay was performed (for full 
details of the method see 2.2.8).  Dextran-red will be taken up by 
endocytosis and traffic through the endocytic pathway.  In cells with 
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perturbed MVB formation resulting in enlarged vesicles such as the 
Vps4E235Q compartment, accumulation of dextran-red will be seen in 
these enlarged endosomal structures (Fig. 5.7A).  Cells treated with 
dextran-red versus cells transfected with Halo-Vps4WT or Halo-Vps4E235Q 
and treated with dextran-red were compared for dextran-red 
accumulation by measuring the fluorescence in the wavelength range of 
dextran-red following detergent-free cell lysis and pull-downs with the 
HaloLink® resin.  The Halo-Vps4E235Q transfected cell pull-downs 
accumulated a large proportion of dextran red as indicated by the relative 
fluorescent units (Fig. 5.7B).  In contrast, cells expressing the Halo-
Vps4WT protein showed little dextran-red detection, giving only a slight 
increase in fluorescence over untransfected cells treated with dextran-
red (Fig. 5.7B).  These findings provide evidence for the ability of this 
developed method to isolate intact Vps4E235Q vesicular compartments. 
 
 
5.2.7  Overexpression of Vps4WT can negate the typical 
enlarged endosomal structures produced due to 
overexpression of Vps4E235Q 
 
As from previous work it was suggested that intact vesicular structures 
containing the Vps4E235Q protein could be isolated, it may be 
hypothesised that a large-scale isolation of these compartments could 
result in assays being developed to study the uptake and inward 
vesiculation in vitro using these intact vesicles with endogenous ESCRT 
machinery already present.  An initial predicament with such an 
approach is that the Vps4E235Q remains bound to the membrane and 
inhibits the proper inward vesiculation process that occurs to deliver 
cargo to the MVB lumen.  As a result, it was investigated as to what the 
consequence of overexpressing both wild-type and  ATP-ase  dead  
mutant  proteins in  the  same  cells  would  be.   It was  
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Figure 5.7 – Halo-Vps4
E235Q 
compartments loaded with dextran-red can be affinity 
purified as intact membranous compartments.  A. Cos-7 cells were transfected with 
GFP-Vps4E235Q (green) and loaded with dextran-red (red), fixed and processed for 
immunofluorescence.  Note the Vps4E235Q swollen compartments where dextran is 
contained within.  B. NRK cells were untransfected (UT) or transfected with Halo-
Vps4WT or Halo-Vps4E235Q and dextran-red (Dex) added post-transfection.  Cells were 
lysed in detergent free TESA buffer, and affinity purified using HaloLink® resin.  Bound 
fractions were read on a Fluoro-scan plate reader (see 2.2.8), with values normalised 
per mg of protein, and untransfected cells plus dextran-red taken as zero RFUs 
(averaged over two experiments). 
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discovered that upon expression of GFP-Vps4WT with Halo-Vps4E235Q in 
HeLa cells that the induced vacuolation by Vps4E235Q was abrogated by 
co-expression of the wild-type Vps4 protein (Fig. 5.8).  The resultant 
phenotype of this co-expression resembled a typified Vps4WT alone 
overexpression phenotype, that is, diffuse cytoplasmic non-membranous 
staining.  These results suggest that the Vps4E235Q-induced vacuolation 
phenotype may possibly be rescued with wild-type Vps4 protein, which 
could be a useful finding if in vitro assays were to be performed on 
Vps4E235Q vesicle compartment isolations.  However, it should be noted 
that the GFP-Vps4 construct tends to express at higher levels than the 
Halo-Vps4 construct, thus this might account for the overcoming of the 
Vps4E235Q vacuolation phenotype in this case. 
 
 
Figure 5.8 – Co-expression of GFP-Vps4
WT
 with Halo-Vps4
E235Q
 negates the 
dominant negative phenotype of Halo-Vps4
E235Q
.  GFP-Vps4WT (a; green) was co-
transfected with Halo-Vps4E235Q (b; red) using standard methods.  16 hours post-
transfection cells were incubated with the diAcFAM Halo-ligand and then fixed, as 
described in 2.2.8.  Cells were viewed under a confocal microscope, and the merged 
image is shown in c.  Halo-Vps4E235Q single transfections gave a swollen endosomal 
phenotype (not shown), which is not seen when co-transfected with the wild-type Vps4 
protein as shown here. 
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5.3  Discussion 
 
The MVB compartment has not yet fully been characterised.  The 
development of an assay that allows for the isolation of the Vps4E235Q 
induced compartment by affinity isolation methods may provide a unique 
approach to offer useful information with regards to the proteomic 
complement of the Vps4E235Q compartment. 
 
As the assay depends on the amount of GFP-Vps4E235Q present for 
isolation, low and inconsistent transfection efficiencies provide difficulties 
in interpreting meaningful results, and is one problem that needs to be 
addressed.  Thus it was decided to pursue the production of stable cell 
lines in order to avoid transfection issues and allow for larger scale 
isolation of Vps4E235Q compartments.  Furthermore, the recent 
introduction of the HaloTag® system by Promega allowed a seemingly 
more efficient and possibly more specific approach to affinity isolation.  
Transient transfections demonstrated that it was possible to produce 
cells that inducibly express Halo-Vps4E235Q (and Halo-Vps4WT).  However 
despite isolation of a large number of cell colonies that grew under the 
harsh selective antibiotic-present conditions (for selection of stably 
transfected cells), none of the colonies screened showed any apparent 
Halo-Vps4E235Q or Halo-Vps4WT expression, with or without the presence 
of doxycycline.  Given the timescale of the work already carried out in 
attempting to produce stable inducible cell lines, this was not further 
pursued. 
 
Despite the failings of stable cell line production, transient transfections 
using HaloTag® technology for affinity isolation of Vps4E235Q 
compartments yielded promising results, showing affinity isolation of the 
ESCRT-I component TSG101 as well as ESCRT-III component CHMP3.  
Notably however CHMP4A was not detected.  The antibody used for 
detection of CHMP4 was raised against the CHMP4A sequence, and 
given the fact that there are two other isoforms of CHMP4 (B and C), it is 
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possible that the antibody used does not recognise these isoforms 
efficiently, if at all.  These isoforms of CHMP4 may also be cell-type 
specific.  It may be then that CHMP4A is not expressed in the cell lines 
used for these experiments.  The possibility that CHMP4 is not present 
on this complex however cannot be fully excluded.  Detection of two 
ESCRT proteins from affinity isolations provides evidence that an 
ESCRT-related complex can and has been successfully isolated.  
Whether the isolation was of a protein complex or rather of an actual 
membranous vesicular compartment containing protein complexes is not 
fully known.  However, evidence from dextran-red studies performed 
show that in cells expressing Halo-Vps4E235Q that pull-downs are likely to 
be of intact compartments when lysed under non-detergent conditions, 
given the increase in dextran-red fluorescence. 
 
Running a 2-d gel from affinity purified Halo-Vps4E235Q transfected NRK 
lysates has shown that various proteins may be isolated from the 
Vps4E235Q compartment.  A large number of individual spots were seen 
from this gel, and this suggests that there is a good possibility that there 
are a number of various MVB and ESCRT-related proteins not yet 
identified.  It is possible and indeed likely that a significant proportion of 
these spots are in fact simply cargo and other proteins pulled down given 
the affinity isolation method.  This is why a fuller approach utilising this 
method would involve a parallel running of Halo-Vps4WT affinity purified 
cell lysates which would serve as an efficient control for identification of 
non-specific pull-downs and non-MVB related proteins (see Fig. 5.9).  
The other predicament with the approach used is the inconsistency and 
low percentage of successful transfection methods.  With the pursuit of 
inducible stable cell lines resulting in little success, other approaches 
would need to be considered.  Retroviral delivery of DNA constructs is an 
alternative to transient transfections however as dominant negative 
ESCRT components including Vps4E235Q have been shown to inhibit 
retrovirus budding and thus perturb virus production, this approach is not 
viable when looking to express dominant negative ESCRT proteins.  One 
further method however would be to use adenoviral delivery of DNA 
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encoding for dominant negative Vps4E235Q.  This approach has already 
been used for expression of Vps4E235Q in mammalian cells [135].  This 
method should not be impaired by the expression of dominant negative 
ESCRT components (as adenoviruses are not dependant upon ESCRT 
machinery for their exiting infected cells) and gives near to 100% 
infectivity and thus expression of protein in practically 100% of the cell 
population, allowing for much better affinity isolation of Vps4E235Q 
compartments and subsequent studies.  Although the production of 
inducible stable cell lines was unsuccessful in this case, this approach 
could be further pursued.  However, it may result in a very time-
consuming process that is not guaranteed to result in positive stable 
cells. 
 
The successful isolation of Halo-Vps4E235Q vesicular compartments as 
demonstrated by dextran-red studies is an important finding.  This 
method relies on the uptake of the dextran-red into swollen 
compartments induced by Halo-Vps4E235Q expression.  By lysing the 
cells in the absence of detergents, we hoped to keep the membrane 
compartment that Halo-Vps4E235Q protein is contained to intact.  Thus in 
the case of Halo-Vps4WT expression, which is largely cytosolic, 
fluorescence corresponding to dextran-red should be limited as no 
compartments containing accumulated dextran-red would be expected to 
be isolated.  In contrast, we might expect the HaloResin® to affinity 
isolate Halo-Vps4E235Q compartments, and if these compartments have 
intact membranes then in the case of dextran-red loading, dextran-red 
would also be isolated.  If our lysis method did not result in purification of 
intact membrane compartments but rather just protein complexes, the 
dextran-red should be released into the cell lysate and not affinity 
purified, giving a similar fluorescent result to Halo-Vps4WT (see Fig. 5.9).  
Thus we interpret a rise in fluorescence with the Halo-Vps4E235Q 
transfected cell pull-downs to be indicative of an intact membrane 
compartment having been isolated.  The apparent findings that this 
method can isolate intact compartments opens up the possibility of 
various other experiments on such compartments, including the possible 
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development of an in vitro invagination assay, which to date there is no 
such assay known to have been developed.  In theory, by affinity 
purification of Halo-Vps4E235Q compartments from cells expressing this 
protein, a large-scale isolation could result in a large number of purified 
compartments that contain the endogenous proteinacious ESCRT 
machinery.  By removal of the dominant negative Halo-Vps4E235Q from 
the membranes of such compartments, a cell-free invagination assay 
could be set-up to investigate more fully the process of inward 
invagination and delivery of cargo into the lumen of the ‘MVB’ 
compartment.  Results from co-transfections of Vps4WT and Vps4E235Q 
suggest that the dominant negative phenotype and membrane binding of 
the Vps4E235Q protein can be overcome by expression of the wild-type 
protein.  A scenario then can be envisaged where purification of Vps4WT 
protein would allow one to incubate the Halo-Vps4E235Q compartments 
with an excess of Vps4WT and thus compete off the dominant negative 
protein, yielding the intact ESCRT-containing compartment and allowing 
invagination to occur.   
 
Such an assay would rely on the fluid phase uptake of an assayable 
marker resulting in lumenal vesicles containing this marker.  A 
fluorescent marker that is quenchable would be ideal, such as ANTS 
which is quenchable by the non-membrane permeable DPX.  ANTS/DPX 
dye quenchable assays have already been used to measure the fusion 
between two populations of vesicles [148, 149].  Once a successful and 
consistent assay had been established, other effects on inward 
invagination could be investigated.  For example, purified cell cytosols 
containing dominant negative proteins and possible inhibitors of ESCRT 
and related proteins could be added to this cell-free invagination assay 
and their effects on invagination investigated.  Development of such an 
assay may be able to answer questions such as: What is the core 
machinery needed for invagination and lumenal delivery of cargo?  Is 
PIKfyve necessary for proper invagination?  How important are specific 
lipids?  Is ESCRT-III alone sufficient for cargo delivery?  In short, an 
assay like this could help us determine what proteins are needed 
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specifically for invagination of the MVB membrane, what proteins are 
needed for other processes on the MVB, such as cargo concentration 
and protein recognition, and if there is any overlap between such roles.  
Being able to answer these questions would vastly improve our 
understanding of trafficking events in the endo-lysosomal pathway.  For 
example, although CHMP3 and the ESCRT-III complex has been 
proposed to be involved in the final stages of vesicle formation in the 
lumen of the MVB, recent evidence suggests that this may not be the 
case as gene silencing of CHMP3 does not inhibit the delivery of EGFR 
into the MVB lumen, but does inhibit its degradation [56].  Combining this 
with evidence that CHMP3 may bind PtdIns(3,5)P2 and that PIKfyve is 
necessary for degradation but not silencing of signalling receptors [71, 
84], it may be hypothesised that ESCRT-III may not be involved as first 
thought in the formation of vesicles at the MVB, but rather in proper 
trafficking and fusion of the MVB to the lysosome.   
 
The HaloTag® is still a relatively recent technology.  Much of the work 
contained in this chapter has relied on the viability of this tag for isolation 
using a resin that covalently binds this tag.  Certainly the Halo-ligand use 
in this work suggests that this part of the technology is reliable given the 
distinct phenotypes seen in immunofluorescent studies.  Despite the 
HaloTag® technology being so new, there are some studies in the 
literature that have successfully used this tag [150-153].  In particular, 
one study used the HaloLink® resin to develop a rapid single-tube 
method for small-scale isolation of polyclonal antibodies [150].  These 
studies suggest then that the HaloTag® technology is a viable and useful 
technology, and that the approach that has been utilised in this chapter 
for the isolation of the Vps4E235Q compartment is feasible. 
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5.4  Conclusion 
 
The full proteomic complement of the functional MVB compartment is not 
known.  An affinity pull-down method has been developed that may 
enable us to be able to determine such an endogenous proteomic make-
up of a cellular MVB compartment, which has yielded promising results 
with ESCRT components already having been affinity purified and 
detected.  Further work using this approach may help us better 
understand the endogenous proteins involved in MVB biogenesis, and 
may result in the discovery of novel ESCRT-related proteins.  
Furthermore, by perfecting this method it may be possible to set up a 
further novel assay which would assay the invagination of MVB 
membranes, helping us more fully understand the process of mammalian 
MVB formation which is still not properly understood. 
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6  Cellular effects of truncations and mutant forms 
of the ESCRT-III component CHMP3 and roles for 
ESCRT proteins in cytokinesis
*
 
 
 
6.1  Introduction 
 
One useful tool for investigating a protein’s cellular function is the use of 
dominant negative forms of the given protein and over-expression of 
such mutants to investigate cellular effects of the mutation.  Studies like 
these can help better understand a normal function of the protein, by 
seeing ways in which impaired function results in abnormal cellular 
processes.  As already discussed in chapter 1, one of the effects that 
mutant forms of ESCRT and related proteins can have is perturbing 
proper retroviral budding in HIV-infected cells.  These studies have often 
involved the use of dominant negative proteins which suggest the 
normally functioning protein counterparts play a key role in this process.  
Another useful approach is the use of siRNA which has also helped 
elucidate protein cellular function.  This method relies on the silencing of 
endogenously expressed protein and thus offers a different approach to 
over-expression studies. 
 
One truncation of CHMP3, which removed the whole C-terminus, 
resulted in a dominant negative N-terminal CHMP3 protein that displayed 
endosomal defects such as impaired MVB biogenesis and the swollen 
endosomal phenotype paralleled to the class E phenotype first described 
in yeast [71].  This dominant negative construct, termed CHMP31-112, has 
been previously used in our lab and in various studies, including those 
described in chapter 3 of this thesis.  It has been suggested that the C-
terminus acts as an autoinhibitory domain, which in the cytosolic form of 
CHMP proteins inhibits the N-terminal end of the protein from membrane 
localisation and proper protein function [78]. The C-terminal 
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autoinhibitory domain is proposed to be released from N-terminal 
inhibition prior to allowing full N-terminal binding to the endosomal 
membrane.  One recent study has highlighted the importance of normal 
CHMP proteins, in particular, truncations of the C-terminus of CHMP3 
[78].  This study showed that indeed the CHMP31-113 truncation had 
significant inhibitory effects on HIV-1 viral budding; however other 
truncations including CHMP31-150, CHMP31-179 and CHMP31-200 had 
much more pronounced effects on viral budding and particle formation 
[78].  From this study it was hypothesised that these truncations that 
produced a longer CHMP3 dominant negative protein (the native protein 
is 222 amino acids in length) than the CHMP31-112 truncation would also 
give stronger endosomal dominant negative phenotypes.  This would 
then make such constructs quite helpful for studies relating to ESCRT 
proteins, given the usefulness of dominant negative proteins for 
understanding better the native protein’s function. 
 
It has also recently emerged that one function of the native ESCRT 
proteins seems to be that of playing an important role in the cellular 
process of cytokinesis [104, 105, 154].  The process of cytokinesis is a 
highly precise yet complex process necessary for the formation of two 
daughter cells from a single parent cell.  During the final stages of 
cytokinesis, a mid-body is formed which is a thin membrane tether-like 
structure connecting the two daughter cells together.  The end of 
cytokinesis is typified by the abscission of this structure at the mid-body, 
which seems to be an event heavily reliant on membrane dynamics [155-
158].  There are several theories as to how this abscission occurs to 
separate the two daughter cells.  Perhaps the most favourable theory is 
that of the trafficking of membrane vesicles to the mid-body where 
perhaps some apparent fusion event occurs allowing the separation of 
the two cells and abscission of the plasma membrane at this region 
[156].  It has recently been shown that some ESCRT and ESCRT-related 
proteins are present at the mid-body and mutations or silencing of such 
proteins results in impaired cytokinesis, which has been paralleled to 
impaired retroviral budding [104, 105]. 
 142 
 
Following on from this recent work, several of the already described 
constructs for expression of dominant negative truncated forms of 
CHMP3 that lack the C-terminal autoinhibitory domain were produced.  
Specifically, both GFP- and FLAG-tagged forms of CHMP31-150 and 
CHMP31-179 were made.  The aim of this chapter was to better 
characterise these truncated proteins in terms of sub-cellular localisation 
and effects within the cell, namely receptor trafficking through the endo-
lysosomal pathway, and the effects of such truncations on cellular events 
such as cytokinesis.  Furthermore, to try and better understand the role 
of the N-terminus of CHMPs in endosomal membrane lipid binding, 
several further mutations were made which substituted positive residues 
from the N-terminus with uncharged residues, as these positive amino 
acids were thought to be essential for membrane binding of CHMP3.  
These mutations had recently been described and have been suggested 
to cause the loss of membrane association and swollen endosomal 
phenotypes when mutated from dominant negative CHMP3 constructs 
that typically bind membranes when overexpressed in mammalian cells 
[159].  Much of this work then was largely focussing on CHMP3, to 
provide better understanding of this protein and membrane events it is 
involved with.  This focus was influenced by previous results that had 
been obtained that showed the importance of CHMP3 with regards to 
binding of endosomal lipids, in particular PtdIns(3,5)P2, with the aim of 
being able to more clearly grasp the specificity of such events that occur 
at the endosomal membrane. 
 
 
 
*The work described in this chapter was submitted to the Biochemistry Journal and 
accepted for publication on 12 December, 2007: 
Dukes JD, Richardson JD, Simmons R, Whitley P.  A dominant negative ESCRT-III 
protein perturbs cytokinesis and trafficking to lysosomes.  Biochem J, 2008. Apr 15; 
411(2): 233-239 
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6.2  Results 
 
 
6.2.1  Expression of CHMP3 truncations result in swollen 
endosomal phenotypes and localisation to a hybrid early-
late endosomal compartment 
 
Previously, dominant negative truncation constructs of CHMP3 used in 
our lab included a GFP- and FLAG-tagged CHMP31-112 construct, a 
truncation that removed amino acids 113-222 from the C-terminus of 
CHMP3.  Overexpression of the GFP form of this construct in 
mammalian cells resulted in some localisation in the nucleus, with 
endosomal localisation that resulted in swollen vacuoles (Fig 6.1).  This 
construct has been further shown to localise in part to structures 
containing both early and late endosomal markers, thus being thought to 
be a ‘hybrid’ endosomal compartment.  Despite this construct giving a 
swollen endosomal phenotype, the phenotype was not always regular.  
Additionally, the often overpowering level of GFP localisation in the 
nucleus often gave difficulties in viewing lower level expressing cells. 
 
In an attempt to obtain a dominant negative construct more suited to 
giving a consistently distinct phenotype with perhaps less nuclear 
staining, several truncations resulting in dominant negative proteins of 
varying lengths were cloned.  By using the pEGFPN1 and pFLAG-
CMV5c vectors, both GFP- and FLAG-tagged (respectively) versions of 
CHMP31-150 and CHMP31-179 (deleting amino acids 151-222 and 180-222 
respectively) constructs were made.  It has been reported that 
expression of the full length wild-type CHMP protein with a GFP tag 
present at the N-terminus results in a swollen endosomal phenotype [78, 
160].  However the constructs used for these studies were made with the 
fusion of GFP on the C-terminus, thus eliminating the likelihood of any 
endosomal defects with the wild-type protein expression (see Fig. 6.1 for 
full length CHMP3 expression). 
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Figure 6.1 – Expression of an N-terminal CHMP3 construct and full length CHMP3 
in Cos-7 cells.  (a) Cos-7 cells were transiently transfected with CHMP31-112GFP 
(green) as previously described.  This panel shows an example of a lower-level 
expressing cell with less nuclear expression than often seen.  This cell has a distinct 
phenotype however expressing cells were not always consistently similar to this 
example, normally with large nuclear expression.  (b) Cos-7 cells were also transfected 
with a full-length CHMP3 construct with a GFP tag (green) present at the C-terminus of 
the protein.  Note in the upper cell the high nuclear expression and also the diffuse non-
membranous cytosolic distribution of the protein in general. 
 
To investigate the sub-cellular localisation of the truncated CHMP31-150 
and CHMP31-179 constructs, transfected cells were co-stained with the 
early and late endosomal markers, EEA-1 and M6PR respectively.  
Previous reports had suggested that the overexpression of CHMP31-150 
and CHMP31-179 proteins resulted in a largely plasma membrane 
localisation, in particular with CHMP31-150 [78].  In experiments carried 
out for this study however, it was found that overexpression by transient 
transfection of both CHMP31-150 and CHMP31-179 resulted in a largely 
peri-nuclear punctate membrane-bound distribution, with an apparent 
swollen endosomal phenotype (Fig 6.2a, g, j).  At very high expression 
levels of CHMP31-150 some cells were seen to seemingly have a plasma 
membrane localisation of CHMP31-150 (Fig 6.2d),  
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Figure 6.2 – Overexpression and sub-cellular localisation of truncated CHMP3 
proteins in mammalian cells.  Cos-7 cells were transfected with either CHMP31-
150GFP (a-f; green) or CHMP31-179GFP (g-l; green) and either stained for EEA1 (b, e, h; 
red) or M6PR (k; red).  Panels c, f, i and l show merged image, with yellow indicating 
co-localisation.  Insets in upper right corner of panels represent magnified images of 
boxed area in panel.  Note the difference in EEA1 and M6PR staining in transfected 
cells when compared with neighbouring untransfected cells (b, e, h, k).  Also note panel 
d, which represents two cells highly over-expressing CHMP31-150GFP with a large 
localisation to the plasma membrane. 
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however this was not a typical observation nor was it seen in cells 
expressing at lower levels.  Despite a few cells that were very highly 
expressing CHMP31-150GFP exhibiting some plasma membrane 
localisation, the overwhelming majority of transfected cells showed a 
typical endosomal staining as seen in Fig. 6.1a.  Furthermore, 
expression of dominant negative truncations resulted in localisation to 
both early endosomal structures as indicated by colocalisation with EEA1 
(Fig. 6.2a-i) and late endosomal structures, demonstrated by 
colocalisation with the late endosomal marker M6PR (Fig. 6.2j-l).  This 
phenomenon was seen for expression of both CHMP31-150GFP and 
CHMP31-179GFP (CHMP31-150 localisation with M6PR not shown).  This 
suggests that these truncations localise to what may be considered a 
hybrid compartment containing both early and late endosomal markers, 
and is a similar finding to previous studies carried out with the CHMP31-
112 construct.  It should be noted that these findings were also seen when 
expressing the FLAG-tagged constructs described instead of the GFP-
fusion versions and were also expressed in HeLa cells where similar 
results were obtained (data not shown). 
 
The studies carried out that focused on the expression of the two 
dominant negative CHMP3 truncations, CHMP31-150 and CHMP31-179, 
revealed interesting immunofluorescence results.  From an endosomal-
defect phenotypic point of view, the CHMP31-179 truncation appears from 
immunofluorescence studies to give the clearest, most consistent, and 
most drastic swollen endosomal phenotype.  As a result of this general 
finding, which appeared to be true for both FLAG- and GFP-fusion 
proteins, the CHMP31-179 construct was the favoured truncation when 
used for overexpression studies.  An additional advantage of the 
CHMP31-179 protein is that it appeared to give very low nuclear staining, 
which was a desired trait for overexpression immunofluorescence 
studies involving the GFP-fusion protein. 
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6.2.2  Expression of truncated CHMP3 results in the 
accumulation of ubiquitin on endosomal structures 
containing the truncated protein 
 
One of the key events in the sorting of receptor membrane proteins into 
MVBs for ultimate degradation via the lysosome is the addition of a 
single or several ubiquitin molecules onto the target receptor protein.  
ESCRT-related proteins as well as actual ESCRT components contain 
ubiquitin recognition motifs that allow delivery of ubiquitylated cargo into 
the MVB lumen.  Defects in proper MVB biogenesis then can result in the 
accumulation of ubiquitylated cargo on endosomal membranes, cargo 
that has failed to be sorted into the MVB lumen and deubiquitylated.  To 
test the effects of truncated CHMP3 protein expression on proper 
trafficking to the lysosome via the MVB, CHMP31-179 constructs were 
expressed in mammalian cells and stained for ubiquitin.  Overexpression 
of CHMP31-179 resulted in large accumulation of ubiquitin when compared 
with untransfected cells (Fig. 6.3).  This ubiquitin colocalises to the GFP 
signal indicating that in such cases the ubiquitylated cargo is present on 
the CHMP31-179-containing endosomal membrane.  Note in untransfected 
cells the distribution of ubiquitin within the cell is much more diffuse and 
very little appears to be membrane-bound unlike cells expressing 
CHMP31-179GFP where a large proportion of ubiquitin is membranous. 
 
 
6.2.3  CHMP3 truncations perturb proper EGF degradation  
 
Colocalisation of the truncated CHMP3 protein with ubiquitin does 
provide some evidence that this dominant negative protein causes 
trafficking defects by the accumulation on enlarged endosomal 
membranes of ubiquitylated cargo.    However,  it is possible that the 
GFP-fusion  constructs  themselves  
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Figure 6.3 – Expression of CHMP3
1-179
 results in the accumulation of ubiquitin on 
enlarged membranes in mammalian cells.  Cos-7 cells were transfected with the 
CHMP31-179GFP construct (green; a) and 24 hours post-transfection were stained for 
ubiquitin (red; b).  Merged images are shown in panel c where yellow indicates 
colocalisation.  Boxed areas are magnified in the upper right corner of each panel.  
Note the distribution  of   ubiquitin  staining  in  panels  b  and  c  in  cells   that   are   
not   expressing CHMP31-179GFP. 
 
undergo ubiquitylation and thus this may account for some of the 
colocalisation observed.   To better clarify whether or not CHMP31-179 
actually perturbs proper receptor sorting into MVBs and delays 
subsequent lysosomal degradation, a more relevant assay is needed 
that actually monitors such an endocytosed receptor that would typically 
follow the MVB-lysosomal pathway.  EGFR is such a receptor that is 
commonly used in such studies as it has been shown to almost 
exclusively follow the MVB-lysosomal pathway of degradation following 
stimulation with EGF and endocytosis into the cell.  There are two 
simplistic approaches that one could use for such an assay; firstly EGF 
stimulation followed by staining of the EGFR protein for 
immunofluorescence studies, or alternatively one could use a fluorescent 
or similarly labelled EGF and follow this ligand (which would relate to the 
degradation state of the receptor) via immunofluorescence.  One 
practical problem with the former of the two approaches is that despite 
numerous commercial antibodies to EGFR are available, it appears to be 
very difficult to detect any EGFR with antibodies in HeLa and other 
mammalian cell lines.  A431 cells do express high amounts of EGFR 
[161], and thus this can be detected better with antibodies.  However as 
A431 cells do not grow in monolayers and are relatively small cells, they 
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are not very amenable from an immunofluorescent imaging perspective.  
The advantage of using the approach of fluorescently labelled EGF is 
also that very little to no background would be picked up in 
immunofluorescence staining as no staining with antibodies would be 
required.  Thus for these studies it was decided that a fluorescently 
labelled EGF would be used to follow the degradation of EGFR in cells 
expressing CHMP31-179GFP. 
 
After 2 min of stimulation with EGF in HeLa cells there was a clear 
accumulation of EGF at the plasma membrane suggesting that EGF was 
rapidly binding to its receptor (Fig. 6.4a-c).  On separate coverslips, cells 
were stimulated with fluorescent EGF for 60 min.  Cells were then 
washed, fixed and viewed on a confocal microscope, where it was found 
that in cells which expressed the truncated CHMP31-179 protein there 
appeared to be impaired degradation kinetics of EGFR as indicated by 
the accumulation of fluorescent-EGF in transfected cells (Fig. 6.4d-f).  
This was not seen in untransfected cells treated similarly that were not 
expressing CHMP31-179 (Fig. 6.4d-f, indicated by cells marked with ‘*’). 
 
 
6.2.4  Mutants of N-terminal truncated CHMP3 display 
similar phenotypes and sub-cellular localisation to non-
mutated truncations 
 
To try and better understand the mechanisms by which CHMPs (in 
particular CHMP3) bind the endosomal membrane in a specific manner 
via their N-terminus, mutations in positive residues that were thought to 
be key to membrane binding have been recently performed.  It was 
reported that particular mutations in the N-terminal region resulted in a 
loss of membrane association with the truncated CHMP31-150 construct.  
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Furthermore, these mutations reversed the dominant negative effect on 
HIV-1 viral budding, allowing budding to occur in contrast to the non-
mutated CHMP31-150 which drastically inhibited viral budding [159].  It 
was decided to introduce two of these mutations into the CHMP31-
179GFP constructs to more extensively characterise their effects on 
membrane binding and possibly look at other effects they may have in 
mammalian cells.  The first mutant, which has been termed CHMP31-
179GFPM1, was a triple point-mutation which resulted in the amino acid 
changes R24S, K25A, and R28N (the original mutation previously 
described was R24S/K25A/R28S).  The second mutation was a double 
point mutation of R32A and R35S and has been termed CHMP31-
179GFPM2. 
 
Despite previous reports of these mutations leading to loss of membrane 
binding compared with their non-mutated dominant negative 
counterparts [159], it was found that expression of the mutants CHMP31-
179GFPM1 and CHMP31-179GFPM2 still resulted in being largely membrane 
bound, giving a swollen endosomal phenotype (Fig. 6.5, M2 mutant not 
shown).  The swollen endosomes appear by eye to not be as severe as 
the CHMP31-179GFP construct induces; however there was still a clear 
phenotype observed.  As the CHMP31-150GFPM1 mutant was reported in 
a previous study to give the most dramatic effect in reversal of viral 
inhibition especially when compared with CHMP31-150GFPM2, most of the 
ensuing studies were carried out using this mutant for characterisation.  
It was further found that much like CHMP31-179GFP, the CHMP31-
179GFPM1 mutant also localised to compartments containing both EEA1 
and M6PR, thus as described earlier seem to be found in a hybrid early-
late endosomal sub-cellular localisation (Fig. 6.5a-f).  Moreover, 
expression of the CHMP31-179GFPM1 mutant also resulted in the 
accumulation of ubiquitin on membranes (Fig 6.5g-i), and similarly to 
CHMP31-179GFP expression, inhibited the degradation of EGF l), 
suggesting that it too perturbs proper MVB-lysosomal trafficking (Fig 6.5j-
l). 
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Figure 6.5 – Expression of N-terminal truncation mutant CHMP3
1-179
GFP
M1
 results 
in similar sub-cellular localisation and cellular phenotypes compared to its non-
mutated counterpart.  Cos-7 cells (a-i) and HeLa cells (j-l) were transfected with 
CHMP31-179GFPM1 (green), fixed and stained for EEA1 (a-c), M6PR (d-f) or ubiquitin (g-
I; red).  Magnified panels represent the boxed insets, where yellow indicates 
colocalisation.  (j-l) Transfected cells were serum-starved overnight and stimulated with 
Alexa® Fluor 555-conjugated EGF (red) for 60 min and the fixed and mounted in Mowiol 
containing DAPI.  ‘*’ represents an untransfected cell. 
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6.2.5  Truncated CHMP3 and its mutants as well as other 
ESCRT-related proteins localise to the mid-body of 
cytokinesis 
 
As it has been recently reported that ESCRT components may play a 
key role in cytokinesis, the effects of various dominant negative ESCRT 
constructs on cytokinesis were investigated.  When cells overexpressing 
the dominant negative truncation CHMP31-179 were fixed, those at the 
late stages of cytokinesis were observed to contain high concentrations 
of the CHMP31-179 protein apparently present on vesicles at the mid-body 
(Fig. 6.6a-f).  In particular, CHMP31-179 appears to specifically localise to 
the central region of the mid-body, where -tubulin staining is not 
observed, leaving an apparent “pseudo-gap” upon tubulin staining.  This 
phenomenon was observed in both Cos-7 cells as well as HeLa cell 
lines, implying that this may not be cell type specific (Fig. 6.6a-f).  There 
also appears to be equal contribution of CHMP31-179 vesicles at the mid-
body from each daughter cell, and vesicles distributed along the tubulin 
network were often observed.  It is possible that these vesicles were 
being trafficked towards the mid-body, however with the lack of live-cell 
imaging such conclusions as to their direction of travel cannot be made.  
The localisation of the N-terminal mutant of CHMP31-179 and CHMP31-
179M1 was also investigated.  Despite reports of the triple point mutation 
abrogating inhibition of HIV-1 budding, it was found that CHMP31-179M1 
was also present in high concentrations at the mid-body, showing very 
similar results to expression of CHMP31-179 (Fig. 6.6j-l). 
 
In addition to dominant negative CHMP3 being present at the mid-body 
of cytokinesis, the dominant negative ATP-ase defective Vps4E235Q 
protein when overexpressed in transient transfections was also found to 
be concentrated at the mid-body (Fig. 6.7a-c).  Vps4WT and full length 
CHMP3-GFP expression were not found to form vesicular structures, but 
did   appear   to   possibly   be   more   concentrated at  the  mid-body  of  
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Figure 6.6 – Dominant negative CHMP3 truncations localise to the mid-body of 
cytokinesis.  Cos-7 and HeLa cells (as indicated on left of panels) were transfected 
with CHMP31-179GFP (a-i) or CHMP31-179GFPM1 (j-l; green) and allowed to express for 
24 hours before fixing.  Cells were stained for β-tubulin (a-f, j-l) or Rab11 (g-i; red) and 
viewed on a confocal microscope.  Boxed insets are magnified in corners of each 
panel.  Note the mid-body shown usually lacks β-tubulin staining at the very centre.  
Transfected cells are considered as one cell as they have yet to complete cytokinesis. 
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Figure 6.7 – Dominant negative GFP-Vps4
E235Q
, but not GFP-Vps4
WT
 or CHMP3-
GFP localises to membrane compartments at the mid-body of cytokinesis.  Cos-7 
cells were transfected with appropriate GFP-fusion constructs as indicated.  24 hours 
post-transfection cells were fixed and stained for β-tubulin (red).  (a-c) GFP-Vps4E235Q 
(green) localises to the mid-body of cytokinesis on vesicular structures.  (d-f) GFP-
Vps4WT (green) shows a diffuse cytosolic expression with some non-membranous 
expression apparent at the mid-body.  (g-i) CHMP3-GFP (green) expression is similar 
to GFP-Vps4WT being cytosolically localised with apparent higher concentrations at the 
mid-body.  Note CHMP3-GFP is fused to the GFP tag at the C-terminus thus is not 
typically membrane-bound when overexpressed in mammalian cells. 
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cytokinesis when compared with their distribution in the rest of the 
cytoplasm (Fig. 6.7d-i).   
 
Rab11 has been shown to be a recycling endosomal Rab protein, which 
may play a role in vesicle trafficking within the cell [162].  It has also 
been previously shown to localise to the mid-body of cytokinesis, and 
cause defects in cytokinesis when dominant negative versions of it are 
expressed in mammalian cells [163].  This suggests that it is necessary 
for cell abscission during the late-stages of cytokinesis.  Transfected 
cells expressing CHMP31-179GFP were found to have Rab11 at the mid-
body as well (Fig 6.6g-i) although it should be noted that the Rab11 does 
not appear to fully colocalise with CHMP31-179GFP at the dense area of 
the mid-body in which it is found. 
 
 
6.2.6  Expression of dominant negative ESCRT-III and 
related proteins results in cytokinesis defects 
 
HeLa cells plated on 13mm coverslips were transfected with various 
constructs including Vps4E235Q, CHMP31-179GFP and CHMP31-179GFPM1.  
Cells were fixed after 24 hours then stained for β-tubulin and DAPI.  
Transfected cells were counted for the number of multinucleate cells, 
which was defined as any cell which was connected to another cell with 
a continuous plasma membrane, and included cells with two or more 
nuclei.  As seen in Fig. 6.8A, the control cells expressing the parental 
plasmid only (GFP) gave a 12.0% multinucleate cell count, compared 
with only a very slightly increased 13.9% for the GFP-Vps4WT.  However 
for the cells expressing dominant negative components CHMP31-179GFP 
and Vps4E235Q it was found that the percentage of multinucleate cells 
was significantly higher, at 48.1% and 44.4% respectively.   
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Figure 6.8 – CHMP3 and Vps4 dominant negative mutants impair proper 
cytokinesis.  HeLa cells were seeded on 13 mm coverslips 24 hr prior to transfections.  
Cells were then transiently transfected with GFP-Vps4, GFP-Vps4E235Q, CHMP31-179-
GFP, CHMP31-179GFPM1 or GFP alone.  Cells were fixed 24 hr post-transfection and 
immunostained with anti-β-tubulin followed by Alexa® Fluor 568-conjugated IgG 
secondary antibodies and DAPI.  A. All transfected cells present on the coverslip were 
scored for multinucleation and the results were represented graphically as percentages 
of multinucleate cells (averaged over 3 experiments; error bars are ±SD, n=3).  Results 
were analysed by Chi-squared analysis and dominant negative mutants found to be 
significantly different to GFP control (p<0.001).  Total numbers of cells over 3 separate 
experiments counted: GFP = 867, Vps4 = 1440, Vps4EQ = 871, CHMP31-179 = 1441, 
CHMP31-179M1 = 1800.  B. A field of view at 400 x magnification to show cells 
transfected with CHMP31-179GFP and its effects on cytokinesis.  Cells denoted by ‘*’ 
represent a single multinucleated transfected cell.  Cells marked as ‘#’ represent a 
transfected cell that is mononucleate.  In this case a multinucleation count would have 
resulted in 3 positive cells and 1 negative cell for multinucleation. 
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Furthermore, expression of the mutant CHMP31-179GFPM1 also resulted 
in impaired cytokinesis, giving a 35.7% multinucleate count.  All 
percentages of multinucleate cells stated were taken as an average of 
three separate experiments.  Chi-squared analysis was performed on the 
data to determine if the various constructs gave percentages that were 
significantly different to expression of GFP alone.  It was found that for 
GFP-Vps4E235Q, CHMP31-179GFP and CHMP31-179GFPM1 that all three 
were highly significantly different to GFP alone, with p < 0.001.  Error 
bars on the graph represents the standard deviation for each condition. 
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6.3  Discussion 
 
To provide insight into proper ESCRT function and mechanisms, 
dominant negative ESCRT constructs have previously been useful in 
identification of cellular activities and localisations.  The expression of 
Vps4E235Q in mammalian cells is a good example of this approach.  The 
N-terminal construct of CHMP3 previously used in our lab was the 
CHMP31-112GFP construct.  It is important to note that this and other 
truncated constructs used bear the GFP-fusion tag at the C-terminus.  
This is an important point to make as it has been reported that a GFP-tag 
present at the N-terminus of CHMP proteins can result in a vacuolation 
phenotype and endosomal membrane binding of GFP-CHMP3, for 
example [41, 73, 100, 102, 160].  As shown in Fig. 6.1 however, 
expression of CHMP3-GFP results in a diffuse cytosolic distribution, 
much more consistent with the distribution expected of the wild-type 
CHMP protein.  The reason for endosomal membrane-binding of wild-
type CHMP3 with a bulky tag at its N-terminus may be the same reason 
truncated CHMP3 binds to membranes, that is, perturbing proper 
function of the C-terminal autoinhibitory domain.  This auto-inhibition of 
the C-terminal domain has been proposed to regulate the assembly and 
oligomerisation of ESCRT-III components, such as CHMP3 [78].  
Through specific intramolecular interactions between the acidic C-
terminus and the basic N-terminus, the C-terminal domain is proposed to 
place the CHMP protein in an ‘inactive’ closed form.  By some 
mechanism that may be either one of protein or lipid interactions, the C-
terminus is released from its intramolecular binding of the N-terminus, 
allowing the CHMP protein to be in an open conformation that can result 
in the oligomerisation of CHMP proteins and proper ESCRT-III assembly 
at the endosomal membrane.  The exact mechanism that allows for the 
conversion of the CHMP protein from a closed, inactive autoinhibited 
form to its open and active ESCRT-functioning state is rather speculative 
at this stage and not precisely known. 
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Truncations that remove the auto-inhibitory C-terminal domain have 
been shown to cause dominant negative phenotypes associated with 
impaired CHMP function, such as the inhibition of proper HIV-1 budding.  
It is additionally apparent that removal of even a very short portion of the 
C-terminus of some CHMPs results in impaired cellular functions.  These 
defects are often more perceptible than the removal of the whole C-
terminal half of the protein, suggesting that particular C-terminal residues 
are significant in proper CHMP function.  The CHMP31-179 truncation, 
which is a deletion of the last 43 amino acids from CHMP3, appeared to 
give a more pronounced and penetrant phenotype with respect to 
endosomal swelling when compared with truncations that removed the 
whole C-terminus, namely the CHMP31-112 truncation.    Furthermore this 
observed phenotype was more consistent in cells transfected with 
CHMP31-179 compared to CHMP31-112.  It should be noted however that 
the Vps4 interacting domain is contained at the C-terminus of CHMP 
proteins [77, 89, 90].  As Vps4 is necessary for removal of ESCRT 
proteins from the endosomal membrane and in turn this removal is 
necessary for proper MVB formation, removal of this Vps4 interacting 
domain may be the mechanism for the phenotype observed. 
 
It is interesting to note that previous studies have reported a plasma 
membrane localisation of truncated CHMP3 [78].  In this study however 
this was only seen rarely, and even then only in cells massively 
overexpressing CHMP31-150GFP.  The general trend in transfected cells 
for both CHMP31-150 and CHMP31-179 was a clear, endosomal-membrane 
localised distribution, with a swollen vacuolar phenotype.  Interestingly, 
the truncated CHMP3 localised to a compartment that contained both 
early and late endosomal markers.  Such a compartment has been 
previously described with the CHMP31-112 protein [71].  It is possible that 
the dominant negative proteins inhibit the maturation of the MVB from an 
early endosome to a late endosomal compartment, thus resulting in a 
hybrid compartment seen with such studies.  Another possibility is that 
the MVB that has typically been described as a subset of late 
endosomes, is in fact a hybrid compartment that can contain early and 
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late endosomal markers.  It is likely that at some point in the maturation 
of an MVB that it will be a compartment that possesses early and late 
endosomal characteristics. 
 
This work on the C-terminal truncations of CHMP3, in particular the 
CHMP31-179 mutant, have revealed clear trafficking defects as a result of 
their expression, with accumulation of ubiquitin on CHMP31-179 containing 
enlarged endosomal structures.  It may be suggested that accumulation 
of ubiquitin that colocalises with CHMP31-179GFP may simply be a result 
of ubiquitylation of the GFP-fusion protein itself.  However, there were 
certainly swollen vesicular structures present in transfected cells that 
stained positive for ubiquitin but did not have CHMP31-179GFP associated 
with them, in contrast to the more diffuse non-membranous ubiquitin 
staining in untransfected cells.  Furthermore some enlarged endosomes 
that were CHMP31-179GFP positive did not exhibit any obvious ubiquitin 
staining.  Thus these two points are important to note which favour the 
ubiquitin staining being largely due to ubiquitylated cargo other than the 
overexpressed dominant negative protein.  Despite this, it was important 
to demonstrate that the truncated proteins did in fact disrupt normal 
receptor trafficking and degradation through the endo-lysosomal 
pathway.  Indeed this was found to be the case with the EGF 
degradation study, and a clear accumulation of undegraded EGF was 
seen in cells expressing CHMP31-179GFP, which was not visible in 
untransfected cells.  This further emphasises the need for a fully 
functional CHMP3 protein for proper MVB maturation, cargo sorting and 
degradation via fusion with the lysosome. 
 
The mechanism of N-terminal interaction of CHMP proteins, in particular 
CHMP3, with the endosomal membrane is not well understood.  There is 
some evidence to suggest PtdIns(3,5)P2 may play a role in this process 
[62, 71].  It may be argued that localisation to the endosomal membrane 
is a result of protein-protein interactions, to provide the specificity for 
endosomal localisation.  The problem with this proposal is quite simply 
that in overexpression studies the dominant negative proteins still bind to 
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endosomal membranes.  If in fact it was an initial protein-protein 
interaction to provide the specificity for endosomal membrane binding, 
vastly increasing the numbers of dominant negative CHMP proteins but 
not the interacting partner for this mechanism would not result in such 
large accumulations of the CHMP protein at the endosomal membrane.  
Due to the fact that there appears to be a fair degree of specificity for 
endosomal membrane binding by CHMP3, it might be reasonable to 
assume that localised lipids allow this specificity to occur.  This notion is 
further supported by work on CHMP3 that has shown PtdIns(3,5)P2 
binding occurs in vitro, and also that this lipid may be important in proper 
MVB maturation [62, 71].  Contrary to this line of thinking, it could be 
conceived that a cascade of events occurs in the activation and 
endosomal membrane recruitment of ESCRT complexes.  If indeed an 
initial ESCRT-III activation was necessary for oligomerisation of the 
complex, one could envisage perhaps how a protein-protein interaction 
could provide this initial activation of CHMP proteins, and thus in turn 
these activated CHMPs subsequently activate further CHMP proteins in 
a cascade manner.  In such a scenario as this, the number of “activating 
proteins” would not need to equal the number of CHMP proteins, 
rectifying why membrane recruitment still occurs in overexpression 
studies.  There has however still been no definitive mechanism 
described that accounts for the apparent specificity of CHMP3’s binding 
to endosomal membranes. 
 
As the N-terminus of CHMP3 is enriched with positive residues, it may 
be that particular residues at the N-terminus provide the specific 
interactions with negatively charged lipids such as PtdIns(3,5)P2.  A 
recent study took one of the truncated CHMP3 constructs known to 
inhibit HIV-1 viral budding, CHMP31-150, and mutated several positive 
residues at the N-terminus [159].  Normal expression of CHMP31-150 has 
been reported to bind membranes, however the N-terminal mutants of 
CHMP31-150 were reported to lose membrane association, having a 
cytosolic distribution and losing the ability to inhibit HIV-1 viral budding 
[159].  Surprisingly when these mutants were made in this study to 
 163 
further characterise them and their effects, there was no loss of 
membrane association found with CHMP31-179GFPM1 expression.  This 
mutant being a triple mutation of R24S/K25A/R28N, showed very similar 
properties to its non-mutated counterpart, CHMP31-179GFP and it also 
localised to a similar compartment giving comparable trafficking defects 
with CHMP31-179GFP.  Furthermore the double mutant CHMP31-
179GFPM2 (R32A/R35S) gave identical results to that of the M1 mutant.  It 
should be noted that these results were seen in Cos-7 and HeLa cells 
whereas the original mutations were expressed in 293T cell lines, so it 
cannot be completely excluded that there is some cell-type specificity, 
however this seems quite unlikely.  One possible reason for this 
discrepancy of results may be that of the bulky GFP tag’s position on the 
constructs.  In the previously reported study that showed loss of 
membrane localisation of the triple M1 mutant, the GFP tag appears to 
have been fused to the N-terminus, compared with this study that cloned 
the GFP tag onto the end of the protein at the C-terminus.  It is possible 
that this bulky tag by being at the N-terminus of the protein affects the 
membrane binding in some capacity.  The bulky GFP tag present at the 
N-terminus may interfere in some way with the membrane association 
that occurs in the absence of C-terminal autoinhibition.  When positive 
residues at the N-terminus that may be involved in electrostatic 
membrane binding are removed by point mutations, the remaining 
electrostatic charges present at the N-terminus are not strong enough to 
maintain membrane association, thus the protein resides largely in the 
cytosol.  In the case of a bulky GFP tag being present at the C-terminus, 
this stoichiometric hindrance at the N-terminus is not present, hence 
membrane association without certain positive residues can still occur.  
This is just one suggested possibility for why these findings contradict 
those previously reported, and would obviously need further investigation 
to see if this was the case. 
 
Cytokinesis is a crucial process that is necessary for the growth and 
proliferation of any mammalian cell.  Much work has been done to help 
us understand the processes involved in cytokinesis better, however the 
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final stages that involve the separation of the two daughter cells is not 
well understood.  In mammalian cells it seems apparent that some Rab 
GTPase proteins are essential for cytokinesis, in particular Rab11 [164, 
165].  Rab11 has been shown to be an endosomal recycling Rab, 
involved with vesicular trafficking to and from endosomes [reviewed in 
10, 166, 167].  These results suggest then that the events that occur at 
the mid-body prior to abscission involve a range of endosomal proteins 
and trafficking events for successful completion of cytokinesis.  
 
Previous work involving ESCRTs and cytokinesis has mainly looked at 
the localisation of ESCRT-1 components with regards to the mid-body in 
cytokinesis late-stages [105].  Carlton and Martin-Seranno showed that 
TSG101 and possibly other ESCRT-I proteins were recruited to the mid-
body just prior to abscission and are necessary for proper completion of 
cytokinesis [105].  It was speculated then that as ESCRT-III may be the 
last ESCRT complex before cargo delivery into the MVB lumen that this 
ESCRT complex along with other ESCRT components would also be 
found at the mid-body.  As clearly seen in Fig. 6.6 it has been 
demonstrated that this is indeed the case, and not only are dominant 
negative ESCRT proteins found at the mid-body, but also in a similar 
fashion we see Vps4E235Q, the dominant negative form of Vps4. 
 
The expression of dominant negative ESCRT proteins clearly resulted in 
impaired cytokinesis, as demonstrated by Fig. 6.8.  The large increase in 
percentage of multinucleated cells with dominant negative constructs 
indicates that the function of these proteins is necessary for proper 
cytokinesis.  As immunofluorescence studies exhibit, this is particularly 
true of the late stages of cytokinesis when the mid-body has been 
formed.  Interestingly, when overexpressing Vps4WT, it was found that 
slightly higher concentrations were possibly present at the mid-body 
between the staining of the two tubulin stacks.  This may simply be due 
to its cytosolic localisation.  Alternatively, it may also demonstrate the 
importance of this protein in the completion of cytokinesis, hence why it 
is observed at the mid-body in slightly higher concentrations compared 
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with the cytosol.  It must be noted that these concentrations did not 
appear to be obviously membranous bound, unlike the dominant 
negative CHMP31-179GFP or GFP-Vps4E235Q where expression was 
clearly vesicular at the mid-body (see Fig. 6.6).  Interestingly, GFP-
CHMP31-179 expression resulted in a very high percentage of 
multinucleate cells, where almost every other transfected cell was 
multinucleate.  This is the highest percentage of multinucleate cells that 
has been seen also upon examination of the literature. 
 
It is much hypothesised that the AAA-ATPase Vps4 is involved in the 
final delivery of cargo into the MVB lumen, via a mechanism that involves 
ESCRT-III machinery removal.  Through some mechanism not yet clear, 
the removal of this ESCRT complex by Vps4 allows the completed 
formation of inwardly budding vesicles to occur and delivery of such 
vesicles into the MVB lumen.  This process requires an assembled 
ESCRT complex that includes ESCRT-III as well as ESCRT-I and -II, 
and a functional Vps4 protein [4].  It may be hypothesized then that in the 
late stages of cytokinesis, ESCRT-positive vesicles are trafficked to the 
mid-body with equal contribution from each daughter cell, where in the 
presence of Vps4, budding events occur with the plasma membrane 
which allows for final abscission of the two daughter cells, completing 
cytokinesis.  There are obviously many other proteins involved in this 
process and present at the mid-body.  However it is likely that the main 
events leading to abscission certainly involve participation from Vps4 and 
functional ESCRT complexes along with other proteins that help direct 
this event. 
 
Overexpressing N-terminal mutants of truncated CHMP3 has been 
previously shown to resolve the inhibition of HIV-1 viral budding [159].  
However in the case of cytokinesis, there seems to be very little 
difference in the impairment that CHMP31-179 and the M1 mutant have on 
this process.  This is somewhat of a surprise, as there can be many 
parallels drawn between the events of viral budding and mid-body 
abscission in cytokinesis, thus one might expect similar effects of a 
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mutant on these processes.  These findings may highlight the fact that 
there are important differences between these two events in terms of 
membrane dynamics, or alternatively it could as already suggested be 
the result of altered membrane association due to the size and position 
of the fusion tag used for the construct.  One issue these results do 
seem to emphasize however is the importance of a fully functional 
CHMP3 protein for the proper completion of cytokinesis to occur. 
 
 
6.4  Conclusion 
 
Dominant negative proteins have in the past provided useful clues for a 
protein’s cellular function and processes that rely on such a functional 
protein [71, 78].  This study has further demonstrated the necessity of a 
fully functional CHMP3 protein in the process of cytokinesis by 
expression of various truncated forms of CHMP3.  This is an exciting 
time in the field of cytokinesis, membrane trafficking and viral budding as 
there appears to be many parallels between these events and the protein 
machinery required for such membrane events to occur.  There is some 
very recent evidence to support the role of ESCRT proteins in 
cytokinesis, which comes by way of analysis of archaeal genomes, which 
has found homologues of ESCRT-III proteins present despite the fact 
that archaea do not have an endocytic pathway [90].  Thus given these 
recent advances in ESCRT proteins and cytokinesis it may be 
hypothesized that these bacterial homologues could play a role in cell 
division. 
 
The dominant negative truncations of the ESCRT-III component CHMP3 
also highlight the importance of this protein in receptor trafficking but also 
the importance of the separate domains contained within the protein.  
Our lab currently operate with a working model that the localisation of the 
ESCRT-III components is largely due to endosomally localised lipids, in 
particular PtdIns(3,5)P2 which CHMP3 has been shown in vitro to 
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specifically bind to.  Overexpression of mutant forms of CHMP3 results in 
the vast majority of the expressed protein being bound to endosomal 
membranes, lending weight to the theory that lipid specificity is 
necessary for ESCRT-III complex formation.  However to define this 
specificity more work needs to be done as it appears that even with point 
mutations of apparent key positive residues at the N-terminus of CHMP3 
still results in a membrane-bound truncated CHMP3 protein when 
expressed in mammalian cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 168 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 169 
7  Overall Discussion 
 
The recent advances in our understanding of MVB formation and the 
endo-lysosomal trafficking pathway have been intriguing and 
demonstrated that these processes are highly complex yet also tightly 
regulated [57, 75, 79, 89, 168].  Despite this, several of the fundamental 
processes involved are not understood at all.  With regards to the work 
carried out in this thesis and the components that work has been focused 
on, there are four key questions that have yet to be fully answered.  
 
(i) What is the basis or mechanism for CHMP binding to the 
endosomal membrane and removal of autoinhibition?  The work in 
chapter 6 of this thesis demonstrates the importance of a functional 
autoinhibitory C-terminal domain in CHMPs for proper cellular function.  
It may be suggested that CHMP binding to the membrane occurs via 
interactions with other proteins such as earlier ESCRT complexes 
(ESCRT-I or –II) or other ESCRT-related proteins, such as ALIX.  As 
already discussed however, one dilemma with this mechanism is that in 
overexpression studies, dominant negative CHMPs display endosomal 
binding phenotypes where the majority of the protein appears to be 
membrane associated [4, 35, 45, 65, 78, 159].  If the localisation of 
CHMPs to the MVB membrane was dependent upon protein-protein 
interactions we might expect there to be less binding to the membrane 
than that seen in these overexpression studies.  This would be due to the 
limited relative (endogenous) expression of the protein interacting 
partner.  One possible mechanism to explain membrane association of 
overexpressed protein would be a cascade mechanism. This would allow 
for significantly less of the interacting partner to recruit the CHMP to the 
membrane if in turn these CHMP proteins recruited further CHMPs to the 
membrane, once recruited themselves.  Alternatively, direct association 
with membrane lipids could provide the basis for CHMP membrane 
recruitment.  Certainly PtdIns(3)P is required for ESCRT-0 components 
(HRS) to be recruited to the endosomal membrane, and its 
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phosphorylated product PtdIns(3,5)P2 also seems to be important in 
endo-lysosomal trafficking [62, 67, 71, 87].  CHMP3 has been shown to 
bind PtdIns(3,5)P2 in vitro and so may be an effector of this lipid, 
however there is little current in vivo evidence to support the in vitro 
binding studies [71].  The studies carried out on SopB in chapter 3 of this 
thesis demonstrate the importance of PtdIns(3,5)P2 in the normal 
degradation kinetics of endocytosed receptors that traffic through the 
MVB-lysosomal pathway.  Furthermore, there are parallels in the 
literature between RNA gene silencing of CHMP3 and similar silencing of 
PIKfyve, which produces PtdIns(3,5)P2.  However, these studies suggest 
a role for both proteins not in MVB vesicle formation per se but rather in 
trafficking and fusion of the MVB to the lysosome [56, 84].  Very recently 
a study used a PIKfyve inhibitor to demonstrate the effects of PIKfyve 
inhibition within mammalian cells, resulting in enlarged endosomal 
structures, impaired endosomal trafficking and viral budding, similarly to 
truncations of CHMP3 [78, 138].  It would be very interesting then to see 
the effects of this inhibitor on CHMP membrane binding.  If indeed 
CHMP3 is an effector of PtdIns(3,5)P2 one might expect a dominant 
negative form of CHMP3, such as the CHMP31-179 construct, to not 
associate with endosomal membranes due to the lack of PtdIns(3,5)P2 
production.  Additionally, it has been reported that the truncated 
dominant negative CHMP3 localises to the plasma membrane [78].  In 
studies carried out in this thesis, plasma membrane association of 
truncated CHMP3 was rarely seen and even then only in cells with 
abnormally high levels of protein expression.  However this evidence 
may suggest a lipid interaction is the cause for membrane association.  It 
may be that at very high protein levels the CHMP3 protein will interact 
promiscuously with negatively charged lipids found at the plasma 
membrane, hence why this localisation has been described.  Despite 
this, the highly charged nature of the CHMP proteins itself may be 
enough to explain non-specific localisation to the plasma membrane at 
very high protein expression levels.  This may occur when the positively 
charged N-terminus is exposed through release of the C-terminus, which 
would allow electrostatic interactions with negatively charged lipids. 
 171 
It must also be questioned whether the release of the C-terminal 
autoinhibitory domain is a consequence of membrane binding or a 
necessity for membrane binding?  How is the autoinhibitory domain 
removed from interacting with the N-terminus?  It is likely that protein-
protein interactions may serve to allow the C-terminus to be removed 
from binding the N-terminus which in turn exposes the membrane 
binding region of the CHMP protein, and allows specific binding to the 
endosomal membrane.  What protein(s) and specific membrane 
components serve this purpose however are unknown, if indeed this is 
the mechanism that is occurring. 
 
(ii)  Does ESCRT-III play a role in MVB formation and vesicle 
formation or rather some other role such as trafficking to and 
fusion with the lysosome?  The studies carried out in this thesis 
demonstrate the importance of normally functioning CHMP3 in receptor 
degradation.  This evidence however does not specify where the CHMP3 
functions in terms of receptor degradation.  For example, in chapter 3 the 
phosphatase SopB delayed the degradation of EGFR, and in chapter 5, 
EGF degradation was inhibited by expression of truncated CHMP3 
proteins. The lack of normal degradation kinetics of EGF and EGFR then 
could be attributed to either failed delivery into the MVB lumen or failed 
fusion/trafficking of the MVB to the lysosome, as these experiments did 
not allow for the two situations to be distinguished.  Both scenarios would 
result in an elevated amount of the endocytosed receptor/growth factor 
being detected.  Traditional models for ESCRT complexes have shown 
the three separate complexes in a ‘conveyor-belt’ style mechanism, 
where cargo is fed from one ESCRT complex to the next, with the 
ESCRT-III complex being the last ESCRT complex prior to delivery of 
cargo into the lumen of the MVB [4].  This mechanism did seem probable 
considering the fact that ATPase defective Vps4 protein expression 
resulted in cargo failing to be delivered into the lumen of the MVB [52, 
53, 89, 90].  Furthermore, Vps4 has been shown to interact with CHMP 
proteins of the ESCRT-III complex via its MIT domain.  Thus although 
Vps4 may be necessary for removal of all ESCRT proteins from the MVB 
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membrane, its membrane recruitment would appear to be dependent 
upon ESCRT-III [89, 90].  This evidence would seem to suggest that 
ESCRT-III may be involved in the formation and possible fission of 
vesicles that invaginate into the MVB lumen. 
 
More recently however, it has been shown that gene knockdown of 
CHMP3 by siRNA does not impair the silencing of endocytosed 
receptors that traffic through the MVB, however the degradation of these 
receptors are impaired by CHMP3 silencing [56].  This evidence then 
suggests that the ESCRT-III complex, or components of it, may actually 
play a role in lysosomal fusion as opposed to MVB vesicle formation.  
This on the other hand poses problems with rectifying the exact role of 
Vps4 in MVB formation, as Vps4 has been shown to bind CHMPs for its 
localisation, and is necessary for CHMP removal as well as ESCRT-
protein removal in general from the endosomal membrane.  It has further 
been proposed that this action by Vps4 of removing ESCRT proteins 
may be the driving force behind vesicle fission, although strong evidence 
for this mechanism is still lacking [57].  Additionally, CHMPs have been 
implicated in both HIV-1 budding and membrane events at the mid-body 
of cytokinesis (chapter 6).  This would suggest that these proteins are 
involved in some manner with membrane events that lead to fission or 
abscission.  Alternatively, one must remember that although ESCRT-III 
has been described as a complex consisting of at least four separate 
CHMP proteins, there have been to date seven different CHMP families 
described in mammals [76].  Vps4 has been also shown to interact with 
CHMP5, which is not traditionally attributed to being part of the ESCRT-
III complex [90].  It is possible that the various CHMP proteins in 
mammalian cells may play slightly different roles than their counterparts 
play in yeast.  For example, some CHMPs may be involved in vesicle 
formation at the MVB, whereas others may play a role in lysosomal 
fusion.  However this is purely speculative at this point in time.  It is 
apparent though that as the literature becomes more in depth with 
studies on ESCRT-III proteins, that the roles of these proteins are more 
complex than initially thought.  This also further highlights the relevance 
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of the assay development carried out in chapter 5, as purification and 
characterisation of an endogenous Vps4E235Q compartment may allow 
for identification of novel ESCRT proteins that help explain the apparent 
gaps in our understanding of the process of MVB biogenesis and the role 
of ESCRT-III in this process. 
 
(iii)  What drives the inward invagination at the MVB?  This question 
has been the basis for much of the work carried out in the literature with 
ESCRT proteins.  Our understanding of the invagination process that 
takes place away from the cytoplasm is very limited, and likely to be very 
different to the mechanisms that take place when vesicles bud towards 
the cytoplasm.  For example, much of the budding that occurs in 
endocytosis is coat-driven, for example with proteins such as clathrin.  
There is little evidence however to suggest the budding at the MVB is 
driven by the coating with such proteins.  Although ESCRT proteins 
seem to be key players in this process, other proteins such as SNARE 
proteins may mediate the reactions that allow inward budding at the 
MVB.  However no SNARE-like proteins have yet been identified as 
being necessary or present with the ESCRT machinery [168].  This again 
demonstrates that proteomic analysis of the Vps4E235Q compartment as 
described in chapter 5 could be of great benefit.  A recent attractive 
model that has been proposed for vesicle formation is the concentric 
circle model, which diverges away from the traditional conveyor-belt 
model and suggests an alternative circular model [57].  This model starts 
with ESCRT-0 components at the centre of where invagination occurs, 
with circular formations of ESCRT-I, -II and –III complexes occurring 
where the size of the vesicle is determined by ESCRT-III, being the outer 
circle.  In this model, cargo is delivered to the centre of the circle, and 
along with the physical concentration of cargo and possible local 
asymmetrical lipids such as LBPA, a vesicular pit is formed.  The 
removal of the ESCRT machinery by Vps4 then in some way allows the 
invagination and fission of the membrane of the inwardly budded vesicle.  
The authors remark that in cells infected with HIV-1 that are also 
expressing the ATPase dead Vps4E235Q protein, the diameter of the stalk 
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from the budding virus that has not undergone fission is approximately 
100 Å [39].  This is then comparable to the estimated width of the 
dodecameric Vps4 molecule which has been estimated at 110 Å [169].  
ESCRT protein removal by Vps4 has been suggested to occur via the 
pore of the functional Vps4 homomeric complex.  One could envisage 
that the binding of CHMP proteins to the Vps4 may occur at the 
periphery of the Vps4 complex, where CHMP proteins are then ‘pulled’ 
towards the central pore for removal.  This may then result in the 
membrane drawn together in a circular fashion also towards the centre 
due to the CHMP proteins being bound to the membrane, which may 
produce fission and successful vesicle formation in the MVB lumen (see 
Fig 7.1a-d).  Much of this is again very speculative and needs more work 
to support the theory.  However, it does provide an attractive hypothetical 
mechanism for vesicle formation and fission that may be closer to the 
exact mechanism than previous models have proposed.  This would also 
provide potential explanations for how viruses use ESCRT proteins for 
budding from the plasma membrane as well as provide clues for the 
membrane events that take place for the abscission of cytokinesis (see 
Fig 7.1e-h). 
 
(iv)  What is the role of PIKfyve and its product PtdIns(3,5)P2 in the 
endocytic pathway?  The state of the literature with regards to the 
function of PIKfyve in the endocytic pathway suggests the cellular 
function of this protein is rather complex.  Many different roles have been 
proposed for PIKfyve and consequently PtdIns(3,5)P2.  The work in this 
thesis suggests that this lipid plays a role in endo-lysosomal trafficking.  
As CHMP3 has been shown to bind PtdIns(3,5)P2 in vitro, more work 
should be done to determine the relationship of CHMP3 with this lipid in 
vivo [71].  This was attempted in chapter 3 by use of SopB however due 
to the toxicity of SopB when expressed at high levels from a plasmid, this 
approach could not be taken.  If indeed CHMP3 is shown to be an 
effector of PtdIns(3,5)P2 in vivo then this would lend further weight for 
PIKfyve’s involvement in the MVB-lysosomal pathway.  Several studies  
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Figure 7.1a-d – A proposed mechanism for vesicle budding at the MVB lumen.  
(a) Vps27/HRS recruits the ESCRT-I complex (blue) components to the endosomal 
membrane.  ESCRT-I may form a circle itself around Vps27 (not shown).  Ubiquitylated 
cargo (‘Y’-shaped structures with yellow ligands) is concentrated and the ESCRT-II 
complex (green) is recruited by ESCRT-I.  ESCRT-III (red) is further recruited and is 
bound to the membrane by its N-terminal domain.  The dashed green and red circles 
represent the 3-d circular nature of the oligomerised ESCRT-II and –III complexes.  (b) 
The dodecameric Vps4 is recruited by interaction of its MIT domain with the C-terminus 
of ESCRT-III components.  The ESCRT-III complex is highly oligomerised.  Removal of 
ESCRT-I and –II complexes occurs by Vps4.  (c) The removal of ESCRT-III 
components through the central pore of Vps4 brings the circumference of the budding 
vesicle closer together and hence closer to fission, possibly due to the strong 
electrostatic interactions of ESCRT-III’s N-termini and negatively charged lipids.  (d) 
The fission of the budding vesicle is complete when Vps4 removes the last ESCRT-III 
components.  Figure based on concentric circle model [57]. 
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Figure 7.1e-f – A possible mechanism for viral budding from the plasma 
membrane of mammalian cells with the ESCRT machinery.  (e) Viral particles are 
recruited to the plasma membrane, along with the ESCRT machinery.  ESCRT-I (blue) 
is recruited and through interactions with ALIX (purple), which can act as a “bridge” that 
links ESCRT-I and ESCRT-III (red).  ESCRT-III is in its uninhibited form allowing the N-
terminus to bind to the plasma membrane, possibly through electrostatic interactions 
with negatively charged lipids.  The C-terminus of ESCRT-III interacts with Vps4 which 
removes the ESCRT-I complex.  (f) Removal of ESCRT-III oligomers allows fission of 
the membrane and successful budding of viral particles encapsulated in a membranous 
compartment. 
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Figure 7.1g-h – A potential role for the ESCRT machinery in completion of 
cytokinesis.  (g) Vesicles are trafficked to the mid-body of cytokinesis.  ESCRT-1 
(blue) and ESCRT-III (red) components as well as Vps4 are also trafficked to this 
compartment, where ESCRT-III binds to membranes of the trafficked vesicles and the 
tethered membrane, and recruits Vps4 via interactions with its MIT domain.  Vps4 
removes the ESCRT-I components after ESCRT-III is successfully recruited to 
membranes.  (h) Removal of oligomerised ESCRT-III components at multiple locations 
at the mid-body allows for the abscission event to occur, and membrane fusion events 
that lead to two separate daughter cells being formed, signifying the completion of 
cytokinesis.  It should be noted this is a very simplistic mechanism represented and that 
there are likely to be many other proteins involved in this complex process. 
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are in agreement however that PIKfyve’s role is likely to be one that 
involves proper cargo delivery to the lysosome  [84, 88].    This would be 
consistent with the findings of SopB’s actions within the cell, and also 
would not rule out the possibility of CHMP3 being an effector of 
PtdIns(3,5)P2.  Currently however, the role of PIKfyve appears to be not 
well understood, and further studies to characterise this protein and the 
cellular function of its phosphorylated product PtdIns(3,5)P2 are needed.  
The work in chapter 4 of this thesis then of producing a reliable 
polyclonal antibody that specifically recognises endogenous PIKfyve is 
important and this antibody should be used for further PIKfyve studies, 
such as in verifying gene silencing and PIKfyve inhibition studies. 
 
In conclusion, there has been much recent advancement in the field of 
MVB biogenesis and ESCRT function.  The recent findings of ESCRTs 
being involved in vital cellular processes such as cytokinesis (chapter 6) 
have made this field an even more exciting one to be working in, and 
demonstrate the importance as well as the multi-faceted nature of the 
ESCRT proteins.  The work in this thesis has helped to further 
characterise components of the ESCRT-III complex, as well as provide 
new useful tools in the detection of important cellular proteins that are 
involved in these pathways.  Additionally the development of a method 
that could result in affinity purification of endogenous MVB compartments 
is an exciting prospect.  Such an approach may allow for the 
identification of novel ESCRT proteins, as well as the further 
development of an in vitro budding assay. 
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